Reduction of bone mass without alteration in the composition of bone, leading to fractures. Primary osteoporosis can be of two major types: postmenopausal osteoporosis (OSTEOPOROSIS, POSTMENOPAUSAL) and age-related or senile osteoporosis.
| Excerpt | Reference |
|---|
| "Patchy osteoporosis is the primary roentgenologic manifestation of the reflex sympathetic dystrophy syndrome (RSDS)." | ( Bekerman, C; Genant, HK; Kozin, F; McCarty, DJ, 1976) |
| "Osteoporosis is no disease by itself but a result or a concomitant phenomenon of various diseases." | ( Krokowski, E, 1979) |
| "Osteoporosis is the result of the progressive loss of bone substance which occurs during a lifetime." | ( Camus, JP; Crouzet, J; Prier, A, 1979) |
| "Primary osteoporosis is a ubiquitous disease of unknown etiology." | ( Wallach, S, 1979) |
| "Primary osteoporosis is the ultimate consequence of progressive bone loss, which starts in the middle of the fourth decade." | ( Sandler, RB, 1978) |
| ""Osteoporosis" is no disease by itself, but solely an anatomically equal result of various etiologic and pathogenetic influences on the bone structure or parts of same." | ( Jesserer, H, 1977) |
| "A high-turnover osteoporosis is proved by bone histomorphometry." | ( Dammann, HG; Kruse, HP; Kuhlencordt, F; Montz, R; Schreiber, HW, 1977) |
| "Osteoporosis is defined as 'too little normal bone', the disorder being rarer in children than adults." | ( Dent, CE, 1977) |
| "Osteoporosis is seen with increasing frequency in hemodialyzed patients." | ( David, DS, 1975) |
| "Osteoporosis is predisposed by amyothenia respectively in activity and is initiated by reduced blood circulation of the sustentaculum." | ( Fricke, M; Krokowski, E, 1975) |
| "Low-bone-turnover osteoporosis is a common complication of primary biliary cirrhosis (PBC)." | ( del Rio, L; Gómez, R; Guañabens, N; Muñoz, J; Parés, A; Roca, M; Rodés, J, 1992) |
| "Osteoporosis is characterized by a reduction in bone mass." | ( Matkovic, V, 1992) |
| "Osteoporosis is a recognized complication following partial gastrectomy and is more common than osteomalacia." | ( Ell, PJ; Hall, ML; Hobsley, M; Tovey, FI, 1991) |
| "Osteoporosis is the most common metabolic bone disorder in the United States." | ( Levin, RM, 1991) |
| "Osteoporosis is a major public health problem." | ( Nicholson, GC; Stewart, GO, 1991) |
| "Osteoporosis is a disease characterized by a reduction in bone density which predisposes to fracture after even minimal trauma." | ( Baylink, DJ; Dure-Smith, BA; Farley, SM; Kraenzlin, ME; Libanati, CR; Schulz, EE, 1991) |
| "Osteoporosis is an important medical condition which is expensive in morbidity and mortality." | ( Ullrich, I, 1991) |
| "Idiopathic juvenile osteoporosis is a rare cause of osteoporosis during childhood." | ( Baroncelli, GI; Bertelloni, S; Calderazzi, A; Perri, G; Saggese, G, 1991) |
| "Osteoporosis is a common disease that results in 1." | ( Rubin, CD, 1991) |
| "Osteoporosis is one of the most common complications of streak gonad syndrome (SGS), however its pathogenesis is still unclear." | ( Bösze, P; Holló, I; Horváth, C; Kollin, E; Lakatos, P; László, J; Tarján, G; Vargha, P; Zséli, J, 1991) |
| "Corticoid osteoporosis is the most important of the so-called secondary forms of osteoporosis." | ( Ringe, JD, 1990) |
| "Osteoporosis is a serious side effect of systemic treatment with steroids." | ( Medici, TC; Rüegsegger, P, 1990) |
| "Osteoporosis is a growing disease, and attention should be directed to possible means of preventing and treating this disease." | ( Christiansen, C, 1990) |
| "Once osteoporosis is established as a disease entity, a variety of medical therapies have proven efficacy." | ( Bockman, RS; Weinerman, SA, 1990) |
| "Osteoporosis is common in patients requiring long-term treatment with glucocorticoids." | ( Lukert, BP; Raisz, LG, 1990) |
| "Osteoporosis is a known consequence of anorexia nervosa (AN) in adults, but the mechanism of bone loss is not established, and there have been no studies of bone mass in women developing AN before attaining peak bone mass." | ( Biller, BM; Herzog, DB; Holzman, S; Klibanski, A; Rosenthal, DI; Saxe, V, 1989) |
| "Acute osteoporosis is known to occur after immobilization in spinal cord injured patients and is related to an early increase in osteoclastic bone resorption." | ( Alexandre, C; Chappard, D; Minaire, P; Morukov, BV; Palle, S; Riffat, G; Rodionova, SS; Vico, L, 1989) |
| "Osteoporosis is a major public health problem whose impact will only continue to increase in the United States." | ( Lindsay, R, 1989) |
| "Osteoporosis is a devastating, morbid, and costly condition whose ravages are felt most profoundly by women over age 70 years." | ( Greenspan, SL; Resnick, NM, 1989) |
| "Postmenopausal osteoporosis is a common disorder." | ( Huskisson, EC; Spector, TD, 1989) |
| "Although osteoporosis is an age-related disorder, the accelerated bone loss observed in postmenopausal women may be preventable with early diagnosis and adequate estrogen replacement." | ( Brooks, P; Burnier, AM; Martin, PL; Quigley, ME, 1987) |
| "Osteoporosis is clearly more easily prevented than treated." | ( Lindsay, R, 1988) |
| "When osteoporosis is already apparent on radiological examination, fluoride (+ calcium) is generally given over 3-4 years, while calcitonin therapy is appropriate in acute painful and rapidly progressive osteoporosis with fresh vertebral fractures." | ( Dambacher, MA, 1988) |
| "The severity of the osteoporosis is directly related to the severity of the calcium malabsorption." | ( Bridges, A; Deam, S; Horowitz, M; Morris, HA; Need, AG; Nordin, BE; Philcox, JC; Robertson, A; Seamark, RF, 1985) |
| "Prednisone-induced osteoporosis is very frequent in the long-term treatment of sarcoidosis (sarcoidosis 4:45-48, 1987)." | ( Montemurro, L; Rizzato, G; Schiraldi, G; Sisti, S; Tosi, G; Zanni, D, 1988) |
| "Osteoporosis is a disease leading to enhanced fragility of bone in association with minimal trauma." | ( Galanski, M; Hesch, RD; Prokop, M; Rittinghaus, EF, 1988) |
| "Osteoporosis is the most important consequence of ovarian failure because it causes considerable morbidity and mortality." | ( Cheang, A; Kottegoda, SR; Ratnam, SS, 1987) |
| "Postmenopausal osteoporosis is a common disorder associated with significant morbidity and mortality through fractures of the femoral neck, vertebrae and distal forearm." | ( Rodysill, KJ, 1987) |
| "Osteoporosis is a common condition of the elderly population that entails considerable morbidity and mortality." | ( Heidrich, F; Thompson, RS, 1987) |
| "Postmenopausal osteoporosis is a common disabling condition, which is almost completely preventable with oestrogen therapy." | ( Brincat, M; Savvas, M; Studd, JW, 1987) |
| "Osteoporosis is a major public health problem, and its prevalence may be increasing." | ( Lindsay, R, 1987) |
| "Prevention of osteoporosis is clearly the preferred approach, since treatment of the established disorder is less than satisfactory." | ( Lindsay, R, 1987) |
| "Osteoporosis is a common complication of corticosteroid therapy and it is associated with both decreased bone formation and increased bone resorption." | ( Hartley, TF; Need, AG; Nordin, BE; Philcox, JC, 1986) |
| "Osteoporosis is a major public health problem because the incidence of hip, wrist, and vertebral fractures associated with bone loss is high." | ( Bauwens, SF; Boh, LE; Drinka, PJ, 1986) |
| "Osteoporosis is a major public health problem, particularly for the postmenopausal woman." | ( Lindsay, R; Silverberg, SJ, 1987) |
| "Osteoporosis is extremely common in alcoholics whereas osteomalacia is exceptional." | ( Pitts, TO; Van Thiel, DH, 1986) |
| "Osteoporosis is a serious metabolic bone disorder that results in fractures of the wrist, hip and vertebrae." | ( Coralli, CH; Raisz, LG; Wood, CL, 1986) |
| "Regional migratory osteoporosis is a disorder of unknown etiology, characterized by successive episodes of joint pain, accompanied by localized osteoporosis." | ( Hodsman, AB; Mavichak, V; Murray, TM; Robert, NJ; Sutton, RA, 1986) |
| "The development of osteoporosis is multifactorial, but seems to arise mainly through reduction in bone formation and reduced dietary protein and calcium intake." | ( Bremer, G; Franck, H; Keck, E, 1986) |
| "Osteoporosis is the most common bone disorder in the United States." | ( Davies, R; Saha, S, 1985) |
| "This progressive osteoporosis is associated with and could well result from a steady decline in calcium absorption which is at least partially attributable to vitamin-D deficiency and reversible on vitamin-D treatment." | ( Nordin, BE, 1971) |
| "Osteoporosis is a common disorder in women." | ( Lukert, BP, 1982) |
| "Osteoporosis is a skeletal condition in which there is a loss of bone mass, evident radiographically by diffuse rarefaction or clinically by overt fractures." | ( Lane, JM; Vigorita, VJ, 1984) |
| "Osteoporosis is the reduction of expected bone mass." | ( Dixon, AS; Woolf, AD, 1984) |
| "Osteoporosis is a major public health problem." | ( Wingate, L, 1984) |
| "Osteoporosis is a common and important feature of rheumatoid disease which can be further influenced by the treatment administered." | ( Schorn, D, 1983) |
| "Osteoporosis is the most important finding." | ( Andria, G; Bartolomeo-De Iuri, A; Del Giudice, E; Palescandolo, P; Sartorio, R; Strisciuglio, P; Tamburrini, O, 1984) |
| "Osteoporosis is a major cause of disability in elderly subjects." | ( Johannesson, A; Raisz, LG, 1984) |
| "Post-menopausal osteoporosis is certainly one of the diseases that has been most widely investigated densitometrically." | ( Nuti, R; Righi, G; Turchetti, V, 1983) |
| "Osteoporosis is a prime example of a disease which is, at least partially, nutritionally related and of great importance in this population." | ( Hickler, RB; Wayne, KS, 1984) |
| "Osteoporosis is an accepted fact of the female's aging process." | ( Linnell, S; Morton, M; Oyster, N, 1984) |
| "Postmenopausal osteoporosis is a histologically heterogeneous disorder with morphologic expression in bone that cannot be predicted by single or combined routine clinical and laboratory parameters." | ( Avioli, LV; Bergfeld, MA; Murphy, WA; Teitelbaum, SL; Whyte, MP, 1982) |
| "Osteoporosis is not a disease in itself and, hence, the management and prognosis in any individual case depends on the aetiology." | ( Jesserer, H, 1982) |
| "Osteoporosis is the most important metabolic bone disease and places an increasing burden on the healthcare system." | ( Hosking, DJ; Lyons, AR; Patel, S, 1993) |
| "In conclusion, male osteoporosis is frequently associated with major risk factors." | ( Alvarez, L; Guañabens, N; Hernandez, MV; Martinez de Osaba, MJ; Monegal, A; Muñoz-Gomez, J; Peris, P; Suris, X, 1995) |
| "Osteoporosis is a common disorder affecting the health of many adults." | ( Pilbeam, CC; Prestwood, KM; Raisz, LG, 1995) |
| "Osteoporosis is best managed by prevention, with maximisation of peak bone density and reduction of subsequent bone loss." | ( Grill, V; Martin, TJ, 1995) |
| "Osteoporosis is a well-recognized complication of long-term heparin use." | ( Deschamps, P; Hirsh, J; Shaughnessy, SG; Young, E, 1995) |
| "Iatrogenic osteoporosis is a very common secondary osteoporosis is found in patients treated with large dosage of glucocorticosteroid of long duration." | ( Wang, JZ; Zheng, LM, 1994) |
| "Osteoporosis is defined pathologically as an absolute decrease in the amount of bone, leading to fracture after minimal trauma at the aged." | ( Okada, M; Yamazaki, Y, 1994) |
| "Osteoporosis is not a disease resulting from obvious deficiencies in vitamin D, calcium, and phosphate." | ( Bikle, DD, 1994) |
| "When osteoporosis is already established, there are the following strategies: diminishing patients anxiety, non-narcotic analgesics and early mobilization after acute vertebra compression." | ( Seitz, M, 1994) |
| "Osteoporosis is a serious health problem for women over 45 years of age." | ( Forsbach, G; Santos, A, 1994) |
| "Steroid-induced osteoporosis is characterized by both increased bone resorption and inhibition of bone formation." | ( Adami, S; Rossini, M, 1993) |
| "Osteoporosis is a disease that characteristically afflicts postmenopausal women." | ( Meacham, S; Taper, LJ; Volpe, SL, 1993) |
| "Osteoporosis is a multifactorial disease with dimensions of genetics, endocrine function, exercise and nutritional considerations." | ( Saltman, PD; Strause, LG, 1993) |
| "Osteoporosis is not usually considered to be reversible, as it is a consequence of the ageing process." | ( Montemurro, L; Rizzato, G, 1993) |
| "Osteoporosis is a major complication of long-term steroid use." | ( Chung, KC; Shen, WJ; Wang, GJ, 1995) |
| "Osteoporosis is greatly increasing in prevalence as the population ages." | ( Daly, PA, 1995) |
| "On a global scale, osteoporosis is a major and growing public health problem." | ( Chorev, M; Dresner-Pollak, R; Eshel, Y; Rosenblatt, M, 1995) |
| "Osteoporosis is a significant health problem and contributor to disability and premature mortality among older men." | ( Anderson, SJ; Cauley, JA; Charron, M; Glynn, NW; Kuller, LH; Meilahn, EN, 1995) |
| "Osteoporosis is a disease that plagues older individuals, particularly women." | ( Imrie, R; Licata, A; Lonzer, MD; Rogers, D; Secic, M; Worley, D, 1996) |
| "When osteoporosis is diagnosed in men or premenopausal women, underlying pathology could be considered." | ( Kemink, SA; Kloppenborg, PW; Smals, AG, 1996) |
| "Risk fractures for osteoporosis are numerous." | ( Wark, JD, 1996) |
| "Osteoporosis is an increasingly prevalent chronic and debilitating disease." | ( Kessenich, CR, 1996) |
| "Osteoporosis is a leading cause of disability and death in older Americans; women are at higher risk than men." | ( Cáceres, B; Haines, ST; Yancey, L, 1996) |
| "Osteoporosis is a common disease among patients undergoing transplantation." | ( Arranz, R; Carmona, L; Carvajal, I; Castañeda, S; Díaz, A; García-Vadillo, A, 1997) |
| "Osteoporosis is widely accepted as a "female disease" occurring primarily in postmenopausal women." | ( McGee, C, 1997) |
| "Osteoporosis is a public health scourge that is usually eminently preventable." | ( Deal, CL, 1997) |
| "Osteoporosis is a recognized complication of corticosteroid therapy." | ( Adachi, JD; Bensen, WG; Brown, J; Chines, AA; Hanley, D; Hodsman, A; Josse, R; Kendler, DL; Lentle, B; Olszynski, W; Ste-Marie, LG; Tenenhouse, A, 1997) |
| "Osteoporosis is a common and costly condition that can cause disability or death." | ( Watts, NB, 1997) |
| "In adolescence, osteoporosis is usually due to idiopathic juvenile osteoporosis or secondary to amenorrhoea or anorexia nervosa." | ( Naganathan, V; Sambrook, PN, 1997) |
| "Currently, primary osteoporosis is the most frequent metabolic disease in women after menopause [1]." | ( Becker, P; Brock, J; Dorfling, P; Sasse, T; Schuhr, T, 1998) |
| "Osteoporosis is a metabolic bone disease characterized by an increased risk of fractures, especially hip, wrist and vertebral fractures." | ( Hardouin, P, 1997) |
| "Osteoporosis is a major complication of long-term corticosteroid administration, but the magnitude of the effect in patients with chronic obstructive pulmonary disease (COPD) is not well defined." | ( Bender, E; Ensrud, KE; Genant, HK; Griffith, JM; McEvoy, CE; Niewoehner, DE; Yu, W, 1998) |
| "Osteoporosis is an old and continuing problem which has been a challenge to medical research and care throughout the history of mankind." | ( Fujita, T, 1997) |
| "Osteoporosis is a well-recognized adverse effect of corticosteroid therapy." | ( Cortet, B; Di Munno, O; Goemaere, S; Horlait, S; Hughes, RA; Ittner, J; Laan, R; Oriente, P; Pouillès, JM; Roux, C, 1998) |
| "Osteoporosis is present in over half of all patients with anorexia nervosa." | ( Grinspoon, S; Herzog, D; Klibanski, A, 1997) |
| "Although osteoporosis is generally regarded as a disease of women, up to 30% of hip fractures and 20% of vertebral fractures occur in men." | ( Boyle, IT; Compston, J; Cooper, C; Eastell, R; Fogelman, I; Francis, RM; Hosking, DJ; Purdie, DW; Ralston, S; Reeve, J; Reid, DM; Russell, RG; Stevenson, JC, 1998) |
| "Osteoporosis is common in patients with Cushing's disease and is likely due to an imbalance between bone formation and resorption." | ( Colao, A; Di Somma, C; Faggiano, A; Klain, M; Lombardi, G; Merola, B; Pivonello, R; Salvatore, M; Tripodi, FS, 1998) |
| "Osteoporosis is a common complication of long-term glucocorticoid therapy for which there is no well-proved preventive or restorative treatment." | ( Brown, JP; Czachur, M; Daifotis, AG; Delmas, PD; Emkey, R; Goemaere, S; Hawkins, F; Liberman, UA; Malice, MP; Saag, KG; Schnitzer, TJ; Thamsborg, G, 1998) |
| "Osteoporosis is the most frequent metabolic condition experienced by elderly individuals." | ( Devogelaer, JP, 1998) |
| "Osteoporosis is common in patients with chronic cholestatic liver disease, and atraumatic spinal fracture is a recognized complication after orthotopic liver transplantation." | ( Day, CP; Francis, RM; Hudson, M; Manas, DM; Reeves, HL, 1998) |
| "Osteoporosis is common in subjects over 70 years of age." | ( Constantin, A; Laroche, M; Mazières, B; Rolland, Y; Salles, JP; Tackzuck, J, 1998) |
| "Osteopenia and osteoporosis are frequent complications after kidney transplantation." | ( Grotz, WH; Kirste, G; Niessen, A; Olschewski, M; Reichelt, A; Rump, LC; Schmidt-Gayk, H; Schollmeyer, PJ, 1998) |
| "Osteoporosis is a well-known complication of thyrotoxicosis." | ( Carpinelli, A; Del Puente, AE; Esposito Del Puente, A; Lupoli, G; Nuzzo, V; Oriente, P; Rampone, E, 1998) |
| "Osteoporosis is one of the most serious bone-related pathogenic states, as it causes serious loss of quality of life." | ( Fukuzaki, K; Haraguchi, R; Horai, N; Izpisua-Belmonte, JC; Izumi, H; Kitajima, I; Maruyama, I; Minami, T; Miyado, K; Nagata, R; Nakamura, S; Suzuki, K; Tohno, Y; Toyoda, T; Yamada, G, 1998) |
| "Osteopenia or osteoporosis is common in patients with inflammatory bowel disease." | ( Sninsky, CA; Valentine, JF, 1999) |
| "Osteoporosis is less common among African Americans and Mexican Americans than among whites, and there is little evidence that dairy products have an effect on osteoporosis among racial minorities." | ( Barnard, ND; Bertron, P; Mills, M, 1999) |
| "Osteoporosis is a complex disease, and allelic variation in many other candidate-genes including those that encode growth factors, cytokines, calciotropic hormones, and bone matrix proteins are likely to also play a role and warrant systematic investigation." | ( Cauley, JA; Ferrell, RE; Zmuda, JM, 1999) |
| "Because osteoporosis is a common complication of primary biliary cirrhosis, we evaluated the effects of calcitriol (1alpha, 25-dihydroxyvitamin D3) on bone mineral density in 34 women with primary biliary cirrhosis (stage I disease in 16 patients, stage II in 9, stage III in 4, and stage IV in 5)." | ( Habu, D; Kuroki, T; Masaki, K; Nishiguchi, S; Ochi, H; Shiomi, S; Takeda, T, 1999) |
| "Osteoporosis is a major public health problem, responsible for a great number of fractures, associated with devastating costs to society." | ( Cocchi, D; Paganelli, C; Zaffe, D, 1999) |
| "Osteoporosis is associated with cirrhosis of the liver, but the effects of therapy for osteoporosis associated with cirrhosis are still controversial." | ( Habu, D; Kuroki, T; Masaki, K; Nishiguchi, S; Ochi, H; Shiomi, S; Takeda, T; Tanaka, T, 1999) |
| "Osteoporosis is very common in patients with end-stage pulmonary disease." | ( Addesso, V; Donovan, D; McGregor, C; Papadopoulos, A; Schulman, LL; Shane, E; Staron, RB, 1999) |
| "Idiopathic juvenile osteoporosis is a rare form of bone demineralization which occurs during childhood." | ( Bourrillon, A; Job-Deslandre, C; Joseph-Gaudry, J; Mazda, K, 1999) |
| "Osteoporosis is a serious complication of systemic glucocorticoid use." | ( Dunstan, CR; Gori, F; Hofbauer, LC; Khosla, S; Lacey, DL; Riggs, BL; Spelsberg, TC, 1999) |
| "Osteoporosis is for a long time a "silent" disease and the first symptoms such as back pain, loss of height, kyphosis, and fractures are late complications." | ( Bailer, U; de Zwaan, M; el Giamal, N; Kasper, S; Lennkh, C; Nagy, C; Strnad, A; Vytiska, E, 1999) |
| "In many countries osteoporosis is the most common metabolic bone diseases." | ( Châtel, R; Szathmári, M, 1999) |
| "Osteoporosis is a frequent complication of rheumatoid arthritis (RA)." | ( Acquista, CA; Cantatore, FP; Pipitone, V, 1999) |
| "Prevention of osteoporosis is a major public health issue." | ( Bounds, W; Davies, MC; Guillebaud, JG; Gulekli, B; Hall, M; Jacobs, HS; MacDougall, J; Overton, CE, 1999) |
| "Osteoporosis is a condition in which an imbalance appears between bone resorption and formation, with bone resorption exceeding formation." | ( Cantatore, FP; Pipitone, V, 1999) |
| "Osteoporosis is considered a systemic disease involving decreased bone mineral content and increased fracture risk." | ( Freudenthaler, F; Kudlacek, S; Willvonseder, R, 1999) |
| "Osteoporosis is generally considered an age-related reduction in the quantity and quality of bone, but it need not be considered an inevitable consequence of aging." | ( Dombrowski, HT, 2000) |
| "Osteoporosis is known to be associated with Crohn's disease." | ( Berdon, W; Bilezikian, JP; Gertner, JM; Harbison, M; Horlick, M; Levine, LS; Levy, J; Oberfield, SE; Thearle, M, 2000) |
| "Osteoporosis is an important age-related disease, constituting a major risk of fracture in the elderly, and in postmenopausal women in particular." | ( Payer, J, 2000) |
| "Osteoporosis is a major cause of morbidity worldwide." | ( Alfvén, T; Carlsson, MD; Elinder, CG; Grubb, A; Hellström, L; Järup, L; Persson, B; Pettersson, C; Schütz, A; Spång, G, 2000) |
| "Osteoporosis is a common complication of Cushing's disease/syndrome." | ( Crouzet, J; Fournier, JJ; Khanine, V; Luton, JP; Requeda, E; Simon, F, 2000) |
| "Thus, osteoporosis is frequent in Addison's disease and cortisoluria could be a useful tool to predict this complication." | ( Boutsen, Y; Devogelaer, JP; Donckier, J; Heureux, F; Jamart, J; Maiter, D, 2000) |
| "Osteoporosis is not a significant problem in the majority of patients with primary biliary cirrhosis (PBC)." | ( Schalm, SW; van Buuren, HR; Vleggaar, FP; Wolfhagen, FH, 2000) |
| "Osteoporosis is a common and costly disease." | ( Green, SS; Milott, JL; Schapira, MM, 2000) |
| "The pathogenesis of osteoporosis is complex and multifactorial." | ( Rosen, CJ, 2000) |
| "Osteoporosis is a significant problem in older men, 30% of all hip fractures occur in men and the mortality rate following hip fracture exceeds that of women." | ( Kenny, AM; Marcello, KM; Prestwood, KM; Raisz, LG, 2000) |
| "Osteopenia/osteoporosis is being increasingly reported as a complication of many chronic diseases, even in children." | ( Bardare, M; Bianchi, ML; Boncompagni, A; Brandi, ML; Cimaz, R; Corona, F; Falcini, F; Galbiati, E; Giuntini, D; Lepore, L; Luisetto, G; Picco, P; Zulian, F, 2000) |
| "Although osteoporosis is a significant public health problem for aging men as well as women, the cause of osteoporosis in men remains largely unknown." | ( Katz, MS, 2000) |
| "Osteoporosis is characterized by low bone mass and disruption of bone architecture, resulting in reduced bone strength and increased risk of fractures." | ( Bertoldo, F; Cappellini, MD; D'Agruma, L; Gasparini, P; Iolascon, A; Iolascon, G; Perrotta, S; Servedio, V; Siciliani, MC, 2000) |
| "Osteoporosis is a common complication of primary biliary cirrhosis but there is no accepted therapy for the osteoporosis." | ( Dickson, ER; Jorgensen, RA; Khosla, S; Lindor, KD; Tiegs, RD, 2000) |
| "As osteoporosis is a well known complication of endogenous and exogenous glucocorticoid excess, it is likely that patients with incidentally discovered adrenocortical adenomas have impaired bone mass due to subclinical hypercortisolism." | ( Alì, A; Angeli, A; Osella, G; Paccotti, P; Peretti, P; Reimondo, G; Terzolo, M, 2001) |
| "Osteoporosis is a well known side-effect of long-term treatment with glucocorticoids." | ( Ando, Y; Asano, Y; Kusano, E; Sasaki, N; Tsuda, E; Yano, K, 2001) |
| "Osteoporosis is a systemic skeletal disease characterized by low bone mass and microarchitectural deterioration of bone tissue." | ( Bonjour, JP; Ferrari, SL; Rizzoli, R, 2001) |
| "Drug treatments for osteoporosis are intended to inhibit bone resorption, reduce the rate of bone turnover, and increase bone mass." | ( Baran, D, 2001) |
| "Osteoporosis is a major health care problem internationally with important implications for health care costs, morbidity, and mortality." | ( Eisman, JA, 2001) |
| "Osteoporosis is a major source of morbidity after renal transplantation." | ( Erdal, R; Guvener, N; Haberal, M; Işiklar, I; Turan, M; Ugur, A, 2001) |
| "Osteoporosis is a well-documented complication of organ transplantation." | ( Adachi, JD; Arlen, DJ; Ioannidis, G; Lambert, K, 2001) |
| "Fractures due to osteoporosis are one of the major complications after heart transplantation, occurring mostly during the first 6 months after the graft, with an incidence ranging from 18% to 50% for vertebral fractures." | ( Berguer, DG; Burckhardt, P; Goy, JJ; Krieg, MA; Sandini, L; Seydoux, C; Thiébaud, D, 2001) |
| "Although osteoporosis is a typical feature of hypogonadism, the influence of testosterone levels and other hormonal factors on bone mass of eugonadal males is unknown." | ( Díaz-Curiel, M; Hawkins, F; Martínez Díaz-Guerra, G; Rapado, A; Ruiz Díaz, MA, 2001) |
| "Osteoporosis is a disease characterised by low bone mass, structural deterioration of bone and increased risk of fracture." | ( Morley, P; Whitfield, JF; Willick, GE, 2001) |
| "Osteoporosis is not a specific complication of PBC." | ( Bassendine, M; Francis, R; James, O; Jones, D; Newton, J; Prince, M; Rawlings, D, 2001) |
| "Osteoporosis is a serious complication of kidney transplantation." | ( Basadonna, GP; Bia, MJ; Brickel, HM; Cruz, DN; Friedman, AL; Gundberg, CG; Insogna, KL; Kliger, AS; Lorber, MI; Mitnick, MA; Simpson, CA; Wysolmerski, JJ, 2001) |
| "Osteoporosis is a major health problem for men and women." | ( Boling, EP, 2001) |
| "Osteoporosis is a disease affecting mainly women but also an increasing number of men." | ( Fassbender, WJ; Görtz, B, 2001) |
| "Generalized osteoporosis is a result of different causes and pathogenic mechanisms, which often combine forces to become clinically relevant." | ( Himmelreich, G; Loew, A; Riess, H, 2001) |
| "Osteoporosis is a prevalent condition among elderly women and is associated with an increased risk for fractures." | ( Bruder, JM; Rubin, CD; Wang, CY, 2001) |
| "Osteoporosis is increasingly recognised." | ( Diamond, T; Ferris, L; Fiatarone-Singh, M; Flicker, L; Lord, S; MacLennan, A; Nowson, C; O'Neil, S; Sambrook, P; Williamson, M, 2001) |
| "Osteoporosis is associated with significant morbidity and mortality in men." | ( Diamond, T; Ferris, L; Fiatarone-Singh, M; Flicker, L; Lord, S; MacLennan, A; Nowson, C; O'Neil, S; Sambrook, P; Williamson, M, 2001) |
| "Osteoporosis is a common extraintestinal complication of inflammatory bowel disease." | ( Lichtenstein, GR, 2001) |
| "Osteoporosis is a major clinical problem in chronic inflammatory diseases such as rheumatoid arthritis." | ( Armour, KE; Armour, KJ; Liew, FY; Ralston, SH; Reid, DM; van't Hof, RJ; Wei, XQ, 2001) |
| "Osteoporosis is a condition of increasing importance and prevalence in all parts of the world and particularly in Asia." | ( Mundy, GR, 2002) |
| "Since osteoporosis is mediated both by decreased osteoblastic bone formation and by increased osteoclastic bone resorption, we assessed whether oxidized lipids regulate the osteoclastic potential of marrow hematopoietic cells." | ( Demer, LL; Parhami, F; Territo, M; Tetradis, S; Tintut, Y; Tsingotjidou, A, 2002) |
| "Osteoporosis is a common manifestation of Cushing's syndrome, but the mechanisms responsible for this abnormality have not been defined." | ( Foss, MC; Lanna, CM; Montenegro, RM; Moreira, AC; Paula, FJ, 2002) |
| "Depression and osteoporosis are the commonest problems in elderly subjects." | ( Dhar, HL, 2001) |
| "Osteoporosis is a common disease among patients undergoing transplantation and a loss of bone mass is usually detected after bone marrow transplantation (BMT), particularly during the immediate post-BMT period." | ( Cha, BY; Han, JH; Kang, MI; Kang, SK; Kim, CC; Lee, KW; Lee, WY; Oh, ES; Oh, KW; Son, HY, 2002) |
| "Osteopenia and osteoporosis are thus frequently observed in patients with ANCA-associated vasculities." | ( Boomsma, MM; Karsijns, M; Kramer, AB; Piers, DA; Stegeman, CA; Tervaert, JW, 2002) |
| "Osteoporosis is defined as a progressive systemic skeletal disease characterised by low bone mass and microarchitectural deterioration of bone tissue, with a consequent increase in bone fragility and susceptibility to fracture." | ( García-Cohen, EC; Rodríguez-Martínez, MA, 2002) |
| "Osteoporosis is a substantial cause of morbidity and mortality in the United States." | ( Kirk, JK; Nichols, M; Spangler, JG, 2002) |
| "Osteoporosis is an important and debilitating side effect of androgen deprivation therapy, although precise estimates of its incidence, degree and cost are not completely elucidated." | ( Ross, RW; Small, EJ, 2002) |
| "Osteoporosis is a major public health problem all over the world." | ( Gera, I, 2002) |
| "Osteoporosis is under-diagnosed and under-treated in this group of elderly hip fracture patients." | ( De Geus-Wenceslau, CM; Juby, AG, 2002) |
| "Osteoporosis is a disease characterized by low bone mineral density (BMD) and up to 80% of its variance is under genetic control." | ( Adami, S; Braga, V; Gatti, D; Malerba, G; Mirandola, S; Mottes, M; Rossini, M; Sangalli, A; Zamboni, M, 2002) |
| "Osteoporosis is the most common human bone disease." | ( Vered, I; Werner, P, 2002) |
| "Osteoporosis is one of the leading causes of morbidity and mortality in the elderly population." | ( Boyanov, M; Popivanov, P, 2002) |
| "Osteoporosis is a common and serious complication of solid organ transplantation." | ( Alexander, GJ; Compston, JE; Garrahan, NJ; Ninkovic, M; Vedi, S, 2002) |
| "Osteoporosis is a systemic skeletal disorder leading to decreased bone mineralisation and a propensity for fracture." | ( Buchman, A; DeSantis, A, 2002) |
| "Osteoporosis is a major and growing problem for older women and men in western society." | ( Doggrell, SA, 2002) |
| "We conclude that osteoporosis is a very common condition in patients with end-stage pulmonary disease, independent of the underlying diagnosis." | ( Boehler, A; Russi, EW; Schmid, C; Seifert, B; Speich, R; Tschopp, O; Weder, W, 2002) |
| "Osteoporosis is a common disease in the elderly, and the fractures that result from this disorder affect 40 % of women and 14 % of men over the age of 50 years." | ( Eastell, R; Lambert, H, 2002) |
| "Osteoporosis is almost universal in very old age, and is a major cause of morbidity and mortality in the elderly of both sexes." | ( Fraser, WD; Jackson, MJ; Lowe, NM, 2002) |
| "Osteoporosis is a common disease characterized by decreased bone mass and increased fracture risk in postmenopausal women and the elderly." | ( Flik, KR; Gardner, MJ; Lane, JM; Mooar, P, 2002) |
| "In Crohn's disease, osteoporosis is frequently found." | ( Corstens, FH; de Jong, DJ; Mannaerts, L; Naber, AH; van Rossum, LG, 2002) |
| "Osteoporosis is a chronic disease that affects a large number of both men and women and is characterized by a decrease in bone mass, as well as weakened bones." | ( Rotella, DP, 2002) |
| "Secondary osteoporosis is a feature of rheumatoid arthritis (RA)." | ( Alí, I; Dílek, K; Göksal, K; Güner, T; Hüseyin, T, 2002) |
| "Osteoporosis is a disease manifested in drastic bone loss resulting in osteopenia and high risk for fractures." | ( Bex, FJ; Bodine, PV; Borella, LE; Gazit, D; Kelly, P; Kharode, YP; Komm, BS; Moutsatsos, IK; Turgeman, G; Zhou, S; Zilberman, Y, 2002) |
| "Osteoporosis is an important complication of androgen deprivation therapy (ADT)." | ( Smith, MR, 2002) |
| "Osteoporosis is characterised by low bone mass and microarchitectural deterioration of bone tissue, leading to enhanced bone fragility and consequent increase in fracture risk." | ( Francis, RM; Tuck, SP, 2002) |
| "Osteoporosis is a rare but potentially severe complication under high-dose, long-term unfractionated heparin therapy." | ( Handschin, AE; Kock, HJ, 2002) |
| "Periarticular osteoporosis is an early finding in the hands of patients with rheumatoid arthritis (RA), due to release of bone resorbing cytokines from the inflamed synovium." | ( Adams, J; Bruce, IN; Harrison, BJ; Herrick, AL; Hutchinson, CE, 2002) |
| "Osteoporosis is a major clinical problem in older women and men." | ( Deal, C; Srivastava, M, 2002) |
| "All aspects of osteoporosis care and its fracture complications - including classification, diagnosis, management and methods for screening, as well as prevention and reducing fracture risk - were reviewed, revised as required and expressed as a set of recommendations." | ( Brown, JP; Josse, RG, 2002) |
| "Osteoporosis is a common health problem, especially in the elderly and in women after menopause." | ( Akşen, F; Düz, MZ; Kaya, A; Mustafa, D; Sert, C, 2002) |
| "Osteoporosis is a major problem of health care delivery services, both in the developed and developing countries." | ( Pande, KC, 2002) |
| "Osteoporosis is a debilitating disease that affects many older people." | ( Prentice, A, 2002) |
| "Osteoporosis is a growing global problem." | ( Liebman, M; Weaver, CM, 2002) |
| "The concept that osteoporosis is a disease characterized exclusively to a reduction in bone density, now leaves room for consideration that corresponds with the concepts of quantitative and quality elements." | ( Coaccioli, S; Di Cato, L; Ponteggia, F; Ponteggia, M; Puxeddu, A, 2002) |
| "Osteoporosis is a complication of androgen deprivation therapy in men with prostate carcinoma." | ( Smith, MR, 2003) |
| "Osteoporosis is a major cause of morbidity in liver transplant recipients and is associated with multiple factors." | ( Baruch, Y; Ish-Shalom, S; Kramsky, R; Raz, B; Segal, E; Tamir, A, 2003) |
| "Osteoporosis is a significant problem in women and men." | ( Moyad, MA, 2002) |
| "Osteoporosis is characterized by reduced bone density and strength." | ( Deavall, DG; Moggs, JG; Orphanides, G, 2003) |
| "Osteoporosis is a very prevalent complication of anorexia nervosa." | ( Mehler, PS, 2003) |
| "Osteoporosis is associated with increased risk of fractures at most skeletal sites." | ( Sohen, S, 2003) |
| "Osteoporosis is a frequent complication in Crohn's disease." | ( Adler, G; Boehm, BO; Hofbauer, LC; Klaus, J; Kratzer, W; Mason, R; Reinshagen, M; Steinkamp, M; von Tirpitz, C, 2003) |
| "Osteoporosis is considered as one of frequent diseases developing in menopausal women and old men." | ( Kozłowska-Wojciechowska, M; Makarewicz-Wujec, M; Nowicka, G, 2002) |
| "Osteoporosis is a silent epidemic in the world today." | ( Alagiakrishnan, K; Hanley, D; Juby, A; Sclater, A; Tymchak, W, 2003) |
| "Osteoporosis is a common complication of anorexia nervosa (AN)." | ( Fukuhara, H; Iketani, T; Kiriike, N; Minamikawa, N; Nagao, K; Nagata, T; Shidao, A; Stein, B, 2003) |
| "Osteoporosis is a very common disorder, which results in an increase in fracture risk." | ( Christodoulou, C; Cooper, C, 2003) |
| "Osteoporosis is one of the most common bone-related disorders in the elderly." | ( Deng, HW; Dvornyk, V; Recker, RR, 2003) |
| "Osteoporosis is a serious public health concern." | ( Advani, S; Wimalawansa, SJ, 2003) |
| "Osteoporosis is a disease of excess bone fragility that results from both the loss of bone mass and trabecular bone microarchitecture, thereby creating a very fragile skeleton." | ( Breunig, T; Kinney, JH; Kumer, J; Lane, NE; Modin, G; Wronski, T; Yao, W, 2003) |
| "Osteoporosis is a well-defined health risk in cystic fibrosis (CF) patients due to many factors." | ( Aris, RM; Backlund, DC; Blackwood, AD; Brown, SA; Caminiti, MJ; Hensler, MB; Lark, RK; Lester, GE; Ontjes, DA, 2003) |
| "Osteoporosis is defined as a bone mineral density (BMD) value evaluated by dual-energy X-linked absorptiometry of the lumbar spine of a z score of 2." | ( Godbole, M; Gulati, K; Gulati, S; Singh, U; Srivastava, A, 2003) |
| "Osteoporosis is a common complication of untreated male hypogonadism." | ( Kanumakala, S; Pua, J; Zacharin, MR, 2003) |
| "Osteoporosis is an important and preventable adverse effect of androgen deprivation therapy for prostate cancer." | ( Smith, MR, 2003) |
| "Osteoporosis is a frequent complication after renal transplantation." | ( Gutierrez, A; Moreno, A; Oppenheimer, F; Torregrosa, JV; Vidal, S, 2003) |
| "Osteoporosis is a frequent complication in the course of various gastrointestinal disorders." | ( Reinshagen, M; von Tirpitz, C, 2003) |
| "Osteoporosis is the main cause of bone fragility in this client group and it is commonly associated with postmenopausal women, although other forms exist." | ( Unsworth, J, 2003) |
| "Osteoporosis is a disease that is strongly genetically determined and polymorphisms present in a range of candidate genes may be involved." | ( Devine, A; Dhaliwal, SS; Dick, IM; Li, S; Prince, RL, 2003) |
| "Osteoporosis is characterized by a decrease in bone mass as well as a deterioration of the bone architecture resulting in an increased risk of fracture." | ( Lakatos, P; Takács, I, 2003) |
| "Male osteoporosis is an increasingly important health problem." | ( Campagna, S; Dal Canto, N; Franci, B; Gennari, C; Gennari, L; Gonnelli, S; Lucani, B; Martini, G; Merlotti, D; Nuti, R; Valenti, R, 2003) |
| "Osteoporosis is a systemic disease in which the skeletal condition is characterized by a decreased mass of normally mineralized bone." | ( Bianchi, AE; Sanfilippo, F, 2003) |
| "Male osteoporosis is an important disease, with 25-30% of all hip fractures occurring in men." | ( Drake, WM; Kendler, DL; Orwoll, ES; Rosen, CJ, 2003) |
| "Hypertension and osteoporosis are characteristic clinical features in patients with Cushing's syndrome or in those on glucocorticoid (GC) treatment." | ( Ferrari, P, 2003) |
| "Osteoporosis is an adverse effect of prednisolone therapy, although no study has been conducted on myasthenia gravis patients receiving high-dose prednisolone." | ( Araki, Y; Hayashi, N; Konno, S; Nakazato, A; Nemoto, H; Nomoto, N; Sugimoto, H; Wakata, N, 2004) |
| "Acute osteoporosis is one such effect, and a reproducible osteoporosis model has been established through the administration of the immunosuppressant drug FK506 in rats." | ( Fukunaga, J; Ishiwari, Y; Kirino, S; Lee, YJ; Mizukawa, N; Nagai, N; Sawaki, K; Sugahara, T; Takagi, S; Tsujigiwa, H; Ueno, T; Yamaai, T; Yamachika, E, 2004) |
| "Senile osteoporosis is the endpoint of a continuum that starts after the third decade of life when peak bone mass is attained and then is followed by a progressive and irreversible decline in bone mass." | ( Duque, G; Kremer, R; Macoritto, M, 2004) |
| "Osteoporosis is common, asymptomatic and usually undetected until a fracture occurs." | ( Braddon, J; Phillips, P, 2004) |
| "Osteoporosis is a preventable disease that affects millions of Americans, particularly older women." | ( Busen, NH, 2004) |
| "Osteoporosis is a major public health problem with an increase of its prevalence with age and growing consequences because of the increase of life expectancy." | ( Bonjour, JP; Chevalley, T; Rizzoli, R, 2004) |
| "Osteoporosis is increasingly recognized as a major source of morbidity following renal transplantation." | ( Cassidy, MJ; Godber, IM; Hosking, DJ; Porter, CJ; Roe, SD, 2005) |
| "Osteopenia and osteoporosis are common in male transplant recipients, and the hip and radius are the most severely affected sites." | ( Cassidy, MJ; Godber, IM; Hosking, DJ; Porter, CJ; Roe, SD, 2005) |
| "Osteoporosis is a decrease in bone mineral density (BMD) that predisposes individuals to fractures." | ( Campbell, JR; Novotny, L; Puzas, JE; Rosier, RN, 2004) |
| "Osteoporosis is a cause of considerable morbidity and mortality in men and women." | ( Fish, SA; Kirk, D, 2004) |
| "Osteoporosis is a significant comorbidity in SLE." | ( Fortin, PJ; Gladman, DD; Ibanez, D; Pineau, CA; Urowitz, MB, 2004) |
| "Osteoporosis is characterised by excess bone fragility resulting from bone loss and altered bone microarchitecture." | ( Fromigué, O; Marie, PJ; Modrowski, D, 2004) |
| "Periarticular osteoporosis is one of the first radiological signs of rheumatoid arthritis (RA)." | ( Black, AJ; Mackenzie, LM; Reid, DM; Stewart, A, 2004) |
| "Osteoporosis is characterized by a decrease in bone mass and a change in bone microarchitecture." | ( Alcalay, M; Bontoux, D; Debiais, F; Deplas, A; Thomas, P, 2004) |
| "Osteoporosis is a common metabolic disease characterized by low bone mass and microarchitectural deterioration of bone tissue." | ( Bernard, A; Bo, M; Jin, T; Kong, Q; Nordberg, G; Wang, H; Ye, T; Zhu, G, 2004) |
| "Osteoporosis is characterized by reduced bone mass, abnormal bone architecture and increased fracture risk." | ( Gámez, R; González, J; Más, R; Mendoza, N; Mendoza, S; Noa, M, 2004) |
| "Because osteoporosis is a type of pathology very often encountered in implanted patients and can be studied with in vitro models, the purpose of the present study was to evaluate P558 in vitro through comparison of normal (nOB) with osteopenic (oOB) bone-derived primary rat osteoblasts." | ( Bernauer, J; Borsari, V; Chiesa, R; Chiusoli, L; Cigada, A; Fini, M; Giardino, R; Giavaresi, G; Lenger, H; Rimondini, L; Torricelli, P, 2004) |
| "Osteoporosis is characterized by a decreased bone mass and an increased bone fragility and susceptibility to fracture." | ( Anderson, M; Dreinhöfer, KE; Féron, JM; Herrera, A; Hube, R; Johnell, O; Lidgren, L; Miles, K; Simpson, H; Tarantino, U; Wallace, WA, 2005) |
| "Osteoporosis is one major health condition that contributes to excess morbidity and mortality in women after menopause." | ( Mirza, FS; Prestwood, KM, 2004) |
| "Osteoporosis is often first recognized at the time of a low-trauma fracture." | ( Clapham, S; Eisman, J; Kehoe, L, 2004) |
| "Although osteoporosis is a relatively common complication after allogeneic stem cell transplantation, the role of bisphosphonates in its management has not yet been completely established." | ( Colao, A; Lombardi, G; Ricci, P; Rotoli, B; Selleri, C; Serio, B; Tauchmanovà, L, 2005) |
| "Osteoporosis is still an important health problem in modern societies." | ( Brodowska, A, 2003) |
| "Osteoporosis is a common but neglected problem in India." | ( Handa, R, 2004) |
| "Osteoporosis is among the top 3 medical conditions that are associated with greatest morbidity and reduction of quality of life of Hong Kong elderly subjects." | ( Kung, AW, 2004) |
| "Osteoporosis is the most important metabolic disease leading to fracture and high mortality morbidity rates." | ( Alexandre, N; Fadi, H; Georges, F; Ghassan, M; Joseph, H; Joseph, W; Marie Hélène, GY, 2004) |
| "Steroid-induced osteoporosis is the most common form of osteoporosis in the dermatological diseases, but there have been only few data concerning the treatment based on clinical evidences." | ( Okada, N, 2004) |
| "Osteoporosis is thought to be one possible side-effect of oral anticoagulant therapy, especially after long-term treatment." | ( Kemkes-Matthes, B; Liebig, S; Nees, M; Stracke, H, 2004) |
| "Although osteoporosis is a major health concern for our growing population of the elderly, there continues to be a need for well-designed clinical and animal studies on the link between dietary magnesium (Mg) intake and osteoporosis." | ( Gruber, HE; Rude, RK, 2004) |
| "If osteoporosis is linked with vitamin A (Vit A) A consumption, millions of people could be affected." | ( Crandall, C, 2004) |
| "Osteoporosis is a major and growing healthcare concern as the population ages." | ( Chen, W; Diao, W; Ji, J; Liu, J; Tang, J, 2005) |
| "Osteoporosis is the main cause of fracures in post-menopausal women, a common occurrence worldwide, giving rise to disability and a high cost to health services." | ( Kazantzis, G, 2004) |
| "Osteoporosis is increasingly recognised in men [3-11]." | ( Diamond, TH, 2005) |
| "Treatment of osteoporosis is often inadequate." | ( Arnason, JA; Pickney, CS, 2005) |
| "Osteopenia and osteoporosis are frequent complications of HIV infection and/or its treatment." | ( Claxton, SA; Hoffmann, ME; Mondy, K; Powderly, WG; Royal, M; Stoneman, JS; Tebas, P; Yarasheski, KH, 2005) |
| "Regional migratory osteoporosis is an uncommon self-limiting disease characterized by an arthralgia which migrates between the weight-bearing joints of the lower limb." | ( Barker, T; Becker, E; Donell, ST; Lobo-Mueller, EM; Marshall, TJ; Toms, AP, 2005) |
| "Osteoporosis is a leading public health threat affecting approximately 44 million people in the United States." | ( Gonyeau, MJ, 2005) |
| "Osteoporosis is associated with increased bone resorption together with a decrease in bone formation." | ( Benito-Ruiz, P; Blanch-Rubió, J; Carbonell-Abelló, J; Ciria-Recasens, M; Mariñoso, ML; Pérez-Edo, L; Serrano, S, 2005) |
| "Osteoporosis is the most frequent adverse effect observed during glucocorticoids therapy." | ( Soen, S, 2005) |
| "Osteoporosis is a chronic condition chiefly affecting postmenopausal women, in whom the skeleton loses a significant percentage of its mineralized mass and mechanical resiliency, thereby becoming prone to fracture." | ( Fan, Y; He, W; Liu, J; Peng, X; Shi, F; Wang, H; Wang, S; Xiong, L, 2005) |
| "Osteoporosis is a common complication of ADT." | ( Anastasi, G; Franchina, F; Frisina, N; Galì, A; Gaudio, A; Magno, C; Maisano, D; Melloni, D; Morabito, N, 2005) |
| "Osteoporosis is now recognized as an increasingly prevalent disorder throughout the world." | ( Kleerekoper, M, 2005) |
| "Osteoporosis is a complex multi-factorial disease where environment, diet and genetics play a role in determining susceptibility." | ( Frampton, CM; George, PM; Gilchrist, NL; Morrison, NA; Tilyard, MW; Vaughan, T, 2005) |
| "If patients with osteoporosis are being diagnosed and effective treatments used with increasing frequency in the population, rates of hip and wrist fractures will remain stable or possibly decrease." | ( Adachi, JD; Hawker, G; Jaakkimainen, L; Jaglal, SB; Kreder, H; Mamdani, M; Weller, I, 2005) |
| "Osteoporosis is a common concomitant disease in patients with rheumatic diseases on glucocorticoid (GC) therapy." | ( Bohl, N; Burmester, GR; Buttgereit, F; Loddenkemper, K; Perka, C, 2006) |
| "Osteoporosis is a metabolic bone disorder, leading to bone fragility and fracture." | ( Fogelman, I, 2005) |
| "Osteoporosis is known to impair the process of implant osseointegration." | ( Bauss, F; Eberhardt, C; Kurth, AH; Müller, S; Schwarz, M; Steinacker, M, 2005) |
| "Osteoporosis is common in adults who undergo cardiac transplantation." | ( Addesso, V; Addonizio, LJ; Cohen, A; Gao, P; Lamour, JM; Shane, E; Staron, RB, 2005) |
| "Osteoporosis is common in these patients, particularly at the one-third radius, a site sensitive to the catabolic effects of sustained excessive PTH secretion." | ( Addesso, V; Addonizio, LJ; Cohen, A; Gao, P; Lamour, JM; Shane, E; Staron, RB, 2005) |
| "Osteoporosis is a common disorder, especially among elderly post-menopausal women." | ( Bifulco, G; Cascella, T; Colao, A; Lombardi, G; Musella, T; Nappi, C; Orio, F; Palomba, S; Tauchmanova, L, 2005) |
| "Osteoporosis is one of the major health problems in our modern world." | ( Denhardt, DT; Ezura, Y; Karsenty, G; Kondo, H; Nakashima, K; Nifuji, A; Noda, M; Rittling, SR; Takeda, S, 2005) |
| "Although osteoporosis is a worldwide health problem, there are many differences in ethnic groups regarding disease morbidity and drug treatment efficacy." | ( Massart, F, 2005) |
| "Osteoporosis is prevalent in men with an estimated one in eight men older than 50 years suffering from osteoporotic fracture, and a higher mortality rate after fracture among men compared with women." | ( Dorst, A; Faber, H; Farahmand, P; Ringe, JD, 2006) |
| "Osteoporosis is a common problem in orthopedic surgery." | ( Hohlweg-Majert, B; Pfeiffer, BM; Schmelzeisen, R; Schneider, E, 2006) |
| "In men, osteoporosis is a prevalent problem that is under-recognized and undertreated." | ( Amin, S, 2003) |
| "Clinically, osteoporosis is diagnosed using dual energy x-ray absorptiometry." | ( Brennan, O; Kennedy, OD; Lee, TC; O'Brien, FJ, 2005) |
| "Osteoporosis is one of the most important problems in developed societies." | ( Herman, ZS; Krysiak, R; Labuzek, K; Okopień, B, 2005) |
| "Osteoporosis is one of the most serious complications of corticosteroid treatment." | ( Iwamoto, J; Sato, Y; Takeda, T, 2005) |
| "Osteopenia and osteoporosis are common complications of chronic liver disease (CLD)." | ( Graziadei, I; Habior, A; Kaser, A; Kaser, S; Millonig, G; Moschen, AR; Mühllechner, P; Stadlmann, S; Tilg, H; Vogel, W, 2005) |
| "Osteoporosis is a common condition in men affecting approximately 2 million males in the US." | ( Kamel, HK, 2005) |
| "Osteoporosis is frequent in AS and high disease activity is associated with an alteration in vitamin D metabolites and increased levels of bone resorption in active AS." | ( Lange, U; Müller-Ladner, U; Schmidt, KL; Strunk, J; Teichmann, J, 2005) |
| "Osteoporosis is a common complication of ankylosing spondylitis (AS)." | ( Aydin, T; Demir, SE; Karacan, I; Sahin, Z, 2005) |
| "Osteoporosis is characterized by low bone mass and increased susceptibility to fracture." | ( Marie, PJ, 2005) |
| "Osteoporosis is induced by glucocorticoids in rats during a 12-week period." | ( Ajduković, Z; Dordević, LJ; Ignjatović, N; Mihailović, D; Najman, S; Petrović, D; Savić, V; Uskoković, D, 2005) |
| "Osteoporosis is a serious and common condition with very high associated healthcare costs." | ( Jack, D, 2005) |
| "Osteoporosis is one of the most important problems in developed societies." | ( Herman, ZS; Krysiak, R; Labuzek, K; Okopień, B, 2005) |
| "Osteoporosis is a widespread problem, which frequently has devastating health consequences through its association with fragility fractures." | ( Herrmann, M; Herrmann, W; Widmann, T, 2005) |
| "Osteoporosis is a known consequence of spinal cord injury (SCI) and occurs in almost every SCI patient." | ( Dai, LY; Jiang, LS; Jiang, SD, 2006) |
| "Osteoporosis is recognized as a common medical complication of anorexia nervosa (AN)." | ( Kojima, S; Muranaga, T; Nagai, N; Nakahara, T; Naruo, T; Nozoe, S; Tanaka, M, 2006) |
| "Osteoporosis is a common and preventable disorder of the older adult skeleton that predisposes an individual to an increased risk of fracture, a major cause of disability in older adults." | ( Birge, SJ; Wilkins, CH, 2005) |
| "Drug treatment of osteoporosis is based on the knowledge of mechanisms of bone turnover and the manipulation of the cellular components of bone turnover in terms of recruitment, activation and apoptosis of the cells involved." | ( Geusens, P; Reid, D, 2005) |
| "Secondary osteoporosis is common among patients being evaluated for osteoporosis." | ( Kelman, A; Lane, NE, 2005) |
| "Osteoporosis is a disorder in which loss of bone strength leads to fragility fractures." | ( Raisz, LG, 2005) |
| "Osteoporosis is the most common bone disease, affecting millions of people worldwide and leading to significant morbidity and high expenditure." | ( Jadhav, SB; Jain, GK, 2006) |
| "While osteoporosis is increasingly identified and treated with effective medications, calcium is being neglected as a component of osteoporosis management." | ( Drieling, RL; Johns, R; Ma, J; Stafford, RS, 2005) |
| "Osteoporosis is a long-term complication of allogeneic stem cell transplantation (SCT)." | ( Kananen, K; Laitinen, K; Ruutu, T; Välimäki, MJ; Volin, L, 2006) |
| "Osteoporosis is a major health problem characterized by compromised bone strength predisposing patients to an increased risk of fracture." | ( Atik, OS; Eksioglu, F; Satana, T; Uslu, MM, 2006) |
| "Osteoporosis is a common, multifactorial cause of morbidity in patients with beta-thalassemia." | ( Angelopoulos, NG; Goula, A; Ioannis, P; Kaltsas, D; Kaltzidou, V; Katounda, E; Rombopoulos, G; Tolis, G, 2006) |
| "Osteopenia and osteoporosis are well known complications in beta thalassemia major (TM) patients." | ( Kosaryan, M; Shahi, VK; Zadeh, MF, 2004) |
| "Osteoporosis is a systemic skeletal disease characterized by low bone mass and the microarchitectural deterioration of bone tissue." | ( Kobayashi, Y; Takahashi, N, 2006) |
| "Osteoporosis is a metabolic bone disease characterized by reduced bone mass and deterioration of bone microarchitecture." | ( Anastassopoulos, G; Christopoulou, GE; Karamanos, NK; Panagiotopoulos, E; Panteliou, SD; Papadaki, E; Stavropoulou, A, 2006) |
| "Osteoporosis is a major problem in contemporary society." | ( Celik, A; Ciçek, HK; Kepkep, N; Meram, I; Yilmaz, N, 2006) |
| "Osteoporosis is a skeletal chronic multifactorial disease characterised by abnormal low bone mass and microarchitectural deterioration of bone tissue." | ( Brandi, ML; Carbonell Sala, S; Del Monte, F; Falchetti, A; Franceschelli, F; Marini, F; Masi, L, 2005) |
| "Osteoporosis is the most prevalent metabolic bone disease among developed countries." | ( De Paola, V; Gennari, L; Martini, G; Merlotti, D; Nuti, R; Valleggi, F, 2005) |
| "Osteoporosis is prevalent in hemodialysis patients." | ( Barreto, DV; Barreto, FC; Canziani, ME; Carvalho, AB; Draibe, SA; Jorgetti, V; Moyses, RM; Neves, CL, 2006) |
| "Osteoporosis is common in Thai renal allograft recipients, particularly of the lumbar vertebrae." | ( Avihingsanon, Y; Eiam-Ong, S; Kanjanabuch, T; Kingpetch, K; Praditpornsilpa, K; Suwanwalaikorn, S; Techawathanawanna, N; Tungsanga, K, 2005) |
| "Secondary causes of osteoporosis are found in a proportion of patients." | ( Barth, JH; Orme, SM; Rajeswaran, C; Spencer, J, 2007) |
| "Osteoporosis is the most common bone disease in humans and affects both men and women." | ( Clarke, BL; Mauck, KF, 2006) |
| "Fracture healing in osteoporosis is delayed, with reduced callus formation and impaired biomechanical properties of newly formed bone leading to high risk of fixation failure." | ( Adamaszek, S; Baltzer, AW; Egermann, M; Evans, C; Lill, CA; Robbins, P; Schneider, E, 2006) |
| "Osteoporosis is a major public health problem, associated with substantial morbidity and socio-economic burden." | ( Kour, A; Kumar, D; Mahajan, A; Sharma, S; Tandon, VR, 2006) |
| "Osteoporosis is a serious public health issue." | ( Cooper, C; Sambrook, P, 2006) |
| "Osteoporosis is an important cause of morbidity in beta-thalassemia patients." | ( Azar, ST; Habr, D; Inati, A; Koussa, S; Mahfouz, RA; Otrock, ZK; Shamseddeen, WA; Taher, AT, 2006) |
| "Bone loss and osteoporosis are major public health problems in the elderly." | ( McDonald, JM; Yeo, H; Zayzafoon, M, 2006) |
| "Osteoporosis is a disease of bone metabolic disorder, the incidence of which increases sharply in old people." | ( He, X; Li, P; Liu, Y; Ma, QJ; Peng, YF; Yang, XL; Zhang, YH; Zhong, H, 2006) |
| "Osteoporosis is characterized by low bone mass and by changes in the microarchitecture of the bone." | ( Neumann, E, 2006) |
| "Osteoporosis is a common complication in patients with end-stage liver disease and after orthotopic liver transplantation (LT), with resulting increasing fracture rate." | ( Fiore, CE; Giostra, E; Mentha, G; Pennisi, P; Rizzoli, R; Trombetti, A, 2007) |
| "However, because osteoporosis is a complex and heterogeneous disease with different pathogenetic factors, defining the role of the different factors in its development is important in formulating a more selective approach to therapy." | ( Odvina, CV, 2006) |
| "Osteoporosis is a skeletal disease characterized by increased risk of fracture due to reduced bone strength." | ( Inoue, D; Matsumoto, T, 2006) |
| "Osteoporosis is associated with low intake of calcium and other nutrients." | ( Hirota, K; Hirota, T, 2006) |
| "Osteoporosis is a common disease with a strong genetic component characterized by reduced bone mass and increased risk of fragility fractures." | ( de Crombrugghe, B; Ralston, SH, 2006) |
| "In adults, osteoporosis is associated with polymorphisms of vitamin D receptor (VDR), estrogen receptor (ER), and collagen Ialpha1 (COLIA1) genes." | ( Czakó, M; Ertl, T; Funke, S; Kosztolányi, G; Morava, E; Vida, G, 2006) |
| "Osteoporosis is a skeletal disorder characterized by low bone mass and deterioration of bone microarchitecture resulting in bone fragility, which increases the risk of fracture." | ( Bauss, F; Dempster, DW, 2007) |
| "Osteoporosis is a frequent disease among the elderly and has major consequences in terms of mortality, morbidity and cost." | ( Duque, G; Retornaz, F, 2006) |
| "Osteoporosis is a known complication of spinal cord injury (SCI), but its mechanism remains unknown." | ( Dai, LY; Jiang, LS; Jiang, SD, 2006) |
| "Osteoporosis is a major healthcare problem around the world and its importance lies in the fractures that result." | ( Pande, KC; Pande, SK; Veeraji, E, 2006) |
| "Osteoporosis is the most frequent adverse effect of glucocorticoids." | ( Soen, S, 2006) |
| "Osteoporosis is defined as "a systemic skeletal disease characterized by low bone mass and microarchitectural deterioration of bone tissue with a consequent increase in bone fragility and susceptibility to fracture"." | ( Binkley, N, 2006) |
| "Osteoporosis is associated with decreased bone strength as a consequence of decreased bone density and altered quality." | ( Lane, JM; Raphael, B; Serota, AC, 2006) |
| "Osteoporosis is a major public health problem that is characterized by microarchitectural deterioration, low bone mass, and increased risk of fractures." | ( Kolatkar, NS; LeBoff, MS; Mulder, JE, 2006) |
| "Importantly, osteoporosis is a major cause of morbidity and mortality in the elderly population." | ( Nakamura, T, 2007) |
| "Osteoporosis is known to complicate outcomes after lung transplantation (Tx)." | ( Baz, MA; Braith, RW; Casey, DP; Conner, JA; Fulton, MN; Howe, KS; Lisor, CF, 2007) |
| "Osteoporosis is a major health threat." | ( Li, A; Li, Y; Nanes, MS; Strait, K; Weitzmann, MN; Zhang, H, 2007) |
| "Osteoporosis is recognized as a major concern among menopausal women and the elderly." | ( Kang, GJ; Kang, HK; Lee, HJ; Yoo, ES; Yoon, WJ, 2007) |
| "Osteoporosis is a serious public health issue, affecting up to 1 in 2 women and 1 in 5 men over the age of 50 years." | ( Keen, R, 2007) |
| "Osteoporosis is one of the most widespread and destructive bone diseases in our modern world." | ( Denhardt, DT; Ezura, Y; Kato, N; Kitahara, K; Kurosawa, H; Nakashima, K; Noda, M; Rittling, SR, 2007) |
| "Osteoporosis is a systemic disease of the bones with increasing incidence in the elderly." | ( Lümmen, G; Rübben, H; Schneider, T; Sperling, H, 2007) |
| "Transient migratory osteoporosis is characterized by the acute onset of migratory pain at weight-bearing joints." | ( Carty, S; Herdman, G; Srinivasan, U; Williams, F, 2007) |
| "Osteoporosis is a systemic skeletal disease characterized by low bone mass and microarchitectural deterioration of bone tissue, with a consequent increase in bone fragility." | ( Potocki, K, 2006) |
| "Osteoporosis is chronic bone disorder that require persistent treatment." | ( Babić-Naglic, D; Grazio, S, 2006) |
| "Osteoporosis is a serious public health concern." | ( Horvath, PJ; McCann, SE; McLeod, KM; Wactawski-Wende, J, 2007) |
| "Osteoporosis is a reduction in bone mass sufficient to increase the risk of fracture." | ( Auinger, P; Campbell, JR, 2007) |
| "Osteoporosis is a well-known complication of Crohn's disease (CD)." | ( Blázovits, A; Herszényi, L; Lakatos, P; Miheller, P; Muzes, G; Rácz, K; Tulassay, Z, 2007) |
| "Secondary osteoporosis is caused by various non-physiological factors." | ( Lange, U; Müller-Ladner, U, 2007) |
| "Osteoporosis is common in patients with inflammatory bowel disease (IBD)." | ( Abitbol, V; Allez, M; Bouhnik, Y; Briot, K; Charachon, A; Chaussade, S; Coffin, B; Lamarque, D; Roux, C; Roy, C; Seksik, P, 2007) |
| "Osteopenia and osteoporosis are common in HIV-1-infected individuals and represent a challenge in clinical and therapeutic management." | ( Borderi, M; Caudarella, R; Chiodo, F; Cicola, R; De Crignis, E; Gibellini, D; Re, MC; Vescini, F, 2007) |
| "Osteoporosis is a multifactorial chronic disease that may become even more prevalent and more of a public health problem in the decades to come." | ( Boscaro, M; Fiscaletti, P; Francucci, CM; Rilli, S, 2007) |
| "Osteoporosis is a common disease that makes bones prone to fracture and can affect both men and women." | ( Chen, XG; Li, J; Liu, Y; Yu, KQ; Zhang, J; Zhao, Y, 2007) |
| "Osteoporosis is a common adverse reaction induced by glucocorticoid treatment." | ( Ichimura, A; Iwata, H; Nakajima, T; Ochiai, H; Takagi, H; Toriyama, T; Tsuchiya, H; Yamada, S, 2007) |
| "Osteoporosis is a common and severe condition in elderly men, which is poorly characterized." | ( Hofbauer, G; Kneissel, M; Pietschmann, P; Rauner, M; Skalicky, M; Stupphann, D; Viidik, A, 2007) |
| "Osteoporosis is a severe complication of glucocorticoid treatment." | ( Bertoldo, F; Dalle Carbonare, L; Fassina, A; Giannini, S; Lo Cascio, V; Realdi, G; Sella, S; Turco, G; Valenti, MT; Zordan, S, 2007) |
| "Osteoporosis is one of such problem that has been increasingly identified in patients with cancer." | ( González Macías, J; Olmos Martínez, JM, 2007) |
| "Osteoporosis is a chronic condition that generally requires long-term therapy for fracture risk reduction to become apparent." | ( Sambrook, P, 2007) |
| "However, male osteoporosis is a relatively new phenomenon." | ( Caffagni, G; Carani, C; Diazzi, C; Madeo, B; Pignatti, E; Rochira, V; Sanguanini, A; Zirilli, L, 2007) |
| "Osteoporosis is characterized by an increased risk of bone fractures, affecting especially the forearm, vertebrae and hip." | ( Devlin, H; Horner, K, 2008) |
| "Osteoporosis is recognized as a major health threat." | ( Blahos, J, 2007) |
| "Osteoporosis is a complication of hyperparathyroidism (HPT)." | ( Alley, RA; Beyer, TD; Chen, EL; Prinz, RA, 2008) |
| "Osteoporosis is a serious public health issue." | ( Kariuki, JG; Oyoo, GO, 2007) |
| "Osteoporosis is a frequent complication in patients with inflammatory bowel disease." | ( Klaus, J; König, HH; Konnopka, A; Kreck, S; Leidl, R; Matschinger, H; von Tirpitz, C, 2008) |
| "Osteoporosis is a metabolic bone disease characterized by reduced bone quality and quantity." | ( Alt, V; Drosse, I; Heiss, C; Hoesel, LM; Horas, U; Meyer, C; Schieker, M; Schnettler, R; Wehr, U; Wenisch, S, 2008) |
| "Osteoporosis is a potential risk factor affecting implant stability following total joint arthroplasty." | ( Abu-Ali, S; Fotovati, A; Hayashi, K; Naito, M; Nakamura, Y, 2008) |
| "The pathogenesis of osteoporosis is multifactorial." | ( Lanham-New, SA, 2008) |
| "Osteoporosis is a preventable disease characterized by loss of bone mineral density, progression to diminished skeletal integrity, extensive bone fragility, and an increased risk of fracture." | ( Lewiecki, EM, 2008) |
| "Osteoporosis is a common disease in middle-aged and older Americans." | ( Edwards, BJ; Migliorati, CA, 2008) |
| "Osteoporosis is diagnosed by the measurement of bone mineral density, which is a highly heritable and multifactorial trait." | ( Ahmadi, KR; Andrew, T; Arp, P; Deloukas, P; Falchi, M; Gwilliam, R; Hart, D; Hofman, A; Inouye, M; Jhamai, M; Kato, BS; Kumanduri, V; Moorhouse, M; Mullin, BH; Pastinen, TM; Pols, HA; Richards, JB; Rivadeneira, F; Soranzo, N; Spector, TD; Uitterlinden, AG; Valdes, AM; van Meurs, JB; Verlaan, DJ; Whittaker, P; Wilson, SG; Zhai, G; Zhang, F, 2008) |
| "Osteoporosis is characterized by low bone mass with micro architectural deterioration of bone tissue leading to enhance bone fragility, thus increasing the susceptibility to fracture." | ( Malhotra, N; Mithal, A, 2008) |
| "Osteoporosis is a common skeletal disease with a strong genetic component characterized by reduced bone mass and increased risk of fragility fractures." | ( Brandi, ML; Marcucci, G; Massart, F, 2008) |
| "The incidence of osteoporosis is increasing worldwide." | ( Loh, KY; Shong, HK, 2007) |
| "Osteoporosis is the most prevalent skeletal disorder, characterized by a low bone mineral density (BMD) and bone structural deterioration, leading to bone fragility fractures." | ( Akiyama, K; Bi, Y; Chen, W; Gronthos, S; Gutkind, S; Le, A; Liu, Y; Miura, Y; Patel, V; Shi, S; Sonoyama, W; Wang, CY; Yamaza, T; Young, M, 2008) |
| "As osteoporosis is a silent disease, and therapy is required for many months before benefit is realized, strategies to increase bone mineral density (BMD) and improve medication adherence are important aspects of every patient's care plan." | ( Martens, MG; Shaw, H, 2008) |
| "Osteoporosis is influenced by iron overload in hemochromatosis." | ( Fargion, S; Fracanzani, AL; Rossi, V; Sinigaglia, L; Valenti, L; Varenna, M, 2009) |
| "Osteoporosis is observed in a quarter of unselected patients with HHC, independently of the genetic background, and is associated with ALP, hypogonadism, body weight, and severity of iron overload." | ( Fargion, S; Fracanzani, AL; Rossi, V; Sinigaglia, L; Valenti, L; Varenna, M, 2009) |
| "Osteoporosis is a systemic skeletal disorder characterized by low bone mass and microarchitectural deterioration of bone tissue resulting in compromised bone strength and an increased risk of fracture." | ( Hochberg, MC, 2008) |
| "The treatment of osteoporosis is largely based around the use of agents that inhibit bone resorption by osteoclasts." | ( Reid, IR, 2008) |
| "Osteoporosis is caused by a failure of bone homeostasis, but the precise molecular mechanisms controlling bone homeostasis are largely unknown." | ( Takeda, S, 2009) |
| "Osteoporosis is a common condition in men that can have serious clinical consequences." | ( Dorst, A; Faber, H; Farahmand, P; Ringe, JD, 2009) |
| "Osteoporosis is a multifactorial disease entailing a high risk to sustain fragility fractures." | ( Ebert, R; Jakob, F; Seefried, L, 2008) |
| "Osteoporosis is widely prevalent in India and osteoporotic fractures are a common cause of morbidity and mortality." | ( Lakhotia, SM, 2008) |
| "Hypertension and osteoporosis are two major age-related disorders; however, the underlying molecular mechanism for this comorbidity is not known." | ( Asaba, Y; Fukamizu, A; Fukuhara, R; Fumoto, T; Ikeda, K; Ishida, J; Ito, M; Nimura, Y; Takeshita, S; Watanabe, K, 2009) |
| "Osteoporosis is a disease of aging associated with bone loss that often occurs without symptoms until microarchitectural deterioration becomes so significant that bone fracture occurs." | ( Aruoma, OI; Higa, T; Ke, B; Ling, Y; Qiu, W; Xu, Y; Xu, Z, 2009) |
| "Osteoporosis is common in prostate cancer (CaP) patients both before and after institution of androgen deprivation therapy and is associated with significant morbidity." | ( Acharya, NC; Agarwal, MM; Khandelwal, N; Kumar, S; Malhotra, S; Mandal, AK; Rana, SV; Singh, SK, 2008) |
| "Osteoporosis is a major public health problem of older people." | ( Pepersack, T, 2008) |
| "Fracture healing in osteoporosis is delayed." | ( Frosch, KH; Rack, T; Sehmisch, S; Seidlova-Wuttke, D; Stuermer, EK; Stuermer, KM; Tezval, M; Wenda, E; Wuttke, W, 2010) |
| "Male osteoporosis is increasingly recognized as a major public health issue." | ( Boonen, S; Delmas, PD; Eusebio, R; Orwoll, ES; Stoner, KJ; Wenderoth, D, 2009) |
| "Osteoporosis is often treated with bisphosphonates, which reduce fracture risk." | ( Bouxsein, ML; Brouwers, JE; Rietbergen, Bv; Ruchelsman, M, 2009) |
| "Osteoporosis is known to impair the process of implant osseointegration." | ( Chen, J; Du, Z; Xiao, Y; Yan, F, 2009) |
| "Osteoporosis is a silent disease and becomes clinically significant in the presence of fragility fracture." | ( Lo, WY, 2008) |
| "Osteoporosis is a common disorder with significant morbidity and mortality." | ( Lash, RW; McCort, J; Nicholson, JM; Van Harrison, R; Velez, L, 2009) |
| "Osteoporosis is a very common disease, which affects aged elderly people." | ( Gómez de Tejada Romero, MJ; Sosa Henríquez, M, 2009) |
| "Osteoporosis is a growing health concern as the number of senior adults continues to increase worldwide." | ( Berry, SD; Colón-Emeric, C; Curtis, JR; Flood, KL; Lyles, KW; Outman, RC; Saag, KG; Tanner, SB; Warriner, AH; Watts, NB, 2009) |
| "Osteoporosis is a systematic disease characterized by low bone mass and declining bone structure." | ( Bergert, FW; Conrad, D; Ehrenthal, K; Fessler, J; Gross, J; Gundermann, K; Kluthe, B; Lang Heinrich, W; Liesenfeld, A; Loew, PG; Luther, E; Pchalek, R; Seffrin, J; Sterzing, A; Wolfring, HJ; Zimmermann, U, 2009) |
| "Male osteoporosis is an important public health issue and remains undertreated." | ( Chen, JT; Zhong, ZM, 2009) |
| "Osteoporosis is a metabolic condition that is increasing in prevalence as people live longer." | ( Collinge, C; Gehrig, LM; Kaufman, J; Lane, JM; O'Connor, MI; Tosi, LL, 2009) |
| "Osteoporosis is a complex skeletal disorder in which compromised bone strength increases the risk of fragility fractures." | ( Becker, C, 2008) |
| "Osteoporosis is a disease in which the density and quality of bone is reduced, leading to an increase in fragility fractures." | ( Masuda, H; Tanaka, S, 2009) |
| "Osteoporosis is a classical age-related disease that affects women more often than men." | ( Kerschan-Schindl, K; Patsch, J; Pietschmann, P; Rauner, M; Sipos, W, 2009) |
| "Osteoporosis is common in patients with COPD, but its prevalence and progression are not well characterized." | ( Anderson, JA; Calverley, PMA; Celli, B; Ferguson, GT; Jenkins, CR; Jones, PW; Vestbo, J; Willits, LR; Yates, JC, 2009) |
| "Osteoporosis is highly prevalent in patients with COPD, irrespective of gender." | ( Anderson, JA; Calverley, PMA; Celli, B; Ferguson, GT; Jenkins, CR; Jones, PW; Vestbo, J; Willits, LR; Yates, JC, 2009) |
| "Osteoporosis is common in patients with chronic obstructive pulmonary disease (COPD)." | ( McDermott, MT; Valdez, C; Voelkel, NF; Vondracek, SF, 2009) |
| "Post-menopausal osteoporosis is considered to be an inflammatory process, in which numerous pro-inflammatory and T-cell-derived cytokines play a bone-destructive role." | ( Gaffen, SL; Goswami, J; Hernández-Santos, N; Zuniga, LA, 2009) |
| "Male osteoporosis is an increasingly important health problem worldwide." | ( Balaganesh, M; Balasubramanian, K; Ilangovan, R; Queimado, L; Ravi Sankar, B; Sittadjody, S; Sivakumar, R; Srinivasan, N; Srinivasan, S; Subramanian, C; Thompson, DM, 2009) |
| "Postmenopausal osteoporosis is the most frequent metabolic bone disease; it is characterized by a rapid loss of mineralized bone tissue." | ( Bhat, KM; Chamallamudi, MR; Dharmavarapu, PK; Kedage, V; Nampurath, GK; Nayak, SR; Potu, BK; Prasad, K; Rao, MS, 2009) |
| "Osteoporosis is a chronic disease with an enormous impact on health care costs." | ( Dinges, G, 2009) |
| "Osteoporosis is associated with the pathogenesis and risk of urolithiasis, which is higher among postmenopausal women (as opposed to premenopausal)." | ( Hamamoto, S; Hirose, M; Itoh, Y; Kobayashi, T; Kohri, K; Okada, A; Tozawa, K; Yasui, T, 2009) |
| "In conclusion, osteoporosis is a frequent complication that requires detection and treatment to reduce morbidity." | ( Ahmadpoor, P; Ghafari, A; Makhdoomi, K; Rahimi, E; Reisi, S; Sepehrvand, N, 2009) |
| "Osteoporosis is a common complication in thalassemia major (TM)." | ( Cheng, FW; Chu, Y; Lee, V; Leung, TF; Leung, WK; Li, CK; Shing, MM, 2009) |
| "Osteoporosis is common problem accounting for 2 million fractures per year in the United States at a cost of over $17 billion dollars." | ( Gruber, HE; Rude, RK; Singer, FR, 2009) |
| "Osteoporosis is a systemic disease of the skeleton, characterized by reduction of bone mass and concurrent deterioration of bone structure." | ( Ryšavá, L; Stránský, M, 2009) |
| "Osteoporosis is characterised by low bone mass and structural deterioration of bone tissue." | ( Akdeniz, N; Akpolat, V; Celik, MS; Celik, Y; Ozerdem, MS, 2009) |
| "Osteoporosis is accompanied by predominantly metaphyseal fractures with a delayed and qualitatively reduced healing process." | ( Hoerster, AK; Kolios, L; Malcherek, MC; Rack, T; Sehmisch, S; Seidlova-Wuttke, D; Stuermer, EK; Stuermer, KM; Tezval, M; Wuttke, W, 2010) |
| "Osteoporosis is a widespread problem afflicting millions of people." | ( Persson, JL; Wegiel, B, 2010) |
| "Primary osteoporosis is usually a result of reduced bone mineral density as a consequence of natural aging." | ( Hebl, S; Huston, AJ; Ling, MN; Morrow, GR; Mustian, KM; Palesh, OG; Peppone, LJ; Purnell, JQ; Reid, ME; Rosier, RN, 2010) |
| "Osteoporosis is a major public health burden through associated fragility fractures." | ( Cooper, C; Dennison, EM; Earl, S; Harvey, NC; Winsloe, C, 2009) |
| "Osteoporosis is a worldwide major public health problem, defined as "a systemic skeletal disease characterized by low bone mass and microarchitectural deterioration of bone tissue with a consequent increase in bone fragility and susceptibility to fractures"." | ( Aliberti, G; Pisani, D; Rocchietti March, M, 2009) |
| "Osteoporosis is a common complication in chronic cholestasis." | ( Alvarez, L; Combalia, A; de Osaba, MJ; Enjuanes, A; Gonzalez, B; Guañabens, N; Martinez-Ferrer, A; Monegal, A; Parés, A; Peris, P; Ruiz-Gaspà, S, 2010) |
| "Osteoporosis is the most prevalent bone complication in beta-thalassemic patients despite regular transfusions and iron chelation therapy." | ( Abo-Salem, OM; El-Edel, RH; El-Nemr, FM; Ghonaim, MM, 2010) |
| "Osteoporosis is characterized by low bone mineral density (BMD), resulting in increasing susceptibility to bone fractures." | ( Blanch-Rubió, J; Carbonell-Abelló, J; Ciria-Recasens, M; Garcia-Giralt, N; Monfort, J; Monllau, JC; Nogués, X; Pérez-Edo, L; Ruiz-Gaspà, S; Tío, L, 2010) |
| "Osteoporosis is characterized by low bone mineral density and structural deterioration of bone tissue, leading to an increased risk of fractures." | ( Chen, JM; Férec, C; Hou, SX; Li, MM; Li, WF; Yu, B, 2010) |
| "Osteoporosis is a serious health problem worldwide and leads to a significant burden on society." | ( Chen, F; Chen, J; Yun, F; Zhang, J, 2010) |
| "Osteoporosis is a systemic disease, which is characterized by reduced bone mass and microarchitectural deterioration of the bone tissue, resulting in an increased risk of fracture." | ( Mihaljević, I; Mudri, D; Smolić, M; Smolić, R; Tucak-Zorić, S, 2009) |
| "Osteoporosis is a disease of low bone mass most often caused by an increase in bone resorption that is not sufficiently compensated for by a corresponding increase in bone formation." | ( Balaji, S; Balapure, AK; Ducy, P; Gershon, MD; Guo, XE; Karsenty, G; Li, Z; Liu, XS; Lu, X; Mann, JJ; Medhamurthy, R; Suresh, PS; Vidal, M; Yadav, VK, 2010) |
| "Osteoporosis is a bone disease that can reduce both bone mass and bone strength." | ( Chou, P; Renn, JH; Yang, NP, 2010) |
| "Osteoporosis is a problem after transplantation." | ( Bjortuft, O; Bollerslev, J; Forli, L; Gadeholt, G; Godang, K; Isaksen, GA; Kvamsdal, KE; Pripp, AH; Simonsen, S, 2010) |
| "Osteoporosis is a metabolic disease of the bone characterized by reduced bone mass and microstructural deterioration of bone tissue with a consequent increase in bone fragility and risk of vertebral collapse." | ( Crestani, F; Piva, B; Shaladi, AM; Tartari, S, 2009) |
| "Osteoporosis is a major cause of low-energy hip fractures." | ( Abrahamsen, B; Eiken, PA, 2010) |
| "Osteoporosis is a common cause of disability and death in elderly men and women." | ( Duncan, EL; Gunanti, I; Hollingworth, SA; Nissen, LM, 2010) |
| "Osteoporosis is of concern in breast cancer patients who are undergoing chemotherapy." | ( Cheung, MN; Chow, LW; Jin, LJ; Loo, WT; Wang, M, 2010) |
| "The burden of osteoporosis is on the rise and glucocorticoids are one of the leading causes of drug-induced osteoporosis." | ( Gera, C; Vij, AS, 2009) |
| "Male osteoporosis is not the epidemic problem that female osteoporosis is; however, the National Osteoporosis Foundation estimates that over 14 million American men have osteoporosis or low bone mass, and approximately 25% to 30% of all hip fractures occur in male individuals who incur greater morbidity and mortality than their female counterparts." | ( Maricic, M, 2010) |
| "Involutional osteoporosis is one of common diseases related to ageing." | ( Takeuchi, Y, 2010) |
| "Osteoporosis is known to increase in prevalence with age." | ( Kawate, H; Takayanagi, R, 2010) |
| "Although osteoporosis is increasingly shown to occur in a considerable proportion of men, data on risk factors for male osteoporosis are limited." | ( Bae, SJ; Choe, JW; Kim, BJ; Kim, GS; Kim, HK; Kim, HY; Koh, JM; Lee, SH, 2010) |
| "Osteoporosis is a systemic skeletal disease responsible for the high incidence of fractures in older subjects, particularly in postmenopausal women." | ( Cooper, C, 2010) |
| "Osteoporosis is listed by the WHO among the ten most frequent and socio-economically important, chronic diseases of mankind." | ( Ringe, JD, 2010) |
| "Osteoporosis is a major and global public health concern." | ( Barbagallo, M; Dominguez, LJ; Scalisi, R, 2010) |
| "Osteoporosis is a frequent problem in disorders characterized by iron overload, such as the thalassemias and hereditary hemochromatosis." | ( Boskey, AL; Coleman, R; Cunningham-Rundles, S; Doty, SB; Giardina, PJ; Grady, RW; Lin, H; Mayer-Kuckuk, P; Ross, FP; Tsay, J; Vogiatzi, MG; Yang, Z, 2010) |
| "Osteoporosis is characterized by the occurrence of a host of fractures." | ( Boutsen, Y; Devogelaer, JP; Manicourt, DH, 2010) |
| "Osteoporosis is a common complication of aging." | ( Barton, BA; Bouxsein, ML; Brown, KM; Hannan, MT; Kiel, DP; Lang, TF; Magaziner, J; Rubin, CT; Shane, E; Zimmerman, S, 2010) |
| "Osteoporosis is characterized by reduced bone mass and structural deterioration of bone tissue leading to enhanced bone fragility and a consequent increase in fracture risk." | ( Altavilla, D; Bitto, A; D'Anna, R; Granese, R; Irrera, N; Marini, H; Minutoli, L; Polito, F; Squadrito, F, 2010) |
| "Osteopenia and osteoporosis are considered major health problems in patients suffering from thalassemia due to increased life expectancy of those patients." | ( Atfy, M; Fathy, A; Mansor, H; Saeed, J; Salah, H, 2010) |
| "Undertreatment of osteoporosis is common, even for high-risk patients." | ( Arora, T; Becker, DJ; Colon-Emeric, C; Curtis, JR; Delzell, E; Kilgore, ML; Matthews, RS; Morrisey, MA; Saag, KG; Safford, MM; Taylor, A; Warriner, A, 2010) |
| "Drug-induced osteoporosis is common and has a significant impact on the prognosis of patients suffering from chronic debilitating diseases." | ( Canalis, E; Giustina, A; Mazziotti, G, 2010) |
| "Steroid-induced osteoporosis is a serious adverse effect of this drug." | ( Amemiya, N; Itabashi, M; Karasawa, K; Kawanishi, K; Kojima, C; Moriyama, T; Nitta, K; Ogawa, T; Shimizu, A; Shiohira, S; Sugiura, H; Takei, T; Tsuchiya, K; Tsukada, M; Uchida, K, 2010) |
| "Osteoporosis is a slow progressive disease with develops over decades, and where intervention is needed for an extended number of years." | ( Bay-Jensen, AC; Christiansen, C; Henriksen, K; Karsdal, MA, 2010) |
| "Osteoporosis is prevalent in men presenting with prostate cancer and also a common side effect of treatment with luteinizing hormone-releasing hormone agonists, which are associated with decreased BMD and loss of lean body mass and suppress testosterone, unlike bicalutamide, which results in an increase in serum testosterone and oestrogen levels." | ( Parr, NJ; Wadhwa, VK; Weston, R, 2011) |
| "Osteoporosis is one of the recognized features of AS." | ( Huang, CH; Hung, PS; Lee, HS; Shiu, LJ; Tsay, MD; Wei, JC; Wong, RH, 2011) |
| "Osteoporosis is characterized by reduced bone mass and deterioration of bone microarchitecture, resulting in bone fragility and increased susceptibility to fractures." | ( Marie, PJ, 2010) |
| "Osteoporosis is now considered a major health problem in all developed and in most developing (non-African) countries." | ( Neuprez, A; Reginster, JY, 2010) |
| "Osteoporosis is a major health problem worldwide, and most current therapy used in osteoporosis treatment acts by either increasing bone formation or decreasing bone resorption." | ( Kim, HK; Lee, S; Leem, KH, 2011) |
| "Osteoporosis is currently a major public health problem and with predicted demographic changes, its future health and economic impact is likely to be phenomenal." | ( Prabhoo, R; Prabhoo, TR, 2010) |
| "Osteoporosis is not a constant feature in young patients with KS, even without testosterone substitution." | ( Bständig, B; Fénichel, P; Ferrari, P; Hiéronimus, S; Le Duff, F; Lussiez, V, 2011) |
| "Osteoporosis is a common consequence of androgen deprivation therapy (ADT) for prostate cancer." | ( Adler, RA, 2011) |
| "Osteoporosis is a multifactorial disorder with a strong genetic component and vitamin D receptor gene has been suggested as a candidate gene for osteoporosis." | ( Ajeya Kumar, P; Aruna, P; Jyothy, A; Narasimulu, G; Pulla Reddy, B; Sesha Charyulu, M; Sri Manjari, K; Venkata Karunakar, K; Yasovanthi, J, 2011) |
| "Osteoporosis is a systemic skeletal disease characterized by low bone mass and microarchitectural deterioration of bone tissue, with a consequent increase in bone fragility and susceptibility to fracture." | ( Chen, D; Huang, J; Shi, Q; Tang, DZ; Wang, YJ; Yang, F; Yang, Z, 2011) |
| "After patients with osteoporosis are identified, the challenge is to treat them appropriately." | ( Smith, EM, 2011) |
| "Osteoporosis is a bone disease that leads to an increased risk of fracture." | ( Bian, JS; Hu, LF; Lu, M; Wang, XY; Wu, ZY; Xiao, DM; Xu, ZS, 2011) |
| "Risk factors for osteoporosis are prevalent in chronic heroin users who often start using opiates in their late teens." | ( Bloch, N; Dürsteler-MacFarland, KM; Kowalewski, R; Kraenzlin, ME; Stohler, R; Wiesbeck, GA, 2011) |
| "COPD and osteoporosis are strongly associated because of common risk factors such as age, smoking, and inactivity." | ( Boonen, S; Decramer, M; Janssens, W; Lehouck, A, 2011) |
| "Osteoporosis is the most common systemic skeletal disease characterized by low bone mass, increased bone turnover, and subsequent increased susceptibility to fracture." | ( Blat, D; Komosińska-Vassev, K; Olczyk, K; Olczyk, P, 2010) |
| "Osteoporosis is a common disease characterised by a systemic impairment of bone mass and microarchitecture that results in fragility fractures." | ( Hofbauer, LC; Khosla, S; Rachner, TD, 2011) |
| "Osteoporosis is a result of the disruption of bone homeostasis that is carried out by bone-forming osteoblasts and bone-degrading osteoclasts." | ( Leong, WF; Li, B; Ling Chau, JF; Wang, X, 2011) |
| "Osteoporosis is a common condition associated with aging but has been considered to primarily affect women because of the substantial effect of menopause on osteoporosis." | ( Das, S; Gates, BJ, 2011) |
| "Osteoporosis is a major public health issue in Japan, and key factors for its prevention are diet and exercise." | ( Muraki, S, 2011) |
| "Osteoporosis is a common disorder in aging populations that imposes considerable health problems." | ( Hashiguchi, K; Hayashida, N; Irie, S; Morishita, M; Sekitani, Y; Shinkawa, T; Taira, Y; Takamura, N; Teraoka, S; Yoshida, K, 2011) |
| "Osteoporosis is a multifactorial disease with a strong genetic component." | ( Agrawal, A; Bours, MJ; Dagnelie, PC; Gartland, A; Jorgensen, NR; Schwarz, P; Wesselius, A, 2011) |
| "The prevalence of osteoporosis is estimated to be 18% in men, but 30% of all fractures occur in men." | ( Martin, AC, 2011) |
| "Osteoporosis is a global public health that affects postmenopausal women due to the deficiency of estrogen, a hormone that plays an important role in the microarchitecture of bone tissue." | ( Da Cunha, MR; de Abreu Figueira, L; Dias Vecina, CA; Do Prado Ribeiro, DC; Issa, JP; Josédias, F, 2012) |
| "Osteoporosis is uncommon before menopause and dramatically increases in prevalence thereafter." | ( Hayashi, T, 2011) |
| "Osteoporosis is a major public health problem for adults above 55 years of age, which leads to an increase in bone fragility." | ( Brazier, M; Fardellone, P; Kamel, S; Mentaverri, R, 2012) |
| "Osteoporosis is caused by imbalance between osteoclastic bone resorption and osteoblastic bone formation." | ( Nakamura, M; Udagawa, N, 2011) |
| "Osteoporosis is a common complication in children with motor impairments." | ( Berard, C; Poirot, I; Vuillerot, C; Wagner, S, 2011) |
| "Osteoporosis is a common disease in later life, which has become a growing public health problem." | ( Müller, WE; Schloßmacher, U; Schröder, HC; Wang, X; Wiens, M, 2011) |
| "Osteoporosis is a highly prevalent disease and fractures at an advanced age worsen life expectancy." | ( Namba, N; Ozono, K, 2011) |
| "Post pregnancy osteoporosis is rare condition that causes fragile fracture mostly in vertebrae." | ( Chaki, O; Hirata, G, 2011) |
| "Osteoporosis is a systemic skeletal disorder which results from an imbalance in bone remodeling." | ( Hampson, G; Sandhu, SK, 2011) |
| "Osteoporosis is a proven complication of long-term glucocorticoid therapy." | ( Faizah, O; Farihah, HS; Nazrun, SA; Nirwana, SI; Norazlina, M; Norliza, M; Suhana, MR, 2011) |
| "Osteoporosis is characterized by a reduction in bone mineral density (BMD) ." | ( Hirose, M; Niimi, K; Yasui, T, 2011) |
| "Osteoporosis is a major health disorder associated with an increased risk of fracture." | ( Ahmadieh, H; Arabi, A, 2011) |
| "Osteoporosis is a multifactorial genetic disease characterized by reduction of bone mass due to dysregulation of osteoclast differentiation or maturation." | ( Arsenault, M; Boudiffa, M; Elfassihi, L; Ferron, M; Giroux, S; Kisseleva, M; Majerus, PW; Pata, M; Rached, M; Rousseau, F; Vacher, J, 2011) |
| "Because osteoporosis is often a result of aging, many people are not aware that therapies exist to reduce the risk of fracture." | ( Dore, RK, 2012) |
| "Osteoporosis is a bone disease that predisposes to fractures." | ( Garriguet, D, 2011) |
| "Osteoporosis is a condition of excessive and uncoupled bone turnover, in which osteoclastic resorption exceeds osteoblastic bone formation, resulting in an overall net bone loss, bone fragility, and morbidity." | ( Agrawal, A; Boeynaems, JM; Gartland, A; Robaye, B; Skerry, TM; Wang, N, 2012) |
| "Steroid-induced osteoporosis is a textbook example of the secondary type of this medical condition." | ( Sewerynek, E, 2011) |
| "Osteoporosis is a chronic disease of the osseous system characterised by decreased strength of bone tissue, which in turn leads to increased fracture risk." | ( Sewerynek, E; Stuss, M, 2011) |
| "Osteoporosis is a major health problem, and the economic burden is expected to rise due to an increase in life expectancy throughout the world." | ( Brouwer-Brolsma, EM; Brug, J; de Groot, LC; Dhonukshe-Rutten, RA; Enneman, AW; Lips, P; Swart, KM; Uitterlinden, AG; van der Velde, N; van Dijk, SC; van Meurs, JB; van Schoor, NM; van Wijngaarden, JP; Zillikens, MC, 2011) |
| "Osteoporosis is one of the systemic features of COPD." | ( Bai, P; Hou, J; Jin, J; Li, R; Sun, Y; Wang, Y; Zhang, Q, 2011) |
| "Osteoporosis is a common disorder in which diminished bone mass leads to progressive microarchitectural skeletal deterioration and increased fracture risk." | ( Drake, MT; Zhang, W, 2012) |
| "Osteoporosis is a common complication in long-term survivors after liver transplantation (LTX)." | ( Amrein, K; Dimai, HP; Dobnig, H; Fahrleitner-Pammer, A; Kniepeiss, D; Kornprat, P; Pieber, T; Tscheliessnigg, KH; Wagner, D, 2012) |
| "Osteoporosis is the index disease for calcium deficiency, just as rickets/osteomalacia is the index disease for vitamin D deficiency, but there is considerable overlap between them." | ( Nordin, BE, 2010) |
| "Osteoporosis is infrequently addressed during hospitalization for osteoporotic fractures." | ( Agulnek, A; Anderson, J; Andruszyn, L; Baker, DW; Bobb, A; Bunta, AD; Cameron, KA; Dillon, N; Edwards, BJ; Hahr, A; Kazmers, NH; May, M; O'Leary, KJ; Williams, MV, 2012) |
| "Osteoporosis is infrequently addressed during hospitalization for osteoporotic fractures." | ( Agulnek, A; Anderson, J; Andruszyn, L; Baker, DW; Bobb, A; Bunta, AD; Cameron, KA; Dillon, N; Edwards, BJ; Hahr, A; Kazmers, NH; May, M; O'Leary, KJ; Williams, MV, 2012) |
| "Osteoporosis is a major public health problem as a result of associated fragility fractures." | ( Bishop, N; Cooper, C; Fraser, R; Gandhi, SV; Harvey, NC; Javaid, K; Kennedy, S; Papageorghiou, AT; Prentice, A; Schoenmakers, I, 2012) |
| "Osteoporosis is a common, morbid and costly disorder characterized by deterioration in bone strength." | ( Maalouf, NM; Sakhaee, K; Yoon, V, 2012) |
| "Osteoporosis is less common in individuals with high fat mass." | ( Buettner, C; Iqbal, J; Sun, L; Zaidi, M, 2012) |
| "Primary osteoporosis is a rare childhood-onset skeletal condition whose pathogenesis has been largely unknown." | ( Ala-Kokko, L; Bartels, CF; Cole, WG; Deraska, D; Hartikka, H; Jüppner, H; Korvala, J; Mäkitie, O; Männikkö, M; Mora, S; Schnabel, D; Sochett, E; Warman, ML, 2012) |
| "Osteoporosis is a chronic disease characterized by bone loss and increased skeletal fragility." | ( Amling, M; Barvencik, F; Beil, FT; Clarke, IJ; Egermann, M; Oheim, R; Pogoda, P, 2012) |
| "Osteoporosis is a complex disease with various causes, such as estrogen loss, genetics, and aging." | ( Chiba, K; Fujie, A; Fujita, Y; Fukuda, K; Funayama, A; Hao, W; Hashimoto, K; Hoshi, H; Iwasaki, R; Kanagawa, H; Katsuyama, E; Kawamoto, T; Kitagawa, K; Kobayashi, T; Matsumoto, M; Miyamoto, H; Miyamoto, K; Miyamoto, T; Miyauchi, Y; Mori, T; Morioka, H; Nakayama, KI; Ohsawa, I; Ohta, S; Sano, M; Sato, Y; Toyama, Y; Yoshida, S, 2012) |
| "Osteoporosis is a frequent human metabolic bone disorder." | ( Alghamdi, HS; Bronkhorst, EM; Jansen, JA; Junker, R, 2012) |
| "Osteoporosis is a major public health concern in Canada and worldwide." | ( Buchholz, AC; Chouinard, LE; Randall Simpson, J, 2012) |
| "Osteoporosis is a multi-factorial disease with potential contributions from genetic, endocrine functional, exercise related and nutritional factors." | ( Aaseth, J; Andersen, O; Boivin, G, 2012) |
| "Osteoporosis is common in human immunodeficiency virus (HIV)-infected persons." | ( Brown, TT; Walker Harris, V, 2012) |
| "Osteoporosis is characterized by enhanced activity of osteoclasts relative to that of osteoblasts." | ( Deselm, CJ; Teitelbaum, SL; Zou, W, 2012) |
| "Pediatric osteoporosis is uncommon but can result in painful and debilitating insufficiency fractures." | ( Cheema, AM; Dominguez-Bartmess, SN; Szalay, EA; Tandberg, D, 2012) |
| "Osteoporosis is a worldwide health problem predominantly affecting post-menopausal women." | ( Boonmaleerat, K; Kongtawelert, P; Pothacharoen, P; Reutrakul, V; Wanachewin, O, 2012) |
| "Osteoporosis is the most common skeletal disorder and is considered a risk of fracture." | ( Berköz, M; Comelekoglu, U; Eroglu, P; Sagír, O; Yalin, S, 2012) |
| "Osteopenia and osteoporosis are diseases frequently occurring after liver transplantation (OLT)." | ( Hommann, M; Kaemmerer, D; Lehmann, G; Schmidt, B; Settmacher, U; Wolf, G, 2012) |
| "Osteoporosis is a reduction in bone mineral density (BMD)." | ( El-Abd, EE; El-Ashmawy, NE; El-Bahrawy, HA; Haggag, AA; Khedr, NF, 2013) |
| "Osteoporosis is a major growing public health problem and it is clear that much needs to be done to bridge the gap between patients and practitioners." | ( Abdulameer, SA; Hassali, MA; Sahib, MN; Subramaniam, K; Syed Sulaiman, SA, 2013) |
| "Osteoporosis is a reduction in skeletal mass due to an imbalance between bone formation and bone resorption." | ( Jeong, MH; Kang, SS; Kim, HK; Kim, JH; Lee, JS; Park, DS; Park, KS; Yoon, TR, 2012) |
| "Transient osteoporosis is a rare condition causing regional pain, immobility and functional compromise." | ( Jawad, AS; Shaikh, MF; Shenker, NG, 2010) |
| "Osteoporosis is characterized by enhanced differentiation of bone-resorbing osteoclasts, resulting in a rapid loss of functional trabecular bone." | ( Beyer, C; Bottesch, E; Distler, JH; Hillienhof, U; Kleyer, A; Krönke, G; Schett, G; Scholtysek, C; Tuckermann, JP, 2012) |
| "Osteoporosis is an important age-related bone disease characterized by increased bone turnover with insufficient bone formation relative to bone resorption." | ( Marie, PJ; Saidak, Z, 2012) |
| "Osteoporosis is defined as a continuous loss of bone mineral density accompanied by an increased fracture risk in females and males." | ( Kudlacek, S; Puntus, T, 2012) |
| "Osteoporosis is a bone disease that leads to an increased risk of fracture." | ( Bian, W; Huang, K; Liu, H; Liu, S, 2012) |
| "Treatment for osteoporosis is highly warranted in diabetic patients who have multiple risks for fractures." | ( Okazaki, R; Watanabe, R, 2012) |
| "Alcohol induced osteoporosis is characterized by a bone mass decrease and microarchitecture alterations." | ( Benaitreau, D; Benhamou, CL; Chappard, C; Jaffre, C; Jamme, F; Lespessailles, E; Maurel, DB; Pallu, S; Refregiers, M; Rochefort, GY, 2012) |
| "Osteoporosis is a major complication of chronic cholestatic liver disease (CCLD)." | ( de Paula, FJ; Defino, HL; Facincani, I; Jorgetti, V; Mattar, R; Pereira, FA; Ramalho, LN; Volpon, JB, 2012) |
| "Osteoporosis is considered a "silent" disease as there are often no discrete warning signs, until a fracture occurs; therefore, clinicians must be cognizant of the underlying risk for osteoporosis and co-morbid conditions and/or medications that accelerate risk of fracture." | ( Choksi, P; Taxel, P; Van Poznak, C, 2012) |
| "Osteoporosis is a common side effect of treatment with androgen deprivation therapy (ADT) in men with prostate cancer." | ( Davison, J; Millar, H, 2012) |
| "Osteoporosis is a chronic systemic disease characterised by bone loss and microarchitectural deterioration." | ( Amling, M; Ignatius, A; Oheim, R; Pogoda, P, 2012) |
| "Osteoporosis is a common skeletal complication seen in patients with chronic liver disease." | ( Carey, EJ; Yadav, A, 2013) |
| "Osteoporosis is characterized by poor bone quality." | ( Garcia, P; Histing, T; Holstein, JH; Klein, M; Kuntz, S; Menger, MD; Pohlemann, T; Scheuer, C; Stenger, D, 2013) |
| "Osteoporosis is a leading cause of morbidity and mortality in the elderly and influences quality of life, as well as life expectancy." | ( Faliva, MA; Opizzi, A; Perna, S; Rondanelli, M, 2013) |
| "Osteoporosis is a debilitating condition characterized by fractures, pain and premature death." | ( Andersen, S; Jakobsen, A; Laurberg, P; Vestergaard, P, 2013) |
| "Osteoporosis is recognized as the disease of females; however, males are also affected and have serious consequences thereof." | ( Agrawal, NK; Sharma, B, 2013) |
| "Postmenopausal osteoporosis is a complicated and multi-factorial disease." | ( A, J; Li, J; Liu, J; Liu, Y; Ma, B; Sun, J; Wang, Y; Wu, D; Ying, H; Zhang, Q, 2013) |
| "Osteoporosis is a widespread disease characterised by low bone mass and structural deterioration of bone resulting in an increased susceptibility to fractures." | ( Alt, V; Böcker, W; Elkhassawna, T; Govindarajan, P; Heiss, C; Hemdan, NY; Lips, KS; Schlewitz, G; Schliefke, N; Schnettler, R; Thormann, U; Zahner, D, 2013) |
| "Because osteoporosis is associated with increased bone marrow fat content, which in principal can alter DTI parameters, the goal of this study was to examine the potential of MD and FA, in combination with bone marrow fat fraction (FF), to discriminate between healthy, osteopenic and osteoporotic subjects, classified according to DXA criteria." | ( Assako, EP; Capuani, S; Fanucci, E; Iundusi, R; Manenti, G; Masala, S; Simonetti, G; Sorge, R; Tarantino, U, 2013) |
| "Osteoporosis is defined as a reduction of bone density or the presence of a fragility fracture." | ( Amiri, AH; Tarrahi, MJ, 2011) |
| "Osteoporosis is a disease characterised by low bone mass and structural deterioration of bone tissue leading to bone fragility." | ( Leonardi, R; Loreto, C; Musumeci, G; Pichler, K; Reuber, T; Weinberg, AM, 2013) |
| "Osteoporosis is a common pathological condition that influences 20 % of women over 50 years of age." | ( Jiang, Y; Li, N; Wooley, PH; Xu, Z; Yang, SY, 2013) |
| "Osteoporosis is prevalent among Malaysian patients with inflammatory bowel disease and is associated with a 6-fold increased risk of fractures." | ( Ananda, V; Arumugam, K; Goh, KL; Hilmi, I; Sarji, SA; Sunderesvaran, K, 2013) |
| "The risk of osteoporosis is reduced as TGF-β1 increases and increases as OPG was raised." | ( Chen, C; Chen, P; Gong, JJ; He, HB; Lei, DD; Liao, EY; Luo, XH; Wu, XP; Xie, GQ; Zhang, H, 2013) |
| "Both CKD and osteoporosis are frequently observed in the same patients, and often have parallel progression in postmenopausal women." | ( Cheng, MH; Lee, FK; Lee, WL; Tarng, DC; Wang, PH; Yang, WC, 2013) |
| "Osteoporosis is a skeletal disorder characterized by loss of bone mass, decreased bone strength, and an increased risk of bone fracture." | ( Imai, K, 2013) |
| "Osteoporosis is a skeletal disease leading to an increased risk of bone fracture." | ( Abedinpoor, A; Chen, A; Dodge, TR; Hamamura, K; Tanjung, N; Yokota, H; Zhang, P, 2013) |
| "Osteoporosis is one of the major complications of glucocorticoid therapy." | ( Fujii, N; Hamano, T; Inoue, K; Isaka, Y; Kusunoki, Y; Matsui, I; Mikami, S; Nakano, C; Nango, N; Obi, Y; Rakugi, H; Shimomura, A; Tomida, K; Tsubakihara, Y, 2014) |
| "Osteoporosis is a common bone metabolic disorder affecting both men and women." | ( Abdul-Majeed, S; Mohamed, N; Soelaiman, IN, 2013) |
| "Osteoporosis is posing a tremendous healthcare problem globally." | ( Chin, KY; Mo, H; Soelaiman, IN, 2013) |
| "Osteoporosis is a bone pathology leading to increase fractures risk and challenging quality of life." | ( Coxam, V; Guicheux, J; Léotoing, L; Miot-Noirault, E; Wauquier, F; Wittrant, Y, 2013) |
| "Osteoporosis is a major public health concern, characterized by low bone mass and structural deterioration of bone tissue, leading to bone fragility and an increased susceptibility to fracture." | ( Feola, M; Liuni, FM; Pistillo, P; Saturnino, L; Scialdoni, A; Tarantino, U; Tempesta, V, 2013) |
| "Osteoporosis is a high mortality and morbidity ranged skeletal disease and results in high costs of medical care in the European Union." | ( Albayrak, A; Bayir, Y; Bilen, H; Cadirci, E; Halici, Z; Karakus, E; Polat, B; Sahin, A; Yuksel, TN, 2013) |
| "Osteoporosis is one of the deleterious side effects of long-term glucocorticoid therapy." | ( Böcker, W; Dürselen, L; Faulenbach, M; Govindarajan, P; Heiss, C; Huerter, B; Kampschulte, M; Khassawna, T, 2013) |
| "Secondary osteoporosis is also common in men, and causes include androgen deprivation therapy for prostate cancer, glucocorticoid treatment and alcohol excess." | ( Eastell, R; Walsh, JS, 2013) |
| "Osteoporosis is a skeletal disorder characterized by diminished bone strength, which results in an increased risk of fracture." | ( Brandi, ML; Minisola, S, 2013) |
| "Osteoporosis is caused by an imbalance in bone remodeling, a process involving bone-building osteoblasts and bone-resorptive osteoclasts." | ( Brackee, G; Chen, CH; Chen, L; Chyu, MC; Jenkins, M; Kwun, IS; Mo, H; Shen, CL; Wang, S, 2013) |
| "Osteoporosis is a widespread disorder affecting millions of individuals of all ethnic backgrounds worldwide, particularly among older women." | ( Baldi, J; Celi, M; Gasbarra, E; Iundusi, R; Liuni, FM; Rao, C; Tarantino, U, 2013) |
| "Osteoporosis is a disease characterized by reduction in the bone mass and disruption of bone architecture leading to impaired skeletal strength and an increased susceptibility of fractures." | ( Behera, A; Ghosal, K; Silvanus, V; Subramanian, P, 2012) |
| "Because osteoporosis is a disease associated primarily with aging, we hypothesized that age-related bone loss would be attenuated in α-TTP-KO mice." | ( Cross, CE; Gohil, K; Iwaniec, UT; Rust, A; Smith, BJ; Stoecker, BJ; Traber, MG; Turner, RT; Vasu, VT; Zhang, B, 2013) |
| "Osteoporosis is a high-prevalence disease, particularly in developed countries, and results in high costs both to the individual and to society through associated fragility fractures." | ( Brown, L; Poudyal, H, 2013) |
| "Osteoporosis is a major global health problem." | ( Ahmad, F; Ima-Nirwana, S; Mohamad, N; Mohd Ramli, ES; Shuid, AN; Suhaimi, F, 2013) |
| "Osteoporosis is the consequence of an imbalance in bone remodeling caused by excessive resorption or inappropriate bone formation." | ( Brance, ML; Brun, LR; Di Loreto, VE; Lupo, M; Rigalli, A, 2014) |
| "Osteoporosis is a major global health issue in elderly people." | ( Cha, PH; Choi, KY; Min, do S; Zahoor, M, 2014) |
| "Osteoporosis is a metabolic bone disorder that affects both men and women worldwide." | ( Mohamed, N; Rufus, P; Shuid, AN, 2013) |
| "Osteoporosis is regularly mentioned as a secondary consequence of alcoholism, and chronic alcohol abuse is established as an independent risk factor for osteoporosis." | ( Mikosch, P, 2014) |
| "Osteoporosis is a common disorder characterized by compromised bone strength that predisposes patients to increased fracture risk." | ( Liu, J; Miao, D; Sun, W; Wang, H; Wang, Z; Wu, J; Yin, Y, 2014) |
| "Osteopenia and osteoporosis are common in adults with CF, especially in male patients and in patients with low lung function, body weight, and 25-OH vitamin D levels." | ( Gemma, S; Patel, A; Sheikh, S, 2015) |
| "Osteoporosis is a skeletal disorder characterized by low bone mass and increased bone fragility associated with aging, menopause, smoking, obesity, or diabetes." | ( Cates, JM; Cole, HA; Degen, JL; Flick, MJ; Hirotaka, H; Nyman, JS; Ohba, T; Schoenecker, JG, 2014) |
| "Sarcopenia and osteoporosis are important public health problems that occur concurrently." | ( Abreu, E; Bonewald, LF; Brotto, M; Hsu, YH; Huang, J; Karasik, D; Kiel, DP; Mo, C, 2014) |
| "Osteoporosis is a silent disease, characterized by a porous bone micro-structure that enhances risk for fractures and associated disabilities." | ( Abboud-Werner, S; Bendele, M; Callaway, D; Fajardo, R; Guda, T; Herman, B; Horn, D; Lopez-Cruzan, M; Sharma, R; Vanegas, D, 2014) |
| "Osteoporosis is recognized as a worldwide skeletal disorder problem." | ( Anburajan, M; Kumar, DA, 2014) |
| "Comparison of osteoporosis care in breast cancer and non-oncology populations shows that suboptimal bone health care is not isolated to prostate cancer." | ( Alibhai, SM; Tsang, DS, 2014) |
| "Osteoporosis is a progressive bone disease due to low osteoblast activity and/or high osteoclast activity." | ( Soo, C; Ting, K; Velasco, O; Wu, BM; Zhang, X; Zhang, Y, 2014) |
| "Osteoporosis is characterized by low bone mineral density and associated with low impact skeletal fractures most often involving the spine, hip, pelvis, proximal humerus and forearm." | ( Gosch, M; Kammerlander, C; Nicholas, JA, 2014) |
| "Although osteoporosis is a progressive bone disease leading to increased risk of fracture, it has rarely been investigated on a large scale in older people with intellectual disabilities (ID)." | ( Bastiaanse, LP; Echteld, MA; Evenhuis, HM; Mergler, S, 2014) |
| "Osteoporosis is complicated by the occurrence of fragility fractures." | ( Felder, M; Ferrari, S; Krieg, MA; Lamy, O; Meier, C; Mellinghoff, HU; Rizzoli, R, 2014) |
| "Osteoporosis is a chief complication in patients with anorexia nervosa." | ( Araki, M; Hotta, M; Ohwada, R; Urano, A, 2015) |
| "Osteoporosis is the prevalent manifestation of bone involvement in patients with systemic mastocytosis." | ( Adami, S; Biondan, M; Bonadonna, P; Gatti, D; Idolazzi, L; Orsolini, G; Rossini, M; Tripi, G; Viapiana, O; Zanotti, R, 2014) |
| "Osteoporosis is an asymptomatic, systemic bone disease characterized by low bone mass and microarchitectural deterioration of bone tissue, resulting in increased bone fragility." | ( Balercia, G; Biagioli, A; Tirabassi, G, 2014) |
| "Osteoporosis is a chronic disease with an increasing prevalence due to the ageing of the population." | ( Duquet, N, 2014) |
| "In Singapore, male osteoporosis is gaining greater importance due to our ageing population." | ( Goh, LH; How, CH; Lau, TC, 2014) |
| "Osteoporosis is a common, costly and serious disease, which is still too often regarded as an inevitable part of the normal ageing process and therefore sub-optimally treated, especially in the elderly--in fact, only two out of every 10 patients who sustain a hip fracture receive any form of assessment or prophylactic therapy for osteoporosis." | ( Brown, SL; Cassim, B; Davey, MR; de Lange, W; de Villiers, TJ; Ellis, GC; Hough, FS; Lipschitz, S; Lukhele, M; Pettifor, JM, 2014) |
| "Osteoporosis is a disease characterized by low bone mineral density (BMD) and increased risk of fractures." | ( Boue, SM; Bunnell, BA; Burow, ME; Elliott, S; Gimble, JM; Jiang, Q; Ohlstein, JF; Strong, AL; Wang, G; Zhang, Q; Zheng, S, 2014) |
| "The incidence of osteoporosis is high in MHD patients." | ( Fan, WF; Gu, Y; Niu, JY; Wu, Q; Xiao, DM; Ye, XW, 2014) |
| "Osteoporosis is one of the most common bone diseases in the world and results from an imbalance of bone cell functions." | ( Deng, F; Ji, Y; Qiu, H; Wang, L; Watts, DC; Wu, X; You, T, 2014) |
| "Osteoporosis is a disease with great importance in current public health due to the associated risk of fracture; therefore, a rapid and accurate diagnosis becomes increasingly important." | ( de Souza, RA; Mussatto, JC; Pacheco, MT; Perez, MC; Silveira, L; Zângaro, RA, 2015) |
| "Osteoporosis is a major public health issue that is expected to rise as the global population ages." | ( Tou, JC, 2015) |
| "Osteoporosis is one of the skeletal manifestations of NF1, which is associated with increased fracture risk." | ( Benlidayi, IC; Kozanoglu, E; Ortac, EA, 2015) |
| "Osteoporosis is a common health problem." | ( Malek, HA; Samir, SM, 2014) |
| "Osteoporosis is a progressive systemic skeletal disease, in which the equilibrium of bone resorption and bone formation is disturbed." | ( Cai, K; Dong, Y; Hu, X; Jin, Y; Liu, J; Ma, J; Wu, G; Zhang, H, 2014) |
| "Osteoporosis is a systemic and metabolic bone disease." | ( Dai, L; Hu, M; Shen, Z; Wang, Y; Wu, H; Xu, M; Xue, L; Yuan, D; Zhao, H, 2016) |
| "Osteoporosis is simulated in rats by chronic administration of omeprazole or serotonin for 6 months; investigated bone status in the model of liver fibrosis and the administration of serotonin against liver fibrosis." | ( Puzikov, AM, 2014) |
| "The target to treat osteoporosis is prevention for future fractures." | ( Gorai, I, 2015) |
| "Urolithiasis and osteoporosis are two multifactorial diseases which are evidently reciprocal." | ( Balaban, J; Bijelic, R; Milicevic, S, 2014) |
| "Osteoporosis is a condition characterized by a reduced bone mass and a compromized resistance of bone against mechanical loads, which has led us to hypothesize that mechanotransduction by osteocytes is altered in osteoporosis." | ( Bacabac, RG; Bakker, AD; Klein-Nulend, J; van Oers, RF, 2015) |
| "Osteoporosis is regarded as one of the chronic complications of diabetes mellitus that results from reduced bone formation and increased resorption." | ( El-Maraghy, SA; Mehana, NA, 2015) |
| "Osteoporosis is caused by excessive activity of bone-degrading osteoclasts over bone-forming osteoblast." | ( Blangy, A; Busson, M; Cherfils, J; Cres, G; Ferrandez, Y; Malaval, L; Planson, AG; Richard, C; Vives, V; Zeghouf, M, 2015) |
| "Osteoporosis is a disorder of bones with increasing risk among women." | ( Garg, V; Kochhar, A; Munshi, R, 2015) |
| "Osteoporosis is a disease characterized by loss of bone mass and degeneration of the microstructure of bone." | ( Cong, L; Guo, DW; Han, YX; Liang, D; Tu, GJ, 2015) |
| "The intervention of osteoporosis is considered to be one part of bone fracture treatment." | ( Fan, FY; Kuo, CL; Wu, CC; Yang, KC, 2015) |
| "Osteoporosis is more commonly found in women, thus making women more susceptible to fracture than men." | ( Matsushita, H; Wakatsuki, A, 2015) |
| "Osteoporosis is a skeletal disorder characterized by decreased mass and compromised bone strength predisposing to an increased risk of fractures." | ( Canalis, E; Mirza, F, 2015) |
| "Atherosclerosis and osteoporosis are the leading causes of mortality and morbidity." | ( Rajamannan, NM, 2015) |
| "Osteoporosis is a chronic disease associated with decreased bone density that afflicts millions of people worldwide." | ( Moreau, R; Roberts, JL, 2015) |
| "Diabetic osteoporosis is gradually attracted people's attention." | ( Meng, HZ; Yang, MW; Zhang, WL, 2015) |
| "Osteoporosis is a major cause of fractures and associated morbidity in the aged population." | ( Ellinger, I; Föger-Samwald, U; Mechtcheriakova, D; Meshcheryakova, A; Pietschmann, P, 2016) |
| "Generalized osteoporosis is common in patients with inflammatory diseases, possibly because of circulating inflammatory factors that affect osteoblast and osteoclast formation and activity." | ( Bakker, AD; Bravenboer, N; Klein-Nulend, J; Lems, WF; Luyten, FP; Pathak, JL; Verschueren, P, 2015) |
| "Osteoporosis is a disease of the bones resulting in low bone mass that induces fragile bones and hence susceptibility of fracture." | ( Chung, YT; Liou, SH; Pan, WH; Tsai, TL; Tseng, YC; Wang, SL; Wu, TN, 2016) |
| "Osteoporosis is a disease characterized by low bone mass and progressive destruction of bone microstructure, resulting in increased the risk of fracture." | ( Li, F; Li, Y; Lv, J; Ma, J; Ma, X; Meng, X; Sun, X; Zhang, Y; Zhao, B, 2015) |
| "Osteoporosis is a major disease associated with aging." | ( Amstislavskaya, TG; Chen, JH; Ho, YJ; Hsu, CY; Huang, CW; Hung, CS; Kao, PF; Kolosova, NG; Tikhonova, MA; Ting, CH; Tseng, GT, 2015) |
| "Osteoporosis is a systemic skeletal disease with the high incidence, serious complications, financial burden, and heavily decrease in living quality." | ( Bai, YB; Guo, LX; Liu, XD; Ma, YZ; Xi, JC; Xue, HB; Zang, HY, 2015) |
| "Osteoporosis is a syndrome of excessive skeletal fragility characterized by the loss of mass and deterioration of microarchitecture in bone." | ( Li, W; Liu, H; Liu, Y; Zhang, X; Zhou, Y, 2015) |
| "Osteoporosis is a common and under-diagnosed disease characterized by the systemic impairment and structural deterioration of bone tissue, leading to bone fragility and an increased risk of fractures of the hip, spine, and wrist." | ( Kageyama, G, 2015) |
| "Osteoporosis is one of the most common bone diseases, which is characterized by a systemic impairment of bone mass and fragility fractures." | ( Huang, CX; Lv, B; Wang, Y, 2015) |
| "Rates of osteoporosis are significantly lower in regions of the world where olive oil consumption is a dietary cornerstone." | ( Bradshaw, HB; Leishman, E, 2016) |
| "Osteoporosis is one of the most prevalent bone diseases worldwide and is characterised by high levels of bone turnover, a marked loss in bone mass and accumulation of microdamage, which leads to an increased fracture incidence that places a huge burden on global health care systems." | ( Curtin, CM; Duffy, GP; Lee, TC; McCoy, RJ; Mulcahy, LE; O'Brien, FJ; Taylor, D, 2015) |
| "Osteoporosis is an osteolytic disease that features enhanced osteoclast formation and bone resorption." | ( Cheng, J; Lin, X; Liu, Q; Tickner, J; Wang, T; Xu, J; Yang, M; Yao, J; Yuan, J; Zhao, J; Zhou, L, 2016) |
| "Osteoporosis is a global public health problem currently affecting more than 200 million people worldwide." | ( Murray, IR; Simpson, AH, 2016) |
| "Osteoporosis is the radiological image of osteopenia, a pathological concept meaning a smaller quantity of bone per unit of volume." | ( Alaminos, M; Campos, A; Cano, JR; Crespo, PV; Cruz, E; Guerado, E; Sánchez-Quevedo, Mdel C, 2016) |
| "Osteoporosis is the most important factor related to changes in periprosthetic bone mass." | ( Čellár, R; Lacko, M; Schreierová, D; Vaško, G, 2015) |
| "Osteoporosis is a systemic disease characterized by bone degradation and decreased bone mass that promotes increased bone fragility and eventual fracture risk." | ( Buzalaf, MA; Chiba, FY; de Cássia Alves Nunes, R; de Lima Coutinho Mattera, MS; Ervolino, E; Louzada, MJ; Pereira, AG; Pereira, RF; Silva, CA; Sumida, DH, 2016) |
| "Osteoporosis is a growing concern among people living with HIV (PLWH) because of the recognized risk of fractures, which bring with them morbidity and mortality." | ( Negredo, E; Warriner, AH, 2016) |
| "Osteoporosis is recognized as an issue for PLWH." | ( Negredo, E; Warriner, AH, 2016) |
| "Osteoporosis is one of the most frequent manifestations of systemic mastocytosis, particularly in adults." | ( Adami, S; Bonadonna, P; Gatti, D; Idolazzi, L; Kunnathully, V; Orsolini, G; Rossini, M; Tripi, G; Viapiana, O; Zamò, A; Zanotti, R, 2016) |
| "Male osteoporosis is a multifactorial disease, although it is often in part related to hypogonadism." | ( Weber, TJ, 2016) |
| "Osteoporosis is a common complication in patients with rheumatoid arthritis (RA)." | ( Chen, S; Gong, Y; Peng, J; Xiao, Z; Zeng, Q; Zhang, Y, 2016) |
| "Osteoporosis is common in Chinese patients with RA." | ( Chen, S; Gong, Y; Peng, J; Xiao, Z; Zeng, Q; Zhang, Y, 2016) |
| "Osteoporosis is a systemic skeletal disease characterized by low bone mass and micro-architectural deterioration of bone tissue with a consequent increase in bone fragility and susceptibility to fracture." | ( Bhardwaj, A; Osunkwo, I; Sinha, NK; Swe, KM, 2016) |
| "Osteoporosis is a bone pathology leading to increased fracture risk and challenging the quality of life." | ( Madhyastha, H; Madhyastha, R; Maruyama, M; Nakajima, Y; Pengjam, Y; Yamaguchi, Y, 2016) |
| "Osteoporosis is a degenerative bone disease commonly related to aging." | ( Barry, M; Cross, L; Gaharwar, AK; Pearce, H; Tatullo, M, 2016) |
| "Osteoporosis is a most frequent systemic skeletal disease characterized as low bone mineral density and microarchitectural deterioration of bone tissue, resulting in increased bone fragility and fracture risk." | ( Baloch, Z; Huo, Q; Ma, T; Shi, Q; Xie, Y; Zhou, H, 2017) |
| "Osteoporosis is one of the most prevalent skeletal system diseases." | ( Li, X; Yang, HL; Zhang, YY; Zhou, ZY, 2016) |
| "Osteoporosis is a disorder of bone in which the mass of the bone is reduced and the bone's architecture at the microscopic level is disordered." | ( Frassetto, LA; Sebastian, A, 2016) |
| "Osteoporosis is a systemic skeletal disease, which is characterized by a systemic destruction of bone mass and microarchitecture." | ( Bi, Y; Li, Y; Pu, W; Yan, Z; Yuan, X; Zhou, K, 2016) |
| "Osteoporosis is a significant health problem in the developing countries and its prevalence data are important for the estimation of health care burden and policy making." | ( Chin, KY; Ima-Nirwana, S; Kamaruddin, AA; Low, NY, 2016) |
| "Osteoporosis is defined by decreased bone density and microarchitectural deterioration that predispose to fragility fractures." | ( Matikainen, N, 2016) |
| "Osteoporosis is a common complication of chronic obstructive pulmonary disease (COPD)." | ( Kochetkova, E; Maistrovskaia, Y; Nevzorova, V; Ugay, L, 2016) |
| "Osteoporosis is a significant public health issue affecting over half of women aged over 50." | ( Chan, CK; Cooper, C; Dennison, E; Mason, A, 2016) |
| "Obesity and osteoporosis are often concurrently happened in the menopausal women." | ( Cui, L; Fu, Z; Huang, J; Huang, M; Lee, WYW; Li, G; Liang, Y; Lin, S; Suen, CW; Wu, H; Wu, T; Xu, L, 2016) |
| "Osteoporosis is more frequent in inflammatory bowel disease (IBD) patients." | ( Drwęska-Matelska, N; Eder, P; Kaczmarek-Ryś, M; Krela-Kaźmierczak, I; Linke, K; Marcinkowska, M; Michalak, M; Skrzypczak-Zielińska, M; Szymczak, A; Słomski, R; Wysocka, E; Łykowska-Szuber, L, 2016) |
| "Osteoporosis is a condition causing significant morbidity and mortality in the elderly population worldwide." | ( Chin, KY; Mohamad, NV; Soelaiman, IN, 2016) |
| "Osteoporosis is a chronic disease that impairs proper bone remodeling." | ( Beloti, MM; Bombonato-Prado, KF; de Almeida, AL; de Oliveira, FS; de Sousa, LG; Gimenes, R; Hallak Regalo, SC; Rosa, AL; Scalize, PH; Semprini, M; Siessere, S, 2016) |
| "Osteoporosis is a major health threat nowadays." | ( Kõks, S; Laius, O; Maasalu, K; Märtson, A, 2016) |
| "Osteoporosis is a complication of androgen deprivation therapy (ADT) in men with prostate carcinoma." | ( Balsano, M; Doria, C; Maestretti, G; Mosele, GR; Scarpa, RM; Solla, F, 2017) |
| "Postmenopausal osteoporosis is characterized by a reduction in the number of sinusoidal and arterial capillaries in the bone marrow and reduced bone perfusion." | ( Li, F; Lv, J; Ma, J; Ma, X; Song, N; Sun, L; Sun, X; Zhao, Z, 2017) |
| "Osteoporosis is a risk factor for implant fixation failure." | ( Ai, D; Bai, D; Han, X; Shu, R; Song, J; Zhao, M, 2017) |
| "Osteoporosis is a major skeletal disease with low bone mineral density, which leads to an increased risk of bone fracture." | ( Gao, Z; Gou, F; Guo, J; Li, J; Li, X; Liu, D; Tan, N; Wang, Z; Yang, S; Yokota, H; Zhang, J; Zhang, P; Zhao, X, 2017) |
| "Osteoporosis is a bone disease that afflicts millions of people around the world, and a variety of spinal integrity issues, such as degenerative spinal stenosis and spondylolisthesis, are frequently concomitant with osteoporosis and are sometimes treated with spinal interbody fusion surgery." | ( Chen, LH; Chen, WJ; Fu, TS; Ho, NY; Lai, PL; Niu, CC; Tai, CL; Tsai, TT, 2017) |
| "Osteoporosis is a systemic skeletal disorder characterized by low bone mineral density (BMD) that leads to an increase in bone fragility, causing an individual to be at an increased risk for fractures." | ( Bass, MA; Ford, MA; Garner, JC; Haskins, MA; Nahar, VK; Nelson, KM; Sharma, M, 2016) |
| "Osteoporosis is a serious health problem worldwide." | ( Fu, X; Jing, Y; Li, D; Liu, K; Shi, Q; Tao, Y; Yang, H; Zen, K; Zhang, C; Zhang, W; Zhang, Y; Zhao, H; Zhou, X, 2017) |
| "Osteoporosis is a metabolic skeletal disease characterized by an imbalance between osteoclast-mediated bone resorption and osteoblast-mediated bone formation." | ( Calignano, A; Corrado, B; Lama, A; Mattace Raso, G; Meli, R; Paciello, O; Pagano, TB; Pirozzi, C; Russo, S; Santoro, A, 2017) |
| "The treatment of osteoporosis is generally either by inhibition of bone resorption with antiresorptive agents or by stimulation of bone formation with anabolic agents." | ( Chew, CK; Clarke, BL, 2017) |
| "Prevalence of osteoporosis is increasing both in developed and developing countries." | ( Khashayar, P; Larijani, B; Salari, P; Tabatabaei-Malazy, O, 2017) |
| "Osteoporosis is found to have high prevalence after gastrectomy and therefore, it is important to prevent this condition by means of effective medication, such as alendronate sodium hydrate." | ( Akiyama, H; Endo, I; Izumisawa, Y; Kosaka, T; Kunisaki, C; Miyamoto, H; Sato, K; Sato, S; Suematsu, H; Taguri, M; Tanaka, Y; Yamanaka, T; Yukawa, N, 2017) |
| "Osteoporosis is characterised by trabecular bone loss resulting from increased osteoclast activation and unbalanced coupling between resorption and formation, which induces a thinning of trabeculae and trabecular perforations." | ( Abel, RL; Atwood, R; Bhattacharya, R; Boughton, OR; Cobb, JP; Goh, EL; Hansen, U; Jin, A; Karunaratne, A; Ma, S; Patel, B; Vo, NT, 2017) |
| "Osteoporosis is a common disease causing fracture in older populations." | ( Chen, S; Liu, J; Wang, Y; Wu, X; Xiang, T; Yang, Y; Zhou, H, 2017) |
| "It is known that osteoporosis is the most prevalent short-term complication in type 1 diabetes mellitus." | ( Gazzaruso, C; Montalcini, T; Pujia, A, 2017) |
| "Osteoporosis is a major public health problem associated with many factors, and it affects more than 50% of women over 50 years old." | ( Alp, HH; Başbugan, Y; Ediz, L; Huyut, Z; Şekeroğlu, MR; Yildirim, S, 2017) |
| "Osteoporosis is a disease characterized by structural deterioration of bone tissue, leading to skeletal fragility with increased fracture risk." | ( Chen, XY; Gao, CY; Gou, ZR; Ma, L; Mou, XZ; Ting, K; Wang, LH; Wang, XW; Xu, SZ; Yang, F; Yang, GJ; Yang, XY; Zhang, L; Zhang, XL; Zou, H, 2017) |
| "Osteoporosis is a serious public health concern worldwide." | ( He, S; Hu, J; Liu, W; Mao, Z; Ning, R; Yan, B; Yang, J; Zhan, Y, 2017) |
| "Osteoporosis is associated with widespread periodontitis and impaired periodontal healing." | ( Chen, Y; Du, Z; Jiang, J; Lin, M; Luo, K; Xiao, Y; Yan, F; Zheng, B, 2017) |
| "Osteoporosis is an emerging threat to patients with lipodystrophy." | ( Huang, L; Shi, H; Zhou, X, 2017) |
| "Osteoporosis is one of the most common diseases worldwide." | ( Gleitz, S; Hoffmann, DB; Komrakova, M; Kosinsky, RL; Menger, B; Nguyen, HH; Saul, D; Sehmisch, S; Wassmann, M, 2017) |
| "Osteoporosis is characterized by the imbalance of two relatively independent processes-osteoblastogenesis and osteoclastogenesis." | ( Bian, Z; He, Q; Li, M; Tian, F; Wang, X; Yao, W; Zhang, J; Zhu, L, 2017) |
| "Osteoporosis is a common bone disorder where the declined bone mass is far more than normal physiological status and usually associated with enhanced fracture risk, reduced bone strength and even deteriorated quality of life." | ( Hu, J; Huang, H; Huang, J; Tan, X; Xie, Y; Zou, P, 2017) |
| "Osteoporosis is a significant public health problem, and a major cause of the disease is estrogen deficiency following menopause in women." | ( Khosla, S; Monroe, DG, 2018) |
| "In old age, osteoporosis is associated with a substantial burden in terms of morbidity and mortality." | ( Flamaing, J; Gielen, E; Luyten, FP; Vandenbroucke, A, 2017) |
| "Osteoporosis is a common skeletal disease with serious consequences due to osteoporotic fractures and high costs to society for post-fracture care." | ( Lewiecki, EM; Lovato, C, 2017) |
| "Osteoporosis is characterized by low bone mass and qualitative structural abnormalities of bone tissue, leading to increased bone fragility that results in fractures." | ( Cipriani, C; Minisola, S; Occhiuto, M; Pepe, J, 2017) |
| "Osteoporosis is characterized by a reduction in bone mass and bone mineral density, which weakens the bone." | ( Wang, S; Wang, X; Yan, C; Zhang, D; Zhang, M, 2017) |
| "Osteoporosis is one of the most prevalent forms of age-related bone diseases." | ( Antika, LD; Choi, YJ; Kang, MK; Kang, YH; Kim, DY; Kim, YH; Lee, EJ; Oh, H; Park, SH, 2017) |
| "Idiopathic juvenile osteoporosis is a primary osteoporosis of unknown aetiology present in previously well children and is a diagnosis of exclusion." | ( Lim, SY; Tan, LO; Vasanwala, RF, 2017) |
| "BACKGROUND Osteoporosis is diagnosed by bone loss using a radiological parameter called T-score." | ( Böcker, W; Daghma, DES; El Khassawna, T; Engelhardt, M; Heiss, C; Ivo, M; Kauschke, V; Kern, S; Lips, KS; Malhan, D; Rezwan, K; Schmitt, J; Stoetzel, S; Tushtev, K, 2017) |
| "Osteoporosis is a major health problem in postmenopausal women and the elderly that leads to fractures associated with substantial morbidity and mortality." | ( Chen, TH; Chen, WY; Chien, JL; Chou, SJ; Chu, TH; Lu, KC; Shyu, JF; Wang, JW; Yeh, CB; Yen, MH, 2018) |
| "Osteoporosis is a disease characterized by low bone mass and progressive destruction of bone microstructure, resulting in increasing the risk of fracture." | ( Cui, YL; Li, H; Li, RX; Liu, TJ; Lu, YR; Wang, GF; Wang, QS; Zhang, CQ; Zhang, XZ, 2018) |
| "Regional migratory osteoporosis is a rare, but probably underdiagnosed condition with an unclear etiology." | ( Bours, S; Peeters, HRM; Spierings, J, 2018) |
| "Osteoporosis is a common disease characterised by reduced bone mass and an increased risk of fragility fractures." | ( Beattie, JR; Bell, SEJ; Brennan, O; Caraher, MC; Cummins, NM; Idris, AI; O'Brien, FJ; O'Driscoll, O; Ralston, SH; Sophocleous, A; Towler, M, 2018) |
| "Osteoporosis is a progressive bone disorder characterised by imbalance between bone building (anabolism) and resorption (catabolism)." | ( Cook, AE; Diepenhorst, N; Langmead, CJ; Pastoureau, P; Rueda, P; Sabatini, M, 2018) |
| "Osteoporosis is a bone disease characterized by reduced bone mass, which leads to increased risk of bone fractures, and poses a significant risk to public health, especially in the elderly population." | ( Peng, S; Wang, D; Wang, Z; Yang, D; Zhang, J; Zhen, W, 2018) |
| "Osteoporosis is an aging process of skeletal tissues with characteristics of reductions in bone mass and microarchitectural deterioration of bone tissue." | ( Hu, ZQ; Tang, YH; Xin, DW; Xiong, ZF; Xu, CD; Yue, ZS; Zeng, LR, 2018) |
| "Postmenopausal osteoporosis is a highly prevalent disease." | ( Cano, A; Chedraui, P; Goulis, DG; Lambrinoudaki, I; Lopes, P; Mishra, G; Mueck, A; Rees, M; Senturk, LM; Simoncini, T; Stevenson, JC; Stute, P; Tuomikoski, P, 2018) |
| "Osteoporosis is often accompanied by sarcopenia." | ( Ahrabi, A; Böker, KO; Harlas, B; Hoffmann, DB; Komrakova, M; Kosinsky, RL; Saul, D; Sehmisch, S; Wassmann, M; Wigger, R, 2018) |
| "Postmenopausal osteoporosis is a common systemic skeletal disease that is associated with estrogen‑deficiency." | ( Liu, X; Lu, E; Mao, C; Qin, A; Xu, X; Zhang, X, 2018) |
| "Osteoporosis is a global public health concern and, it can result from numerous pathogenic mechanisms, many of which are closely related with age, nutritional disorders, endocrine imbalance, or adverse drug side effects presented by glucocorticoids, heparin, and anti-epileptics." | ( Huang, Y; Leng, B; Li, X; Lin, J; Mei, X; Pan, Y; Qiu, J; Su, Y; Xing, C; Xu, J; Xue, Y; Zhang, W, 2018) |
| "Osteoporosis is a disease characterized by low bone mass, most commonly caused by an increase in bone resorption that is not matched by sufficient bone formation." | ( Han, JJ; Kim, D; Kim, J; Kim, MS; Koo, MA; Kwon, BJ; Lee, MH; Park, JC; Seon, GM, 2018) |
| "Osteoporosis is a metabolic bone disease characterized by low bone mass and micro-architectural deterioration of bone, for which the underlying mechanism is an imbalance between bone resorption and bone remodeling." | ( Chen, X; Hu, HG; Li, Q; Li, X; Liu, C; Su, J; Weng, W; Zhi, X; Zou, Y, 2018) |
| "Culprits of osteoporosis are no longer a matter of speculation based on in vitro observations." | ( Manolagas, SC, 2018) |
| "Osteoporosis is a frequent disease among the elderly especially in postmenopausal women." | ( Wan, JB; Wang, C; Wang, Y; Yan, C; Zhang, D; Zhang, M; Zhang, Q, 2018) |
| "Osteoporosis is a skeletal disorder characterized by diminished bone strength that increases the risk of fracture at instances of trivial trauma." | ( Arora, D; Arora, M; Chawla, J; Sharma, N; Shukla, L, 2018) |
| "Osteoporosis is a frequent complication in patients with chronic liver disease, especially in end-stages and in chronic cholestasis, in addition to non-alcoholic fatty liver disease, haemochromatosis and alcoholism." | ( Guañabens, N; Parés, A, 2018) |
| "Osteoporosis is linked to reduced bone mineral density (BMD) as a major risk factor for fragility fractures." | ( Chai, Y; Hu, C; Lu, S; Wang, Y; Zhong, W; Zhu, Y, 2018) |
| "Osteoporosis is characterized by a reduction of the bone mineral density (BMD) and microarchitectural deterioration of the bone, which lead to bone fragility and susceptibility to fracture." | ( Hong, SG; Hwang, YH; Kim, KJ; Kim, SJ; Mun, SK; Son, YJ; Yee, ST, 2018) |
| "Postmenopausal osteoporosis is a global health issue." | ( Shan, BC; Wang, L; Wang, S; Wang, X; Xu, YJ; Yang, F; Yuan, Y; Zhang, H; Zhang, P; Zhou, ZQ, 2018) |
| "Key Points Osteoporosis is common, difficult to detect and usually untreated." | ( Almqvist, EG; Boström, KB; Dalemo, S; Eggertsen, R; Hjerpe, P, 2018) |
| "Osteoporosis is difficult to treat and is still incurable, and thus prevention is critically important." | ( John Cecily, HS, 2020) |
| "Osteoporosis is a chronic disease in which the skeleton loses a weighty proportion of its mineralized mass and mechanical pliability." | ( Abdallah, HM; Abdel-Naim, AB; Al-Abbasi, FA; Al-Abd, AM; Algandaby, MM; Alghamdi, AA; Eid, BG; El-Halawany, AM, 2018) |
| "Osteoporosis is a debilitating skeletal side effect of androgen deprivation therapy based on gonadotropin-releasing hormone (GnRH) agonist in men." | ( Chin, KY; Mohamad, NV; Soelaiman, IN, 2018) |
| "Osteoporosis is a silent skeletal disease characterized by low bone mass and destruction of skeletal microarchitecture, leading to an increased fracture risk." | ( Chin, KY; Ghafar, NA; Hasan, WNW; Jolly, JJ; Soelaiman, IN, 2018) |
| "Diabetes-associated osteoporosis is mainly caused by the formation and accumulation of advanced glycation end products (AGEs)." | ( Chen, H; Cheng, YZ; Wang, JY; Wang, LT; Yang, L; Yang, SL; Ye, M; Zhang, H; Zhuo, XY, 2018) |
| "Postmenopausal osteoporosis is a common disorder accompanied with estrogen deficiency in women." | ( Elfiky, AA; Sayed, AA, 2018) |
| "Postmenopausal osteoporosis is closely related with the increase of reactive oxygen species and the decrease of antioxidant levels." | ( Bai, XC; Gu, WQ; Li, M; Liu, J; Xia, Y; Xiao, X; Zhao, YY; Zhou, XJ, 2018) |
| "Osteoporosis is defined as a loss of bone mass and deterioration of its architecture resulting in bone weakness, which becomes prone to fracture." | ( Liu, X; Xu, X, 2018) |
| "Post-menopausal osteoporosis is a bone formation disorder induced by estrogen deficiency." | ( Fu, X; Shao, B; Yang, D; Yu, Y, 2018) |
| "Osteoporosis is one of the most common skeletal disorders affecting a significant percentage of people worldwide." | ( Calciolari, E; Dereka, X; Donos, N; Mardas, N, 2018) |
| "Osteoporosis is a multifactorial disease with a strong genetic influence." | ( Abedian, Z; Akhavan-Niaki, H; Amjadi-Moheb, F; Eftekhari, H; Heidari, L; Hosseini, SR; Mafi Golchin, M; Mousavi Kani, SN; Nooreddini, H; Pourbagher, R; Pourreza Baboli, H, 2018) |
| "Osteoporosis is a bone disorder characterized by bone loss and decreased bone strength." | ( Areeckal, AS; Kamath, J; Kocher, M; S, SD; Zawadynski, S, 2018) |
| "Osteoporosis is a major debilitating cause of fractures and decreases the quality of life in elderly patients." | ( Challa, VS; Guntuku, L; Naidu, VGM; Ramavat, RN; Thummuri, D, 2018) |
| "Osteoporosis is one of the major health problems worldwide." | ( Das, N; Gupta, T; Imran, S, 2019) |
| "BACKGROUND Osteoporosis is a major health risk for women worldwide." | ( Fang, J; Gao, K; Huang, C; Li, H; Zhu, J, 2018) |
| "Osteoporosis is a major health issue, especially in older women." | ( Kalkan, R; Tulay, P, 2018) |
| "Osteoporosis is observed in TI and TM." | ( Alfaqih, MA; Alqudah, S; Barqawi, M; Bashir, N; Khader, Y; Saadeh, R, 2018) |
| "Osteoporosis is an important health problem in India owing to the prevalence of vitamin D deficiency across all ages, low level of awareness and higher risk of complications." | ( Ahmad, I; Arshad, MD; Das, SK; Jafar, T; Mahdi, AA; Mahdi, F; Rizvi, I; Waliullah, S, 2016) |
| "Osteoporosis is a systemic skeletal disorder characterizedby reduced bone mass, deteriorated bone structure." | ( Chen, C; Wang, J; Wu, Y; Xing, X; Ye, S, 2019) |
| "Osteoporosis is a systemic bone disease which leads to a reduction in bone mass." | ( Al-E-Ahmad, A; Faghihzadeh, S; Fathi, M; Hosseini, SR; Mosapour, A; Nooreddini, HG; Parsian, H, 2018) |
| "Osteoporosis is the most common bone disease in humans." | ( Aly, H; Bhattacharya, P; Chiocca, EA; Cui, Y; Fu, J; Jiang, J; Johnson, MD; Lawler, SE; Liu, Y; Luo, C; Ma, H; Reiter, RJ; Rozental, R; Wang, X; Yang, H; Yang, Q; Yao, J; Zhang, X; Zhou, S, 2019) |
| "Osteoporosis is the most common osteolytic disease characterized by excessive osteoclast formation and resultant bone loss, which afflicts millions of patients around the world." | ( Cao, Z; Chen, K; Jin, H; Kenny, J; Liu, Q; Liu, Y; Tickner, J; Wang, Q; Wang, Z; Xu, H; Xu, J; Xu, K; Yao, L, 2019) |
| "Osteoporosis is defined by low bone mineral density (BMD), which is mainly due to the imbalances in osteoclast and osteoblast activity." | ( Chang, WC; Chen, BK; Cho, EC; Hsu, YW; Hung, KS; Ikegawa, S; Liao, HT; Lu, HF; Wong, HS, 2018) |
| "Osteoporosis is a common bone disorder that increases susceptibility to fragility bone fractures." | ( Jalali, RK; Jha, S; Kaushal, N; Vohora, D, 2019) |
| "Osteoporosis is characterized by decrease in bone mass and microarchitectural changes in the bone that increases fracture risk." | ( Dasarathy, J; Labrador, H, 2018) |
| "Osteoporosis is a condition characterized by decreased bone density and bone strength, commonly observed among older individuals." | ( Chen, B; Lin, FF; Liu, Y; Lu, QP; Qiu, YR; Xiao, B; Yang, J; Yang, RB; Zhang, MH; Zheng, K, 2019) |
| "Osteoporosis is a bone metabolic disease that affects mostly post-menopausal women." | ( da Cunha, M; de Siqueira, D; Eis, SR; Gomes-Rochette, NF; Graceli, JB; Miguel, EC; Neto, HAR; Oliveira, ALA; Pedrosa, DF; Rangel, LBA; Resgala, LCR; Santana, HS; Silva, IV; Soares, ODR, 2018) |
| "Osteoporosis is a form of osteolytic disease caused by an imbalance in bone homeostasis, with reductions in osteoblast bone formation, and augmented osteoclast formation and resorption resulting in reduced bone mass." | ( Chen, L; He, W; Hong, Z; Kuek, V; Liu, Y; Shao, M; Sun, Y; Tickner, J; Wang, C; Wang, H; Xu, J; Yang, F; Zhou, C; Zou, X, 2019) |
| "Osteoporosis is the most common metabolic bone disease and a major public health problem worldwide." | ( Cheng, L; Zhang, K; Zhang, Z, 2018) |
| "Osteoporosis is a common complication of cerebral palsy and Rett's syndrome." | ( Brezin, F; Dousset, B; Feillet, F; Hernandez, M; Lambert, L; Renard, E; Weryha, G; Wiedemann, A, 2019) |
| "Osteoporosis is a disorder categorized based on the bone mineral density (BMD) and an alteration in the bone micro-architecture had been considered as the major determinant for increasing the fracture risk." | ( Hu, Z; Tang, Y; Xiong, Z; Yue, Z; Zheng, W, 2019) |
| "Osteoporosis is a metabolic bone lesion in which the bone mass is reduced per unit volume due to increased bone resorption." | ( Chen, X; Guo, S; Li, S; Liu, B; Liu, T; Ouyang, Z; Peng, D; Shen, Y; Wan, L; Yin, Z; Zhang, Q; Zhu, W, 2019) |
| "BACKGROUND Osteoporosis is a common disorder leading to bone loss." | ( Dai, X; Ding, W; Shang, X; Zhu, D; Zhu, W, 2019) |
| "Osteoporosis is a systemic skeletal disease of fragility fractures due to the loss of mass and deterioration of the microarchitecture of bone." | ( Bi, DD; Guo, YF; Han, MH; Hao, T; Liu, H; Qi, XY; Wang, XG; Wang, XT; Zhang, BX, 2019) |
| "Osteoporosis is a bone-incapacitating malady and it is characterized by obvious bone mass loss and bone microarchitecture deterioration." | ( Bian, T; Huang, J; Li, C; Liu, Z; Lyu, J; Pi, F; Sun, X; Wei, J; Zhong, Z, 2019) |
| "Osteoporosis is a chronic condition and long-term, sometimes lifelong, management is required." | ( Compston, JE; Leslie, WD; McClung, MR, 2019) |
| "Osteoporosis is a common comorbidity in non-cystic fibrosis (non-CF) bronchiectasis patients." | ( Chung, FT; Huang, HY; Lin, CW; Lo, CY; Pan, YB; Sheng, TF; Wang, CH; Wang, TW; Yang, LY, 2019) |
| "Osteoporosis is a chronic bone lytic disease, because of inadequate bone ossification and/or excessive bone resorption." | ( Chen, L; Feng, H; Li, Z; Lian, Z; Lin, X; Liu, Q; Song, F; Wang, X; Xie, D; Xu, J; Yao, G; Yuan, G; Zheng, J; Zhou, M, 2019) |
| "Osteoporosis is a systemic skeletal disease that causes bone weakness and fragility." | ( Katsuzaki, H; Kuriya, K; Nishio, M; Nishise, M; Okamoto, H; Umekawa, H; Wada, S, 2019) |
| "Osteoporosis is a multifactorial disease in which genetic factors and epigenetic modifications play a major role." | ( Ashma, R; Raje, MM, 2019) |
| "Osteoporosis is a common disorder of bone remodeling, marked by excessive osteoclast formation." | ( Han, SY; Kim, YK, 2019) |
| "Osteoporosis is a disease that is characterized by deterioration of bone tissue and increased risk of fracture as it leads to a decrease in bone mineral density, which is an important public health problem." | ( Inal Kabala, S; Ozcan, HM; Yagar, H, 2019) |
| "Male osteoporosis is a significant but undetermined healthcare problem." | ( Chin, KY; Ima-Nirwana, S, 2019) |
| "Osteoporosis is common in total joint arthroplasty (TJA) patients and likely contributes to the increasing incidence of periprosthetic fracture." | ( Anderson, PA; Bernatz, JT; Binkley, NC; Brooks, AE; Illgen, RI; Squire, MW, 2019) |
| "Osteoporosis is a worldwide epidemic but pharmacological agents to stimulate new bone formation are scarce." | ( Burkhart, C; Haberhauer, G; Heusch, G; Keul, P; Levkau, B; Manthe, K; Vaidya, M; von Wnuck Lipinski, K; Weske, S, 2019) |
| "Osteoporosis is a systemic disease with progressive bone loss." | ( Yang, DH; Yang, MY, 2019) |
| "Diabetic osteoporosis is a severe public health concern in the world." | ( Guo, CJ; Hong, RH; Liang, YM; Pan, HS; Xie, JJ; Zhang, FG, 2019) |
| "Osteoporosis is a common health problem in India, which leads to significant morbidity and mortality in elderly individuals." | ( Asha, HS; Cherian, KE; Kapoor, N; Kuriakose, C; Paul, TV; Thakur, P, 2020) |
| "Osteoporosis is the most common disease involving bone degeneration." | ( Lozano, D; Manzano, M; Mora-Raimundo, P; Vallet-Regí, M, 2019) |
| "Osteoporosis is a prevalent condition among postmenopausal women, and lacks satisfactory therapeutic options." | ( Chen, G; Pan, L; Sun, J; Wang, S; Wu, G, 2019) |
| "Osteoporosis is manifested by reduced bone mass." | ( Cheng, L; Wang, F; Wang, L; Wang, N; Zhang, B, 2019) |
| "Osteoporosis is an ageing disease characterized by elevated osteoclastic bone resorption resulting in bone loss, decrease bone strength, and elevated incidence of fractures." | ( Chen, L; Chen, S; Chen, Y; Cheng, X; Chu, B; Guo, D; Hong, D; Hong, Z; Li, Z; Wang, J, 2019) |
| "Osteoporosis is a growing health problem in Asian countries with a rapidly expanding aging population." | ( Aziz, NA; Chan, CY; Chin, KY; Fairus, A; Ima-Nirwana, S; Mohamed, N; Mohd Rizal, AM; Muhammad, N; Ng, PY; Nor Aini, J; Subramaniam, S, 2019) |
| "Osteoporosis is one of the most frequent diseases related with age." | ( Chen, C; Hu, J; Liang, J; Liu, H; Liu, X; Zhao, H, 2019) |
| "Osteoporosis is a common skeletal disorder resulting in elevated fracture risk." | ( Chen, L; Gan, N; Shao, B; Yang, D; Yu, Y; Zheng, X, 2019) |
| "Osteoporosis is a clinical condition characterized by low bone strength that leads to an increased risk of fracture." | ( Choi, Y; Kim, JK; Kim, P; Kim, WJ; Lee, G; Lee, JS; Nam, YJ; Seo, JH; Song, MJ; Yang, J; Yi, SS, 2019) |
| "Osteoporosis is an abnormal bone remodeling condition characterized by decreased bone density, which leads to high risks of fracture." | ( Choi, CW; Huh, D; Jeong, SY; Jin, HS; Jo, M; Kim, J; Kim, MC; Lee, JW; Lee, SW; Li, WY; Park, E; Park, JH; Park, S; Yeo, S, 2019) |
| "Osteoporosis is a common metabolic bone disease that is often seen in bedridden patients and astronauts." | ( Gao, X; Qu, H; Wang, Z; Yi, J; Zhao, H, 2019) |
| "Osteoporosis is a skeletal disease with decreased bone mass and alteration in microarchitecture of bone tissue, and these changes put patients in risk of bone fracture." | ( Lu, HX; Wang, J, 2019) |
| "Osteoporosis is closely associated with the dysfunction of bone metabolism, which is caused by the imbalance between new bone formation and bone resorption." | ( Bamba, D; Bi, Z; Cai, B; Ding, F; Feng, C; Fu, Y; Gao, M; Gong, R; He, M; Huang, Q; Jin, M; Li, Y; Liu, T; Ma, W; Reiters, R; Sukhareva, N; Sun, Y; Xu, C; Yan, G; Yang, F; Yang, L; Yuan, Y; Zhang, L, 2019) |
| "BACKGROUND Osteoporosis is a common osteopathy, resulting in fractures, especially in elder people." | ( Ma, ZP; Yang, Y; Yang, YF; Zhang, ZF, 2019) |
| "Osteoporosis is characterized by a progressive increase in bone fragility, leading to low bone mass and structural deterioration of bone tissue." | ( Chu, C; Hao, W; Mao, Z; Su, H; Zhu, Y, 2019) |
| "Osteoporosis is characterized by low bone mass and density, as well as change in microarchitecture of bone tissue leading to decreased bone strength." | ( Amelia, Y; Ernanda, SA; Jonatan, A; Juwono, MA; Kartikaningtyas, AN; Maulidya, E; Parhusip, YM; Sananta, P, 2019) |
| "Osteoporosis is a continuous process of loss of bone tissue." | ( Chang, WH; Chen, RM; Lee, YW; Liu, SH; Wang, JL; Wang, W; Yeh, PS, 2019) |
| "Postmenopausal osteoporosis is a common condition characterized by the increase and activation of osteoclasts." | ( Guo, TM; Liu, GX; Qiao, XM; Xing, YL; Yang, L; Zhu, HY, 2019) |
| "Osteoporosis is a chronic, progressive disease in which early diagnosis is very important." | ( Cao, Y; Gao, K; Li, H; Li, Q; Liu, W; Ma, D; Yu, W; Zhu, W, 2019) |
| "Osteoporosis is one of the most commonly diagnosed age-related bone diseases worldwide, and it is also one of the leading causes of fracture." | ( Ding, S; Ding, W; Hu, P; Li, J; Pan, L; Peng, Z; Zhang, T, 2019) |
| "Osteoporosis is a chronic disease whose symptoms include a reduction in bone strength, osteopenia, and damage to the bone microstructure." | ( Hou, T; Yang, X; Zhang, L, 2019) |
| "Osteoporosis is a common bone disease resulting from imbalance between bone formation and bone resorption." | ( Ahn, CB; Hyung, JH; Je, JY; Oh, Y, 2019) |
| "Osteoporosis is highly prevalent in older persons." | ( Al Saedi, A; Duque, G; Nurgali, K; Sharma, S; Summers, MA, 2020) |
| "Postmenopausal osteoporosis is a common and disabling disorder that increases the risk of bone fractures due to estrogen deprivation; this can be simulated in rats by ovariectomy." | ( Abdel-Naim, AB; Barakat, BM; Elshaer, SS; Fayed, HA; Menze, ET, 2019) |
| "Osteoporosis is a skeleton disease affecting 55% of people over age 60, and the number is still increasing due to an ageing population." | ( Hu, H; Li, ZH; Liao, MM; Liu, GD; Ran, B; Wu, YC; Zhang, PG; Zhang, XY, 2020) |
| "Osteoporosis is a skeletal disorder commonly found among the elderly, in which the bones become weak, brittle, and more susceptible to fracture." | ( Abd Aziz, N; Chan, CY; Chin, KY; Fairus, A; Ima-Nirwana, S; Jamil, NA; Mohamed, N; Muhammad, N; Ng, PY; Subramaniam, S, 2019) |
| "Osteoporosis is a bone disease characterized by microarchitectural deterioration, low bone mass, and increased risk of fractures." | ( Jin, Y; Li, L; Ma, C; Tang, Y; Xu, Y; Yang, J, 2019) |
| "Osteoporosis is the most widespread metabolic bone disease characterized by decreased bone mass and bone quality, and its diagnosis and treatment remains challenging." | ( Cai, J; He, B; Wei, J; Wu, T; Zheng, H, 2020) |
| "Osteoporosis is widely regarded as one of the typical aging-related diseases due to the impairment of bone remodeling." | ( Guo, L; Jiang, T; Wang, Y; Yang, X, 2019) |
| "Osteoporosis is an age-related deterioration in bone health that is, at least in part, a stem cell disease." | ( Aguilar-Perez, A; Barrett, T; Bragg, RT; Eisa, N; Elmansi, A; Fulzele, S; Hamrick, M; Hill, W; Isales, C; Kondrikov, D; Kondrikova, G; Lawrence, MM; Mobley, T; Schoeinlein, P; Shi, XM, 2020) |
| "Osteoporosis is caused by disturbance in the dynamic balance of bone remodelling, a physiological process, vital for maintenance of healthy bone tissue in adult humans." | ( Bai, B; Chen, L; Shen, Z; Tang, J; Wang, B; Weng, S; Wu, ZY; Xie, Z; Yan, DY; Yang, L, 2020) |
| "Osteoporosis is also associated with abnormalities of the kynurenine pathway, reflected in an inversion of the ratio between blood levels of the metabolites anthranilic acid and 3-hydroxy-anthranilic acid." | ( Clanchy, FI; Huang, YS; Ogbechi, J; Stone, TW; Topping, LM; Williams, RO, 2020) |
| "Osteoporosis is a chronic bone metabolism disorder affecting millions of the world population." | ( Li, TT; Tzeng, CM; Wang, HL; Yang, F; Zhao, Y, 2020) |
| "Osteoporosis is a metabolic disease characterized by reduced osteoblast differentiation and proliferation." | ( Hu, M; Li, Y; Liu, X; Lu, W; Wang, D; Zhang, X; Zhang, Y, 2020) |
| "Osteoporosis is a devastating disease that features reduced bone quantity and microstructure, which causes fragility fracture and increases mortality, especially in the aged population." | ( Feng, H; Fu, F; Hu, X; Li, Z; Lin, X; Liu, Q; Shao, S; Song, F; Xu, J; Yuan, G; Zhao, J; Zhou, M, 2020) |
| "BACKGROUND Osteoporosis is a metabolic osteopathy characterized by abnormal bone mass and microstructure that has become a public health problem worldwide." | ( Dai, W; Sun, Y; Zhong, G, 2020) |
| "Osteoporosis is the most common condition contributing to 95% of fractures in older patients hospitalized for fracture treatment." | ( Bail, HJ; Gosch, M; Grueninger, S; Kammerlander, C; Stumpf, U; Wicklein, S, 2020) |
| "Osteoporosis is a severe health problem causing bone fragility and consequent fracture." | ( Chen, L; Fang, K; Hong, C; Shen, L; Shen, Z; Tang, J; Wang, B; Weng, S; Wu, Z; Xie, J; Xie, Z; Yan, D; Yang, L, 2020) |
| "Osteoporosis is a progressive systemic disease characterized by low bone mineral density and deterioration of bone microarchitecture." | ( Zhang, J, 2020) |
| "Osteoporosis is a very common disease all over the world, in which a reduction in bone density can lead to an increased risk of fractures and a diminished physical height." | ( Bender, T; Conrad, R; Emmert, D; Heuchemer, L; Kasapovic, A; Marinova, M; Mücke, M; Rasche, T, 2020) |
| "Osteoporosis is a common chronic disease in the elderly population and in some domestic animals." | ( Hu, Y; Huang, J; Tong, X; Yu, Z; Zhang, L; Zhou, Z, 2020) |
| "Osteoporosis is the most widespread metabolic bone disease which represents a major public health burden." | ( Boccaccini, AR; Camargo, WA; Detsch, R; Diba, M; Grünewald, A; Kabiri, Y; Kentgens, APM; Leeuwenburgh, SCG; van den Beucken, JJJP; Zinkevich, T, 2019) |
| "Pharmacotherapy of osteoporosis is the main treatment option for these patients because of strong evidence about the efficacy of available drugs targeting bone metabolism." | ( Gimigliano, F; Iolascon, G; Liguori, S; Moretti, A; Paoletta, M; Toro, G, 2020) |
| "Osteoporosis is commonly underdiagnosed and undertreated." | ( Chuah, SL; Lau, BK; Lee, HK; Leong, TS; Tan, FHS; Teh, CL; Wan, SA, 2020) |
| "Osteoporosis is primarily asymptomatic, and patients with OP suffer from pain, inconvenience, economic pressure and osteoporotic fracture (OPF)." | ( Chen, R; Lee, WH; Shen, ZQ; Sun, Y; Zhao, HB; Zhu, D, 2020) |
| "Osteoporosis is a metabolic bone disease characterized by low bone density resulting in increased fracture susceptibility." | ( Aglan, HA; Ahmed, HH; Ali, MAM; Amr, KS; Mahmoud, NS; Mohamed, MR, 2020) |
| "Osteoporosis is a metabolic disease that affects bone tissue and is highly associated with bone fractures." | ( Barrioni, BR; Martins, T; Mosqueira, L; Ocarino, NM; Pereira, MM; Serakides, R, 2020) |
| "Osteoporosis is a common metabolic bone disorder in the elderly population." | ( Chi, X; Han, Y; Li, F; Li, Z; Qin, Y; Wang, Y; Xiao, J; Xie, W, 2020) |
| "Osteoporosis is a chronic condition that reflects reduced bone strength and an associated increased risk for fracture." | ( Bauer, DC; Clarke, BL; Drake, MT; Tsourdi, E; Yu, EW, 2020) |
| "Postmenopausal osteoporosis is very common in women." | ( Chen, Y; Hu, X; Xia, C; Xie, Z; Yang, M; Zhang, Y, 2020) |
| "Osteoporosis is common in postmenopausal women and elderly people." | ( Chien, RC; Huang, CW; Lin, IJ; Liu, YM; Mau, CZ; Mau, JL, 2020) |
| "Most patients with osteoporosis are postmenopausal women or elderly people with hypoimmunity, so the osteoporosis clinic has become a new hotspot for corona virus infection." | ( Niu, JJ; Shi, JW; Song, DW; Yang, HL; Zou, J, 2020) |
| "Osteoporosis is one of the major health issues associated with menopause-related estrogen deficiency." | ( Chin, KY; Ima-Nirwana, S; Mohamad, NV, 2020) |
| "Osteoporosis is a metabolic bone disease that is characterized by decreased bone density and strength due to excessive loss of bone protein and mineral content, which can be induced by increased osteoclast activity." | ( Huang, MZ; Ning, X; Shang, XW; Shen, ZM; Zhang, H; Zhuang, Y, 2020) |
| "Osteoporosis is a chronic disease of low bone mass and fragility." | ( Goetz, V; Homik, J; Kendler, D; Koller, G; McAlister, FA; Vandermeer, B; Ye, C, 2020) |
| "Osteoporosis is a common and debilitating condition characterized by diminished bone mass and architecture leading to bone fragility." | ( Anderson, PA; Freedman, BA; Thompson, JC; Wanderman, N, 2020) |
| "Osteoporosis is a major problem in patients with Duchenne muscular dystrophy (DMD), due to glucocorticoid therapy and muscle weakness." | ( Hornung, L; Khoury, JC; Rutter, MM; Rybalsky, I; Shellenbarger, KC; Tian, C; Wong, BL, 2020) |
| "Osteoporosis is a common complication in patients with primary biliary cholangitis." | ( Combalia, A; Guañabens, N; Jurado, S; Monegal, A; Parés, A; Peris, P; Ruiz-Gaspà, S, 2020) |
| "Osteoporosis is a bone disease affecting more than 2 million people comprising 1 in 3 women and 1 in 5 men in Canada." | ( Arora, H; Bhullar, KS; Shang, N; Wu, J, 2020) |
| "Osteoporosis is a systemic disease that typically affects older adults and that remains a major threat to global public health owing to its high morbidity and mortality rates." | ( Bao, Y; Lv, X; Ma, B; Tang, Y; Wang, G; Wang, J; Wen, X; Zhang, J, 2020) |
| "Osteoporosis is a common bone disorder with adverse effects on oral osseointegration, and the effects of metformin on bone metabolism have received increasing attention." | ( Du, S; Jiang, H; Lin, J; Shen, X; Xu, R, 2020) |
| "Osteoporosis is a degenerative disease characterized by reduced bone mass, in which deregulated bone remodeling by osteoclasts and osteoblasts is a main pathogenesis." | ( Bae, EJ; Choi, S; Moon, YJ; Park, BH; Ryoo, GH; Ryu, JH, 2020) |
| "Osteoporosis is the most common metabolic bone disease." | ( Huang, N; Li, H; Shao, B; Wu, Y; Yuan, Q; Zhao, Q, 2020) |
| "Osteoporosis is a global chronic disease characterized by severe bone loss and high susceptibility to fragile fracture." | ( Chen, K; Chen, P; Fan, S; Gu, C; Li, M; Lin, X; Liu, X; Liu, Z; Pan, H; Tang, R; Tang, Z; Wang, Q, 2020) |
| "Osteoporosis is the most prevalent metabolic bone disease and one of the most important postmenopausal consequences." | ( Koohpeyma, F; Mostafavi-Pour, Z; Savardashtaki, A; Vakili, S; Zal, F, 2021) |
| "Osteoporosis is characterised by impairment of microarchitecture and bone mass." | ( Dong, LQ; Wu, LG; Xu, C; Zeng, HB; Zhao, XH, 2020) |
| "Osteoporosis is an age-related disease caused by imbalanced bone remodeling resulting from excessive bone resorption." | ( Hong, HS; Hwang, DY; Park, JS; Piao, J; Son, Y, 2020) |
| "Osteoporosis is a threat to aged people who have excessive osteoclast activation and bone resorption, subsequently causing fracture and even disability." | ( Chen, Y; Deng, W; Ding, Z; Jie, L; Ke, M; Li, X; Qu, Y; Tan, Y; Yang, Q; Yu, Q; Zheng, J; Zou, B, 2021) |
| "Osteoporosis is a bone disease that mainly affects older people and postmenopausal women." | ( Oryan, A; Sahvieh, S, 2021) |
| "Osteoporosis is a major systemic disease that can significantly deteriorate the quality of life of the affected individuals." | ( Katz, J; Rotstein, I, 2021) |
| "Osteoporosis is a common metabolic bone disease with high prevalence." | ( Gao, YM; Ni, L; Shi, F, 2022) |
| "Age-related osteoporosis is characterized by the deterioration in bone volume and strength, partly due to the dysfunction of bone marrow mesenchymal stromal/stem cells (MSCs) during aging." | ( Chen, Y; Deng, P; Guo, Y; Li, Q; Lin, W; Liu, W; Liu, Y; Ou, G; Qi, X; Wang, C; Wang, Y; Wu, Y; Yuan, Q; Zhang, S; Zheng, X; Zhou, L, 2020) |
| "Osteoporosis is a disease characterized by low bone mass and an increased risk of fractures." | ( Burger, C; Gravius, S; Haddouti, EM; Hilgers, C; Masson, W; Pflugmacher, R; Randau, TM; Schildberg, FA, 2020) |
| "Osteoporosis is a major cause of morbidity and mortality worldwide and its prevention in order to avert fractures was considered of great importance in maintaining well-being and independence among the elderly." | ( Ringe, JD, 2020) |
| "Osteoporosis is a disease in which bone mineral density decreases due to abnormal activity of osteoclasts, and is commonly found in post-menopausal women who have decreased levels of female hormones." | ( Bae, YS; Cho, KM; Choi, CY; Kim, H; Kim, HH; Kim, KK; Kim, MK; Lee, HY; Lee, M; Park, JS, 2021) |
| "Background-Osteoporosis is characterized by defects in both quality and quantity of bone tissue, which imply high susceptibility to fractures with limitations of autonomy." | ( Beretti, F; Bertucci, E; Gatti, M; Maraldi, T; Palumbo, C; Ribeiro Luz, S; Zavatti, M, 2020) |
| "Osteoporosis is a common disease caused by an imbalance of processes between bone resorption by osteoclasts and bone formation by osteoblasts in postmenopausal women." | ( Choi, CW; Hwang, S; Jeong, H; Jeong, SY; Jin, HS; Kim, J; Lee, CG; Lim, E; Park, E; Yong, Y; Yun, SH, 2020) |
| "Osteoporosis is characterized by impaired bone metabolism." | ( Chen, L; Fang, KH; Hong, CX; Shi, X; Tang, JH; Wang, BZ; Weng, SJ; Wu, ZY; Xie, J; Xie, ZJ; Yan, DY; Yang, L, 2021) |
| "Osteoporosis is a prevalent systemic skeletal disorder entailing bone fragility and increased fracture risk, often emerging in post-menopausal life." | ( Sun, J; Wu, JC; Xu, JC; Zhang, YF; Zhou, ZY, 2021) |
| "Osteoporosis is an osteolytic bone condition characterized by decreased bone strength and increased bone fragility." | ( Chen, R; Hou, L; Li, X; Liang, J; Lin, X; Liu, Q; Su, Y; Wu, Z; Xu, F; Yang, X; Zhao, J, 2021) |
| "Risk factors of osteoporosis are divided into unmodifiable, namely, age, gender, genetic factors, as well as modifiable, including diet, level of physical activity, and the use of stimulants." | ( Dobrowolska, A; Krela-Kaźmierczak, I; Ratajczak, AE; Rychter, AM; Szymczak-Tomczak, A; Zawada, A, 2021) |
| "Osteoporosis is a disease with a high burden of morbidity." | ( Aggarwal, A; Bhadada, SK; Bhansali, A; Garg, A; Pal, R; Ram, S; Rao, SD; Sachdeva, N; Singh, P; Singh, T; Thakur, JS, 2021) |
| "Osteoporosis is a major public health problem around the globe including India, resulting in significant morbidity, mortality, and health care burden." | ( Aggarwal, A; Bhadada, SK; Bhansali, A; Garg, A; Pal, R; Ram, S; Rao, SD; Sachdeva, N; Singh, P; Singh, T; Thakur, JS, 2021) |
| "Osteoporosis is the most common disease involving bone degeneration." | ( Bi, Y; Chai, L; Huang, J; Li, Y; Liu, Y; Song, L; Wang, Q; Zhou, K, 2021) |
| "Osteoporosis is one of the most common extraintestinal complications among patients suffering from inflammatory bowel diseases." | ( Dobrowolska, A; Krela-Kaźmierczak, I; Ratajczak, AE; Rychter, AM; Zawada, A, 2021) |
| "Senile osteoporosis is a major public health concern, and yet, effective treatment methods do not exist." | ( Chen, X; Chen, Z; Wu, Y; Zhang, M; Zhou, Y, 2021) |
| "Osteoporosis is a metabolic skeletal disease characterized by bone loss and an increased risk of fractures." | ( Cha, KH; Choi, JH; Hong, S; Kim, SM; Kwon, DY; Nho, CW; Son, YJ; Yoo, G, 2021) |
| "Osteoporosis is a common phenomenon in HIV patients on tenofovir treatment, but its underlying mechanisms remain to be explored." | ( Duan, L; Li, XF; Lin, W; Liu, JZ; Ren, DC; Song, M; Zhan, ZR, 2021) |
| "As osteoporosis is a frequent complication in patients under chemotherapy, we investigated the effect of vitamin K2 (100 mcg menaquinone-7) and vitamin D3 (10 mcg calcitriol) on bone metabolism in children with ALL." | ( Abdurrezzak, U; Karakukcu, M; Muhtaroglu, S; Ozdemir, MA; Solmaz, I; Unal, E, 2021) |
| "Osteoporosis is a common bone disease that results in elevated risk of fracture, and delayed bone healing and impaired bone regeneration are implicated by this disease." | ( Abdollahifar, MA; Asgary, M; Ebrahimi, V; Fridoni, MJ; Hejazi, F; Kermani, AA; Piryaei, A; Zare, F, 2021) |
| "Osteoporosis is a systemic metabolic disease defined by a decreased bone mineral density, microarchitectural deterioration, and an increased incidence of fragility fractures that may lead to morbidity and mortality." | ( Bilgiç, E; Çetinkaya, MA; Çiftci Dede, E; Korkusuz, F; Korkusuz, P, 2022) |
| "Osteoporosis is a skeletal condition that is characterized by decreasing bone density and deteriorating bone mass." | ( Cui, X; Gao, F; Guo, S; Li, Z; Ma, M; Wang, M; Wang, X; Wang, Z, 2021) |
| "Osteoporosis is a skeletal disorder that is common in postmenopausal women." | ( Baraka, NM; El-Swefy, SE; Elseweidy, MM; Hammad, SK; Shaheen, MA, 2021) |
| "Osteoporosis is characterized by reductions in bone mass, which could be attributed to the dysregulation of bone homeostasis, such as the loss of balance between bone-resorbing osteoclasts and bone-forming osteoblasts." | ( Cheung, SYL; Lee, CW; Lee, OK; Lin, HC; Shin, RL; Wang, AY; Wang, BY, 2021) |
| "Osteoporosis is a major public health problem that is appeared with increasing age." | ( Maryamabadi, A; Nabipour, I; Nekooei, M; Shafiee, SM; Zahiri, M, 2021) |
| "The incidence of osteoporosis is positively correlated with age." | ( Bi, J; Chen, QC; Pu, YL; Zhang, Y, 2021) |
| "Osteoporosis is a metabolic bone-loss disease characterized by abnormally excessive osteoclast formation and bone resorption." | ( Fu, Z; Li, X; Qian, Y; Sun, P; Wang, K; Wang, Y; Yang, Q; Zhang, T, 2021) |
| "Osteoporosis is a systemic bone disease that predisposes patients to bone fracture due to decreased bone density and quality, disrupted bone microarchitecture, and increased bone fragility." | ( Li, YS; Ma, S; Tao, L; Tian, J; Xiao, WF; Xie, WQ; Zhang, YM, 2021) |
| "Osteoporosis is the most prevalent metabolic bone disorder worldwide." | ( Almohaileb, FI; Rasheed, Z, 2022) |
| "Osteoporosis is a common metabolic bone disease mainly involving bone remodeling and blood vessels." | ( Li, Y; Lu, J; Shen, H; Xia, L; Yang, J; Yao, L; Yuan, L; Zhang, H, 2021) |
| "Osteoporosis is damaging the health of women worldwide." | ( Liu, Y; Wang, L; Xiong, J; Yang, Y, 2021) |
| "Osteoporosis is a metabolic disease of the skeletal system which currently affects over 200 million patients worldwide." | ( Kosiorowska, J; Szymańska-Chabowska, A; Tański, W, 2021) |
| "Osteoporosis is a common disease in aging populations." | ( Chang, YW; Gu, W; Li, ZQ; Sun, J; Wei, XE; Zhu, WJ, 2021) |
| "Osteoporosis is a serious health problem, especially in geriatric patients." | ( Chen, X; Jiang, R; Liu, Z; Peng, K; Song, X; Tang, X; Zhang, Q, 2021) |
| "Osteoporosis is characterized by excessive bone resorption due to enhanced osteoclast activation." | ( Chen, Z; Han, X; He, W; He, X; Hong, G; Hong, Z; Li, Z; Pang, F; Shen, Y; Wei, Q; Wu, R; Zhou, L, 2021) |
| "Osteoporosis is a systemic metabolic bone disorder that is caused by an imbalance in the functions of osteoclasts and osteoblasts and is characterized by excessive bone resorption by osteoclasts." | ( Cheon, YH; Cho, HJ; Eun, SY; Kim, JY; Lee, CH; Lee, MS; Park, GD, 2021) |
| "Osteoporosis is a systemic bone disease characterized by reduced bone mass and the deterioration of bone microarchitecture leading to bone fragility and an increased risk of fractures." | ( Jawień, P; Nowak, B; Słupski, W, 2021) |
| "Osteoporosis is a chronic disease that has become a serious public health problem due to the associated reduction in quality of life and its increasing financial burden." | ( Kang, H; Kim, KJ; Lee, J; Lee, Y; Oh, E; Park, C; Park, KH; Son, YJ; Wang, W; Woo, GE, 2021) |
| "Osteoporosis is detrimental to the health of skeletal structure and significantly increases the risks of bone fracture." | ( Chen, Y; Gong, T; Li, Y; Meng, L; Wang, Y; Zhang, J; Zhang, Y, 2021) |
| "Osteoporosis is frequently accompanied by iron disorders." | ( Anderson, GJ; Chang, H; Chang, YZ; Duan, X; Lei, Y; Li, Y; Shen, Y; Zhang, D; Zhao, C, 2021) |
| "Osteoporosis is a systemic skeletal disorder characterized by reduced bone mineral density (BMD) and bone quality and increased bone porosity, which increase the risk of bone fracture." | ( An, N; Feng, M; Feng, W; Liu, J; Lv, C; Mao, Y; Wang, S; Wang, X; Zhong, L, 2022) |
| "Osteoporosis is a common disease closely associated with aging." | ( Gao, F; Wang, J; Wang, XH; Xia, SL; Zhou, XX, 2021) |
| "Osteoporosis is affecting the health of postmenopausal women in the world." | ( Jie, J; Li, W; Wang, G; Xu, X, 2021) |
| "Osteoporosis is a chronic disease characterized by low bone mass caused by increased bone turnover and impaired bone microarchitecture." | ( Kolmas, J; Kołodziejska, B; Stępień, N, 2021) |
| "Osteoporosis is skeletal fragility caused by the excessive bone resorption due to osteoclastogenesis." | ( Khademul Islam, ABMM; Zinnia, MA, 2021) |
| "Osteoporosis is common in children with cerebral palsy, particularly in children with reduced gross motor function, and leads to an increased risk of fractures." | ( Hurley, T; McDonald, D; McDonnell, C; Molloy, E; Stewart, P; Zareen, Z, 2021) |
| "Osteoporosis is a public health concern and a cause of bone loss, increased risk of skeletal fracture, and a heavy economic burden." | ( Guo, D; He, H; Hou, T; Li, B; Xu, W; Zhao, M, 2023) |
| "Osteoporosis is one of the most common diseases affecting bone metabolism." | ( Jiang, J; Liu, L; Luo, J; Wang, X; Weng, Z; Xu, Y; Yang, Y; Ye, J; Zhang, W; Zhou, Z, 2021) |
| "Osteoporosis is a worldwide healthcare challenge." | ( Cai, M; Chen, Y; Li, Y; Min, W; Wang, C; Wang, J; Yan, L; Zhang, R; Zhu, H, 2021) |
| "Osteoporosis is a debilitating disease characterized by reduced bone mineral density and an increased risk of fractures." | ( Brent, MB, 2021) |
| "Osteoporosis is a common medical condition in older ages." | ( Fisher Negev, T; Hadad, V; Katzir, A; Liebergall, M; Or, O; Shabtai, R; Weil, Y, 2021) |
| "Breast cancer and osteoporosis are common diseases that affect the survival and quality of life in postmenopausal women." | ( Cai, SQ; Chen, QQ; Huang, SF; Li, YZ; Lin, S; Lin, ST; Sun, XQ, 2021) |
| "Hypogonadism and osteoporosis are frequently reported in HIV-infected men and, besides multifactorial pathogenesis, they might be directly linked because of testicular involvement in bone health." | ( Cappelli, C; Castelli, F; Delbarba, A; Ferlin, A; Focà, E; Maffezzoni, F; Pezzaioli, LC; Porcelli, T; Quiros-Roldan, ME, 2022) |
| "Osteoporosis is a systemic bone metabolism disorder, which increases the risk of fractures, and in severe cases it may cause disability or even death." | ( Chen, L; Chen, Y; Gao, Y; Li, Y; Lu, Q; Mao, J; Wang, W; Zuo, J, 2022) |
| "Postmenopausal osteoporosis is a chronic population health hazard systemic metabolic disease caused by excessive bone resorption and reduced bone formation." | ( He, R; Lin, N; Qu, H; Wang, C; Zhang, Y, 2021) |
| "Osteoporosis is the most common skeletal disorder worldwide." | ( Collin, A; de Barboza, GD; Picotto, G; Rivoira, M; Rodríguez, V; Tolosa de Talamoni, N, 2022) |
| "Osteoporosis is one of the most common skeletal disorders caused by the imbalance between bone formation and resorption, resulting in quantitative loss of bone tissue." | ( Cho, YW; Choi, JS; Han, J; Jo, DG; Jung, JM; Jung, YJ; Kim, E; Kim, HK; Lee, J; Lee, KS; Park, JH; Park, SY; Sul, JH; Woo, CH; Yeom, SH; Yun, YE, 2021) |
| "Osteoporosis is a common and frequent disease among the elderly with a poor prognosis and high risk of fractured ankles." | ( Jiang, J; Li, Z; Song, X; Wan, L; Wu, D; Yuan, D; Zhang, S, 2021) |
| "Osteoporosis is an age-related disease characterized by low mineral density, compromised bone strength and increased risk of fragility fracture." | ( Dai, M; Lai, Q; Li, X; Liu, X; Liu, Y; Mo, F; Xu, H; Xu, Q; Zhan, P; Zhang, B, 2021) |
| "Osteoporosis is an increasing public health problem in the worldwide and has caused socioeconomic burden." | ( Luan, F; Shen, Z; Shi, Z; Yan, J; Zou, S, 2021) |
| "Osteoporosis is defined as a bone condition characterized by bone mass reduction, bone micro-architectural and quality deterioration, leading to compromised strength and increased chances of fracture." | ( Chen, L; Jiang, X; Lu, T; Miao, Y; Qian, Z; Shen, Y; Wang, Q; Xu, Y, 2021) |
| "Osteoporosis is caused by an imbalance of osteoclasts and osteoblasts, occurring in close proximity to hematopoietic cells in the bone marrow." | ( Agrawal, M; Bick, A; Bouxsein, ML; Brooks, DJ; Charles, JF; Cohen, DN; Ebert, BL; Evans, DM; Gibson, CJ; Griffin, G; Jaiswal, S; Kemp, JP; Kiel, DP; Kim, PG; Lin, AE; McConkey, M; Natarajan, P; Niroula, A; Pirruccello, J; Richards, JB; Sekar, A; Shin, WJ; Shkolnik, V; Słabicki, M; Tsai, JM; Uddin, MM; Wein, MN; Wong, WJ, 2021) |
| "Osteoporosis is characterized by increased bone fragility, and the drugs used at present to treat osteoporosis can cause adverse reactions." | ( Dong, J; Jiang, H; Li, W; Shen, YK; Wang, L; Wu, Q; Xian, CJ; Yao, L; Zhong, J, 2021) |
| "Osteoporosis is characterized by the deterioration of bone structures and decreased bone mass, leading to an increased risk of fracture." | ( Bak, SG; Cheong, SH; Lee, S; Lee, SJ; Lee, SW; Lim, HJ; Park, EJ; Rho, MC; Won, YS, 2021) |
| "Osteoporosis is a public health problem resulting in higher susceptibility to bone fracture." | ( Cao, S; Ding, H; Feng, T; Li, X; Li, Y; Xie, L; Yang, Q, 2022) |
| "Male osteoporosis is a still largely underdiagnosed pathological condition." | ( Bertoldo, F; Bonadonna, S; Brigo, M; Cesareo, R; Chiodini, I; De Geronimo, V; Falchetti, A; Gennari, L; Giovanelli, L; Palermo, A; Salcuni, AS; Scillitani, A; Vescini, F, 2021) |
| "Osteoporosis is a skeletal disorder characterized by a low bone mass and density." | ( Chen, S; Jing, C; Li, B; Liang, H; Liu, C; Na, H; Tan, H; Zhang, C; Zhao, L, 2021) |
| "Osteoporosis is a major health concern in aging populations, where 54% of the U." | ( Akhavan, NS; Arjmandi, BH; Foley, EM; George, KS; Hickner, RC; Kim, JS; Munoz, J; Ormsbee, LT; Siebert, SC, 2022) |
| "Osteoporosis is a common disease characterized by skeletal fragility and microarchitectural deterioration." | ( Luo, Y; Wei, JX; Xiao, JH; Xu, Y, 2022) |
| "Osteoporosis is a common disease in which the risk of fracture increases due to decreased bone mass and qualitative skeletal changes." | ( Bian, J; Chen, R; Li, M; Li, Z; Tang, J; Tian, Y; Xie, Y; Xu, X; Zhang, Y; Zhang, Z, 2022) |
| "Osteoporosis is an age-dependent serious skeletal disease that leads to great suffering for the patient and high social costs, especially as the global population reaches higher age." | ( El Shahawy, M; Gustafsson, KL; Henning, P; Koskela, A; Lerner, UH; Movérare-Skrtic, S; Nilsson, KH; Ohlsson, C; Tuckermann, J; Tuukkanen, J; Wu, J, 2022) |
| "Postmenopausal osteoporosis is a serious concern in aging individuals, but has not been explored for its potential to alter the shape of the inner ear by way of increased remodeling in the otic capsule." | ( Lees, SJ; Niccoli, S; Sanzo, P; Schroeder, L; Silcox, M; Tinius, A; Viola, B; Voth, R; Ward, DL, 2022) |
| "Osteoporosis is the most common bone disease and is characterized by low bone mineral density (BMD) and a high risk of fracture." | ( Bae, JH; Park, D, 2022) |
| "Osteoporosis is a serious health issue among aging postmenopausal women." | ( Chen, KH; Chen, LR; Cheng, CH, 2022) |
| "Osteoporosis is a metabolic bone disease that significantly affects the quality of life and can even lead to death." | ( Gu, J; Qi, J; Qiu, M; Tu, L; Xie, Y; Yang, M; Zhao, M, 2022) |
| "Osteoporosis is the most common diabetes complication." | ( Shu, L; Tang, X; Xiong, Z; Yi, P; Zhang, C, 2022) |
| "Osteoporosis is a bone‑related disease that results from impaired bone formation and excessive bone resorption." | ( Liang, D; Qiu, Y; Tang, C; Tang, G; Zhu, J, 2022) |
| "Osteoporosis is an independent risk factor of colorectal adenoma and high-risk adenoma." | ( Im, JP; Jang, DK; Jeong, JB; Kang, HW; Kim, JS; Kim, JW; Kim, SH; Koh, M; Koh, SJ; Lee, DS; Lee, KL; Lim, YJ; Nam, JH; Oh, DJ; Ryu, KH, 2022) |
| "Osteoporosis is a prevalent disease with a high incidence in women at the onset of menopause mainly because of hormonal changes, genetics, and lifestyle, leading to decreased bone mass and risk of fractures." | ( Bombonato-Prado, KF; Coelho, MC; Coppi, AA; de Sousa, LG; Fernandes, RR; Pitol, DL; Scalize, PH; Semeghini, MS; Siessere, S; Tavares, MS, 2022) |
| "Osteoporosis is a systemic disorder of bone metabolism." | ( Liu, Z; Wu, Y, 2022) |
| "Osteoporosis is a systemic bone disease characterized by decreased bone mass and quality and bone micro‑architecture degradation." | ( Cao, L; Tian, F; Wang, C; Wang, J; Zhang, Y, 2022) |
| "Osteoporosis is the most common metabolic bone disease in the USA and the world." | ( Greenspan, SL; Insogna, KL; LeBoff, MS; Lewiecki, EM; Saag, KG; Singer, AJ; Siris, ES, 2022) |
| "Osteoporosis is an abnormal reduction in bone mass and bone deterioration leading to increased fracture risk." | ( Hsieh, SC; Liu, W; Peterson, J; Tugwell, P; Wells, GA; Zheng, C, 2022) |
| "Osteoporosis is associated with a decrease of bone mineralized component as well as a increase of bone marrow fat." | ( Duan, S; Li, C; Liu, M; Qin, J; Qiu, X; Xin, Y; Yao, Q; Yuan, K; Zheng, X, 2022) |
| "Osteoporosis is a highly prevalent systemic skeletal disease that is characterized by low bone mass and microarchitectural bone deterioration." | ( Baum, T; Beer, M; Boehm, C; Carballido-Gamio, J; Dieckmeyer, M; Karampinos, DC; Karupppasamy, S; Kirschke, JS; Kloth, C; Kronthaler, S; Krug, R; Link, TM; Lisson, CG; Sollmann, N; Vogele, D, 2022) |
| "Osteoporosis is a general bone-related ailment characterized by reduced bone density and quality, elevated bone fragility, and fractures." | ( Hao, P; Li, H; Miao, B; Zhang, Y, 2022) |
| "Diabetes-associated osteoporosis are partly caused by accumulation of advanced glycation endproducts (AGEs)." | ( Chen, H; Cheng, Y; Liang, J; Liu, P; Xiang, Q; Yang, L; Zhang, H, 2022) |
| "Osteoporosis is a very common skeletal disorder that increases the risk of fractures." | ( Gan, L; Li, A; Li, L; Zhu, L; Zuo, L, 2022) |
| "Osteoporosis is a bone metabolic disease characterized by reduced bone mass and deterioration of bone tissue microarchitecture, leading to enhanced skeletal fragility and susceptibility to fracture." | ( Chen, Z; Gao, Z; Liu, X; Xiong, Z, 2022) |
| "Disused osteoporosis is a kind of osteoporosis, a common age-related disease." | ( Jia, Y; Li, B; Liu, J; Liu, X; Liu, Y; Wang, Y; Wang, Z; Xu, Y, 2022) |
| "Secondary osteoporosis is an important issue of clinical care in children with acute and chronic diseases." | ( Breda, L; Chiarelli, F; d'Angelo, DM; Di Donato, G; Di Marcello, F, 2022) |
| "Osteoporosis is associated with an impaired balance between bone resorption and formation, which in turn leads to bone loss and fractures." | ( Baloun, J; Hruskova, H; Pavelka, K; Pekacova, A; Senolt, L; Stepan, JJ; Svec, X; Wenchich, L, 2022) |
| "Osteoporosis is common in patients undergoing spine surgery, and carries a considerable risk of adverse outcomes." | ( Gomez-Salazar, MA; James, AW; Li, Z; Negri, S; Xing, X; Xu, J; Xu, M, 2022) |
| "Osteoporosis is a degenerative skeletal disease essentially caused by bone remodeling disorder." | ( Kou, Y; Li, M; Liu, H; Rong, X; Tang, R; Yang, P; Zhang, Y, 2022) |
| "Diabetic osteoporosis is secondary osteoporosis and a serious complication of diabetes with a high incidence rate and poor prognosis." | ( Ming, J; Tian, Y, 2022) |
| "Osteoporosis is a systemic disease in which bone mass decreases, leading to an increased risk of bone fragility and fracture." | ( Deng, J; Guan, Z; Lin, J; Liu, P; Tao, KT; Wang, D; Zeng, H; Zhang, W, 2023) |
| "Osteoporosis is a widespread bone disease that affects million cases annually." | ( Ayiding, X; Han, R; Li, L, 2022) |
| "OBJECTIVE: Osteoporosis is a severe degenerative chronic metabolic bone disease associated with high fracture risk." | ( Feng, G; Tu, YH; Yang, C; Yang, J; Yuan, Y, 2022) |
| "Osteoporosis is characterized by lowing bone mineral density." | ( Chen, X; Jiang, J; Zhang, Z; Zhou, H, 2022) |
| "Diabetes osteoporosis is considered as a metabolic bone disease of diabetes patients." | ( Huang, X; Li, S; Lu, W; Xiong, L, 2022) |
| "Osteoporosis is another frequent complication of HH, and the underlying mechanisms are poorly understood." | ( Altamura, S; Baschant, U; Hofbauer, LC; Muckenthaler, MU; Rauner, M; Spasić, MV; Steele-Perkins, P; Steinbicker, AU, 2022) |
| "Osteoporosis is considered a widespread health problem that affects senior citizens, particularly older women, after the menopause." | ( Ajlouni, K; Allouh, MZ; Batieha, A; El-Khateeb, M; Elsalem, L; Jaddou, H; Jumaa, D; Khader, Y; Saadeh, R, 2022) |
| "Osteoporosis is defined by loss of bone mass and deteriorated bone microarchitecture." | ( Amorim, T; Bastos, AR; Canadas, RF; Carrillo, AE; Correlo, VM; Fernandes, EM; Freitas, L; Gkiata, P; Koutedakis, Y; Kydonaki, EK; Marques, F; Ntina, G; Oliveira, JM; Pinto, R; Reguengo, H; Reis, RL; Simón, CR; Vliora, M, 2022) |
| "Postmenopausal osteoporosis is a critical issue for female health worldwide." | ( Aboutaleb, H; Ali, SS; Almged, MA; Alsanory, AA; Alsanory, TA; Ezzat, GM; Salama, RHM; Salama, THM, 2023) |
| "Osteoporosis is prevalent and entails alterations of vertebral bone and marrow." | ( Baum, T; Boehm, C; Burian, E; Dieckmeyer, M; Greve, T; Karampinos, DC; Kirschke, JS; Kloth, C; Rayudu, NM; Ruschke, S; Sollmann, N; Subburaj, K, 2022) |
| "Diabetic osteoporosis is a poorly managed serious skeletal complication, characterized by high fracture risk, increased bone resorption, reduced bone formation, and disrupted bone architecture." | ( Nirwan, N; Vohora, D, 2022) |
| "Among these, osteoporosis is the most common metabolic bone disorder." | ( Buda, R; Del Pizzo, F; Di Pietrantonio, N; Di Pietro, N; Di Tomo, P; Epifano, F; Fiorito, S; Genovese, S; Mandatori, D; Pandolfi, A; Pelusi, L; Pipino, C, 2022) |
| "Osteoporosis is a metabolic bone disorder associated with impaired bone microarchitecture leading to fragility fractures." | ( Awasthi, P; Bajpai, R; Goel, A; Khanka, S; Prakash, R; Sahasrabuddhe, AA; Sharma, K; Singh, D, 2022) |
| "Osteoporosis is often accompanied by bone loss with fat accumulation of the red marrow." | ( Kajihara, H; Kawae, N; Kimura, T; Mizushima, A; Nakamura, T; Watanabe, D; Yanagida, K; Yoshida, T, 2022) |
| "Osteoporosis is characterized by low bone mass and changes in bone microarchitecture that increases the risk of fracture." | ( Aurora, R; Veis, D, 2022) |
| "Osteoporosis is more common in people over 60 years old, and the possibility of modic change in 71-80y is higher than in other age groups." | ( Guo, H; Liu, B; Ma, X; Zhang, R; Zhang, Y, 2022) |
| "Osteoporosis is a metabolic, hereditary, progressive disease characterized by unusual bone production across the skeleton and a loss the bone tissue microstructure and mass." | ( Chen, Q; Ding, Y; Huo, J; Wei, X; Zhao, B, 2022) |
| "Osteoporosis is considered a risk factor for osseointegration during implant treatment." | ( Aita, H; Endo, K; Iijima, M; Kawamura, N; Kemuriyama, S; Koshino, H; Maida, T; Nezu, T, 2023) |
| "Osteoporosis is a skeletal system disease characterized by low bone mass and altered bone microarchitecture, with an increased risk of fractures." | ( Cui, Y; Gao, R; Li, M; Liu, H; Rong, X; Zhang, W; Zhu, S, 2022) |
| "Postmenopausal osteoporosis is one of the world's biggest yet unnoticed health issues." | ( Dhaniya, G; Gautam, S; Mishra, PR; Rai, D; Sardar, A; Sinha, S; Tripathi, AK; Trivedi, R, 2022) |
| "Age-induced osteoporosis is a global problem." | ( Lv, Z; Shi, W; Zhang, Q, 2022) |
| "Forearm osteoporosis is a well-known complication of primary hyperparathyroidism (PHPT)." | ( Aydin, H; Bozkur, E; Cakir, İ; Dogansen, SC; Esen, A; Mert, M; Metin, D; Pamuk, N; Piskinpasa, H; Sahbaz, NA; Turgut, S, 2023) |
| "Osteoporosis is an independent risk factor for failure after arthroscopic rotator cuff repair." | ( Bisazza, K; Easley, J; Gadomski, B; Johnson, JW; McGilvray, K; Nelson, B; Regan, D; Troyer, K; von Stade, D; Zhou, T, 2022) |
| "Osteoporosis is a common bone metabolic disease in postmenopausal women, diabetic patients and obese patients and is characterized by an imbalance in bone formation and resorption." | ( Li, J; Tao, L; Yang, K, 2022) |
| "Osteoporosis is often untreated especially in older people." | ( Bee, JKS; Chong, BYK; Joseph, LV; Mamun, K; Sen, HT; Wen, AFYH, 2022) |
| "Osteoporosis is frequently found in chronic diabetic patients, and it results in an increased risk of bone fractures occurring." | ( Isarankura-Na-Ayudhya, C; Klabklai, P; Phetfong, J; Supokawej, A; Tangporncharoen, R; Tawonsawatruk, T, 2022) |
| "Osteoporosis is becoming a global epidemic in aging societies." | ( Chang, YF; Hsu, YH; Hwang, JS; Li, CC; Liang, FW; Wu, CH, 2023) |
| "Osteoporosis is associated with alterations in the levels of specific circulating metabolites." | ( Huang, D; Wang, J; Wang, Y; Zeng, Y, 2022) |
| "Osteoporosis is a common condition in which deteriorating bone tissue results in an increased risk of low trauma fracture." | ( Aninye, IO; Horan, L; McPhee, C, 2022) |
| "Osteoporosis is a common and frequent disease among the elderly with a poor prognosis and a high risk of spinal fractures." | ( Li, Z; Xue, H; Zheng, R; Zhu, H, 2022) |
| "Osteoporosis is a common and frequent disease among the elderly with a poor prognosis and a high risk of spinal fractures." | ( Li, Z; Xue, H; Zheng, R; Zhu, H, 2022) |
| "Osteoporosis is a common and frequent disease among the elderly with a poor prognosis and a high risk of spinal fractures." | ( Li, Z; Xue, H; Zheng, R; Zhu, H, 2022) |
| "Osteoporosis is common in older adults leading to fragility fractures at enormous individual and economic cost." | ( Bishop, S; Gittoes, N; Langley, T; Narayanasamy, M; Paskins, Z; Sahota, O, 2022) |
| "Osteoporosis is common in older adults leading to fragility fractures at enormous individual and economic cost." | ( Bishop, S; Gittoes, N; Langley, T; Narayanasamy, M; Paskins, Z; Sahota, O, 2022) |
| "Osteoporosis is common in older adults leading to fragility fractures at enormous individual and economic cost." | ( Bishop, S; Gittoes, N; Langley, T; Narayanasamy, M; Paskins, Z; Sahota, O, 2022) |
| "Osteoporosis is a systemic skeletal disorder where osteoclasts are prevalent among osteoblasts." | ( Jeong, GS; Kang, H; Kim, EN; Kim, KH; Trang, NM, 2022) |
| "Osteoporosis is a systemic skeletal disorder where osteoclasts are prevalent among osteoblasts." | ( Jeong, GS; Kang, H; Kim, EN; Kim, KH; Trang, NM, 2022) |
| "Osteoporosis is a systemic skeletal disorder where osteoclasts are prevalent among osteoblasts." | ( Jeong, GS; Kang, H; Kim, EN; Kim, KH; Trang, NM, 2022) |
| "Postmenopausal osteoporosis is a significant threat to human health globally." | ( Chen, JX; Hu, XL; Qiu, ZC; Tang, ZL; Wong, MS; Xiao, HH; Yang, L; Zhang, FX; Zhang, J; Zhang, YY, 2022) |
| "Postmenopausal osteoporosis is a significant threat to human health globally." | ( Chen, JX; Hu, XL; Qiu, ZC; Tang, ZL; Wong, MS; Xiao, HH; Yang, L; Zhang, FX; Zhang, J; Zhang, YY, 2022) |
| "Postmenopausal osteoporosis is a significant threat to human health globally." | ( Chen, JX; Hu, XL; Qiu, ZC; Tang, ZL; Wong, MS; Xiao, HH; Yang, L; Zhang, FX; Zhang, J; Zhang, YY, 2022) |
| "Osteoporosis is characterized by deterioration of bone microarchitecture and reduced bone mass and can increase the risk of fracture." | ( Abd Elmageed, ZY; Abdelraheim, MH; Badary, DM; Farrag, MMY; Galal, HA; Mohamed, NM; Sedeek, MI, 2022) |
| "Osteoporosis is characterized by deterioration of bone microarchitecture and reduced bone mass and can increase the risk of fracture." | ( Abd Elmageed, ZY; Abdelraheim, MH; Badary, DM; Farrag, MMY; Galal, HA; Mohamed, NM; Sedeek, MI, 2022) |
| "Osteoporosis is characterized by deterioration of bone microarchitecture and reduced bone mass and can increase the risk of fracture." | ( Abd Elmageed, ZY; Abdelraheim, MH; Badary, DM; Farrag, MMY; Galal, HA; Mohamed, NM; Sedeek, MI, 2022) |
| "Osteoporosis is a metabolic bone disorder that leads to a decline in bone microarchitecture, predisposing individuals to catastrophic fractures." | ( Collins, MT; Farhadi, F; Osamor, CC; Paravastu, SS; Saboury, B; Sheppard, AJ; Wojnowski, NM, 2023) |
| "Osteoporosis is a metabolic bone disorder that leads to a decline in bone microarchitecture, predisposing individuals to catastrophic fractures." | ( Collins, MT; Farhadi, F; Osamor, CC; Paravastu, SS; Saboury, B; Sheppard, AJ; Wojnowski, NM, 2023) |
| "Senile osteoporosis is one of the most common age-related diseases worldwide." | ( He, YT; Hu, Y; Huang, YM; Kuai, Z; Lu, Y; Ren, WY; Shen, JP; Wu, JY; Wu, KF; Xu, B, 2023) |
| "Senile osteoporosis is one of the most common age-related diseases worldwide." | ( He, YT; Hu, Y; Huang, YM; Kuai, Z; Lu, Y; Ren, WY; Shen, JP; Wu, JY; Wu, KF; Xu, B, 2023) |
| "Background: Osteoporosis is a cardinal manifestation of Cushing’s syndrome." | ( Chen, JF; Chen, YN; Shen, FC; Tsai, JR, 2022) |
| "Background: Osteoporosis is a cardinal manifestation of Cushing’s syndrome." | ( Chen, JF; Chen, YN; Shen, FC; Tsai, JR, 2022) |
| "Osteoporosis is defined as a systemic skeletal disease characterized by low bone mass and microarchitectural deterioration of bone tissue, with a consequent increase in bone fragility and susceptibility to fracture." | ( Klara, J; Lewandowska-Łańcucka, J, 2022) |
| "Osteoporosis is defined as a systemic skeletal disease characterized by low bone mass and microarchitectural deterioration of bone tissue, with a consequent increase in bone fragility and susceptibility to fracture." | ( Klara, J; Lewandowska-Łańcucka, J, 2022) |
| "The prevalence of osteoporosis is increasing in the United States." | ( Ayers, C; Fu, R; Harrod, C; Kansagara, D; Kwon, A; Lazur, B, 2023) |
| "Osteoporosis is a complex multifactorial disease that can lead to an increased risk of fracture." | ( Chen, Q; Li, YH; Li, ZH; Mei, QB; Niu, YB; Song, XZ; Sun, Y; Xie, M; Zhang, YH, 2023) |
| "Osteoporosis is a common metabolic bone disease with a rapidly increasing prevalence, characterized by massive bone loss because of excessive osteoclast formation." | ( Chen, G; Dai, J; Fei, J; Hu, J; Hu, Q; Wang, Y; Ye, J; Zhang, P, 2022) |
| "Osteoporosis is a common and serious health issue among postmenopausal women." | ( Carvalho, M; Kunioka, CT; Manso, MC, 2022) |
| "Osteoporosis is a disorder of bone mineralisation occurring in about one third of adults with cystic fibrosis." | ( Chang, AB; Conwell, LS; Jeffery, TC, 2023) |
| "Osteoporosis is the most common bone disorder where the hyperactive osteoclasts represent the leading role during the pathogenesis." | ( Chen, K; Chen, L; He, J; Hu, S; Huang, F; Jiang, H; Jiang, M; Li, X; Lin, D; Lin, X; Liu, Q; Xu, J; Ye, T; Zeng, Y; Zheng, L, 2023) |
| "Osteoporosis is a systemic skeletal disease characterised by low bone mineral density (BMD), degeneration of bone micro-architecture, and impaired bone strength." | ( Azam, Z; Baghel, K; Gupta, RK; Mishra, PK; Saini, C; Sapra, L; Sinha, N; Soni, V; Srivastava, RK, 2023) |
| "Osteoporosis is a progressive metabolic disease characterized by decreased bone mineral density and increased fracture risk." | ( Han, AR; Hong, SM; Lee, AS; Lee, SH; Son, SJ; Sung, MJ, 2023) |
| "Osteoporosis is a common disease of the elderly that affects millions of patients worldwide." | ( Cao, W; Chen, Y; Dong, J; Hao, M; Hu, X; Jin, C; Ke, C; Liu, B; Peng, Z; Weng, H; Zhang, Z; Zhong, J, 2023) |
| "Osteoporosis is a systemic and endocrine bone disorder distinguished by declined bone mineral density, compromised bone strength, and destruction of trabecular structure." | ( Guo, J; Guo, Z; He, J; Ren, R; Shao, J; Sun, K; Wang, X, 2023) |
| "Osteoporosis is the commonest progressive metabolic bone disease, characterized by elevated risk of fragility fractures as a result of a reduced bone mass and microarchitectural deterioration." | ( Formosa, MM; Mangion, D; Pace, NP, 2023) |
| "Osteoporosis is a major health problem in postmenopausal women, and characterized by deteriorated bone mass and micro-architecture." | ( Du, Z; Li, Z; Lin, L; Luo, H; Luo, Z; Tang, J; Wang, S; Yuan, Z; Zhou, JR, 2023) |
| "Osteoporosis is a degenerative bone disease resulting from bone homeostasis imbalance regulated by osteoblasts and osteoclasts." | ( Dai, H; Goto, T; Kang, H; Li, F; Tu, R; Wu, X; Zhao, Y; Zhuang, P, 2023) |
| "Osteoporosis is a bone disease leading to bone fracture and affects 200 million women worldwide." | ( Azadbakht, O; Behrouj, H; Jafarinia, M; Mousavi, S; Razmjoue, D; Sabaghan, M; Sabetian, S; Savardashtaki, A; Vakili, S; Veisi, A; Zal, F, 2023) |
| "Postmenopausal osteoporosis is a multifactorial disease." | ( Gámez Nava, JI; Nuño Arana, I; Pérez Romero, M; Ruiz González, F; Trujillo Rangel, WÁ; Villagómez Vega, A, 2023) |
| "Osteoporosis is a progressive metabolic bone disorder characterised by a decline in bone mineral density (BMD)." | ( Chan, HL; Chung, PT; Ho, KH; Hsu, HY; Huang, SY; Hwang, LC; Lien, HN; Lin, HH; Ma, HC; Tsou, MT, 2023) |
| "Osteoporosis is a chronic disease and public health issue in aging populations." | ( Baldassano, D; Baldassano, S; Caldarella, R; Di Rosa, L; Sabatino, L; Vasto, S, 2023) |
| "Osteoporosis is a prevalent bone metabolic disease in menopause, and long-term medication is accompanied by serious side effects." | ( Dai, ZH; Fang, WL; He, GL; Jin, C; Jin, SQ; Ma, HW; Wu, YH; Xu, C; Xu, CY, 2023) |
| "Osteoporosis is an increasingly prevalent disease." | ( Li, X; Wang, W; Xu, H; Zhao, B, 2023) |
| "The problem of osteoporosis is relevant due to the high frequency of its prevalence throughout the world." | ( Hoina-Kardasevich, O; Shcherbeniuk, N; Yakovleva, O, 2023) |
| "Secondary osteoporosis is commonly caused by long-term intake of glucocorticoids (GCs), such as dexamethasone (DEX)." | ( Abdelaleem, EA; Arafa, EA; Elgendy, NO; Elhemely, MA; Mohamed, WR, 2023) |
| "Osteoporosis is a common skeletal disease; however, effective pharmacological treatments still need to be discovered." | ( Chen, Z; Cho, E; Ding, M; Lee, TH; Park, SW, 2023) |
| "Osteoporosis is a common bone disease caused by an imbalance of bone resorption and formation that results in a loss of total bone density." | ( Bretches, M; Dong, H; Huang, N; Jin, Z; Kang, J; Liu, R; Ning, B; Sun, Z; Yang, SY; Yu, G; Zhang, X; Zhang, Y; Zou, K, 2023) |
| "Osteoporosis is a highly prevalent bone disease occurred commonly in astronauts and postmenopausal women due to mechanical unloading and estrogen deficiency, respectively." | ( Chen, Z; Hu, L; Jia, Y; Liang, S; Liu, H; Liu, S; Qian, A; Ru, K; Wu, Z; Xu, X; Zhang, W, 2023) |
| "Osteoporosis is a skeletal disease characterized by low bone mass, reduced bone strength, and increased fracture risk." | ( Cui, Y; Di, D; Ni, Z; Wang, Q; Wei, M; Zhang, R; Zhou, H, 2023) |
| "Osteoporosis is a common inflammaging-related condition, where long-term accumulation of pro-inflammatory cytokines causes massive bone loss." | ( Dong, H; Jiang, W; Jin, Z; Kang, J; Liu, R; Ning, B; Pan, L; Sun, Z; Zhang, X; Zhang, Y, 2023) |
| "Osteoporosis is characterized by structural changes in the bone such as decreased bone mineral density leading to an increased risk for fractures." | ( Alavi, A; Høilund-Carlsen, PF; Khurana, N; Park, PSU; Raynor, WY; Resto, DA; Werner, TJ, 2023) |
| "Osteoporosis is a prevalent bone metabolic disease in menopause, and long-term medication is accompanied by serious side effects." | ( Dai, ZH; He, GL; Jin, C; Jin, SQ; Sheng, SR; Tian, NF; Wu, YH; Xie, CL; Zhao, BY; Zheng, G; Zhou, X, 2023) |
| "Osteoporosis is a major health problem that is very common worldwide and is characterized by both low bone density and deterioration in bone quality." | ( Altuntas, F; Cuneyit, I; Donmez, AC; Donmez, BO; Karagur, ER; Ocak, M; Ozturk, S; Sarikanat, M; Unal, M, 2023) |
| "Postmenopausal osteoporosis is a systemic metabolic disease that chronically endangers public health and is typically characterized by low bone mineral density and marked bone fragility." | ( Chen, J; Lian, H; Liang, J; Liu, Q; Su, Y; Wang, K; Xu, J; Yang, F; Zhao, J, 2023) |
| "Postmenopausal osteoporosis is a kind of degenerative disease, also described as "invisible killer." | ( Cai, H; He, W; Zhang, H, 2023) |
| "Osteoporosis is a degenerative disease characterized by reduced bone mass, with low peak bone mass being the predominant manifestation during development and having an intrauterine origin." | ( Chen, L; He, H; Jiang, T; Li, B; Wang, H; Xiao, H, 2023) |
| "Osteoporosis is a metabolic bone disease." | ( Cai, G; Chen, H; Chen, L; Cheng, P; Jiang, D; Lu, F; Shen, J; Sun, J; Xu, X; Zhang, J, 2023) |
| "The prevalence of osteoporosis is high among adult thalassemia patients." | ( Chansai, S; Chansung, K; Fucharoen, S; Lanamtieng, T; Phiphitaporn, P; Pongchaiyakul, C; Teawtrakul, N; Wanitpongpun, C; Yamsri, S, 2023) |
| "Osteoporosis is characterized by low bone mass and micro-architectural deterioration of bone tissue leading to increased bone fragility." | ( Bhardwaj, A; Sinha, NK; Swe, KMM, 2023) |
| "Osteoporosis is a metabolic bone disease that commonly results in middle-aged and elderly people following fractures." | ( Chen, C; Chen, R; Geng, B; Wang, H; Xia, Y; Xiao, H; Yang, C; Yang, F, 2023) |
| "Osteoporosis is a chronic bone disorder characterized by decreased bone mass, leading to brittle bones and fractures." | ( Negi, D; Rasool, N; Singh, Y, 2023) |
| "Postmenopausal osteoporosis is the most common type of osteoporosis." | ( Han, B; Han, J; Jiang, Z; Peng, Y; Sun, X; Zhang, W, 2023) |
| "Osteoporosis is an age-related disease of bone metabolism marked by reduced bone mineral density and impaired bone strength." | ( Gao, Z; Li, D; Li, Q; Liu, H; Liu, X, 2023) |
| "Osteoporosis is one of the chronic complications of type 1 diabetes with high risk of fracture." | ( Chen, X; Guo, H; Liu, J; Lv, H; Shang, P; Wang, S; Wang, Y; Wei, Y; Yang, J; Yao, W; Zhang, G; Zhen, C, 2023) |
| "Osteoporosis is a multifactorial disorder in which nutrition is associated with its onset and progression." | ( Fujita, T; Ohishi, T; Takase, H; Takeuchi, Y, 2023) |
| "Osteoporosis is a common metabolic bone disease that benefits from many newly developed anti-osteoporosis medications (AOMs)." | ( Chan, DC; Chen, HM; Fu, SH; Huang, CF; Hwang, JS; Lin, JW; Wang, CY; Wu, CH; Yang, JJ; Yang, RS; Yang, TH, 2023) |
| "Age-related osteoporosis is associated with increased oxidative stress and cellular senescence." | ( Goltzman, D; Li, J; Li, Y; Liu, B; Miao, D; Qin, R; Qiu, Y; Wang, R; Xue, Q; Yang, R; Zhang, J, 2023) |
| "Osteoporosis is characterized by loss of bone mass and susceptibility to fracture." | ( Corbetta, S; Degradi, C; Dito, G; Guabello, G; Longhi, M; Lugaresi, M, 2023) |
| "Osteoporosis is a bone disease characterized by structural deterioration and low bone mass, leading to fractures and significant health complications." | ( Akkouch, A; Frase, D; Gupta, R; Lee, C; Nachiappan, C, 2023) |
| "Osteoporosis is a prevalent condition characterized by low bone density and increased risk of fractures, resulting in a significant healthcare burden." | ( An, J; Liu, X, 2023) |
| "Osteoporosis is a common bone disorder characterized by reduced bone density and increased risk of fractures." | ( Fukaura, S; Iwasaki, Y, 2023) |
| "Osteoporosis is a major public health concern, which requires novel therapeutic strategies to prevent or mitigate bone loss." | ( Cho, IA; Hyun, M; Kim, JW; Koh, JT; Lee, BN; Park, SG; Piao, X; Ryu, JH; Song, JH; Wang, Z, 2023) |
| "Osteoporosis is a fatal bone-wearing malady and a substantial reason behind the impermanence of human life and economic burden." | ( Ali, A; Aqil, M; Jabi, B; Mujeeb, M; Sultana, N; Sultana, Y; Waheed, A; Yaqub Khan, M, 2023) |
| "Osteoporosis is a chronic bone disease affecting both men and women, but it is more prevalent in women." | ( Al-Khadher, MA; Elgzar, WT; Ibrahim, HA; Ismail, NI; Nahari, MH, 2023) |
| "Treatment of osteoporosis is conventional in mild to moderate stages but more complex in severe CKD because evidence about the efficacy and safety of anti-osteoporosis drugs is scant." | ( Lafage-Proust, MH, 2023) |
| "Osteoporosis is not well treated due to the difficulty of finding commonalities between the various types of it." | ( Ge, G; Geng, D; Gu, C; Wang, T; Wu, M; Xia, Y; Xiao, H; Yang, H, 2023) |
| "Disuse osteoporosis is known to be primarily caused by a lack of exercise." | ( Dai, Z; Jia, Y; Li, B; Liu, J; Lyu, F; Qi, H; Wang, L; Wang, Y; Xu, Y; Zhou, X; Zhu, H, 2023) |
| "Osteoporosis is a bone metabolic disease that usually causes fracture." | ( Chen, Y; Li, Y; Sui, X; Sun, X; Wang, Z, 2023) |
| "Osteoporosis is one of the major health problems characterized by decreased bone density and increased risk of fractures." | ( Chen, K; Chen, X; Gan, Z; Huang, J; Shang, X; Xu, M; Yuan, X, 2023) |
| "Osteoporosis is one of the skeletal degenerative diseases accompanied by bone loss and microstructure disruption." | ( Cao, Z; Chen, C; Du, R; Lei, H; Lu, Y; Qin, M; Song, Y; Wang, X; Wu, M; Zhang, C; Zhang, L; Zhou, J, 2023) |
| "Osteoporosis is a degenerative disease affecting millions of elderly people globally and increases the risk of bone fractures due to the reduced bone density." | ( Bai, J; Chu, PK; Gao, A; Ge, G; Geng, D; Liu, X; Wang, G; Wang, H; Wang, Q; Wang, W; Wu, Z; Yu, L, 2023) |
| "Osteoporosis is a systemic bone disease characterized by an imbalance in the relationship between osteoblasts, osteocytes, and osteoclasts." | ( Du, J; Li, X; Liu, B; Sun, K; Wang, Y; Xu, X; Zhang, X, 2023) |
| "Osteoporosis is a common bone disease characterized by loss of bone mass, reduced bone strength, and deterioration of bone microstructure." | ( Bao, X; Guo, J; Hao, D; Huang, D; Ji, J; Liu, J; Liu, S; Wang, X; Wei, L; Wu, S; Xia, Z; Ye, Y; Zhang, Y, 2023) |
| "Osteoporosis is a debilitating condition characterized by reduced bone mass and density, leading to compromised structural integrity of the bones." | ( Hong, S; Jung, HS; Kim, EJ; Kim, EY; Kim, JH; Kim, M; Lee, C; Lee, S; Park, H; Sohn, Y, 2023) |
| Excerpt | Reference |
|---|
| "The aetiology and treatment of the osteoporosis and the periosteal reactions remain obscure." | ( Long, RG; Wills, MR, 1978) |
| "The efficacy of long term treatment of senile osteoporosis by low doses of calcitonin was established using five parameters of calcium kinetics and a quantitative pain scale." | ( Coutris, G; Milhaud, G; Talbot, JN, 1975) |
| "The results suggest that fluoride treatment of osteoporosis can be continued beyond one year." | ( Fuchs, C; Hauswaldt, C; Hesch, RD; Köbberling, J; Unger, KO, 1977) |
| "Even for the treatment of osteoporosis, there may be safer alternative therapies." | ( , 1976) |
| "In Paget's disease and fluoride-treated osteoporosis a thickening of rarefied trabeculae in both was associated in Paget's disease only with an increase in the trabecular number and the transformation of a discontinuous arrangement into a more continuous network." | ( Aaron, JE; de Vernejoul, MC; Kanis, JA, 1992) |
| "Cyclical treatments of osteoporosis utilizing a skeletal Activator of bone remodelling, and sequential therapy with a Depressor to selectively block the resulting phase of osteoclastic resorption have been dubbed 'ADFR' therapy; there is usually a treatment Free interval while the activated bone multicellular units complete the remodelling cycle before the protocol is Repeated." | ( Drost, DJ; Fraher, LJ; Hodsman, AB; Steer, BM, 1991) |
| "Fluoride has been used for the treatment of osteoporosis since 1961, because it increases trabecular bone mass in the spine and may be effective in the treatment of spinal osteoporosis." | ( Inkovaara, JA, 1991) |
| "Clearly, successful treatment of osteoporosis remains an unsolved problem." | ( Lee, JR, 1991) |
| "GH was used to treat osteoporosis in a few clinical trials." | ( Netelenbos, JC; van der Veen, EA, 1990) |
| "The decisive progress in the treatment of osteoporosis is to be expected from an essentially improved and pathophysiologically oriented differential diagnosis and the resulting differential therapy." | ( Abendroth, K, 1990) |
| "When deciding about treatment of osteoporosis in the elderly, it should be noted that few studies have included patients over 75 years of age and that prevention of bone loss is more effective than restoration of lost bone." | ( Meuleman, J, 1989) |
| "Thirteen patients did not have any treatment for osteoporosis and served as a patient control group." | ( Yamada, H, 1989) |
| "It has proved worthwhile to treat osteoporosis simultaneously in two ways." | ( Dambacher, MA, 1988) |
| "Recently, fluoride has been used in the treatment of osteoporosis in an attempt to rebuild bone lost due to this disease." | ( Cheng, PT; Grynpas, MD, 1988) |
| "Report on 3 female patients who, after treatment of an osteoporosis with sodium fluoride, have developed a skeletal fluorosis." | ( Eisengarten, K; Leuschke, W; Schmidt, CW, 1986) |
| "Fluoride treatment of osteoporosis results in tangible improvement, but its pharmacological basis is incompletely understood and therapeutic doses are not tolerated indefinitely or by all patients." | ( Barmes, DE; Schamschula, RG, 1981) |
| "It is concluded that treatment of osteoporosis with 1 alpha-OHD3 and calcium is ineffective and potentially dangerous because it frequently causes hypercalcemia." | ( Alhava, EM; Aro, A; Hoikka, V; Karjalainen, P; Rehnberg, V, 1980) |
| "26 women were treated for osteoporosis with 40 mg of sodium fluoride twice a day (equivalent 36 mg of fluorine) for a longer period." | ( Börner, W; Eichner, R; Henschler, D; Köhler, W; Moll, E, 1981) |
| "New approaches to treatment of osteoporosis will emerge as our understanding of the pathogenesis increases." | ( Pilbeam, CC; Prestwood, KM; Raisz, LG, 1995) |
| "The drug treatment of osteoporosis has to be accompanied by a proper pain therapy as well as a physiotherapeutic, orthopedic and psychososical care." | ( Geidel, H, 1995) |
| "The use of 1,25(OH)2D for treatment of osteoporosis in individuals with adequate nutrition and sunlight exposure may require somewhat higher than physiologic doses to be effective." | ( Bikle, DD, 1994) |
| "Calcium and RKH were effective in treating osteoporosis and they could recover the level of estrogen and 1,25-(OH)2-D3 to normal state, the effect of RKH was better than that of calcium." | ( Li, E; Liu, HD; Tong, XX, 1993) |
| "The efficacy of treatments for osteoporosis does not become evident when evaluated by fracture incidence (FI)." | ( Burckhardt, P; Burnand, B, 1993) |
| "Interest in vitamin D treatment for osteoporosis has recently been revived because of the focus in various parts of the world on the elderly population, which is predominantly vitamin D deficient, in addition to postmenopausal osteoporosis due to estrogen withdrawal, which has been the central theme of osteoporosis research for many years." | ( Fujita, T, 1996) |
| "Long-term heparin treatment causes osteoporosis through an as yet undefined mechanism." | ( Andrew, M; Deschamps, P; Hirsh, J; Muir, JM; Shaughnessy, SG; Weitz, JI; Young, E, 1996) |
| "Many new agents for the treatment of osteoporosis are being examined." | ( Bellantoni, MF, 1996) |
| "The use of 1 alpha-OH-D3 for the treatment of osteoporosis in Canada cannot be supported without larger and longer randomized, controlled clinical trials." | ( Hanley, DA; Hogan, DB; Jones, G; Yendt, E, 1996) |
| "Therapies to prevent bone loss and treat established osteoporosis are uncommonly utilized in glucocorticoid-treated patients with end-stage pulmonary disease." | ( Addesso, V; Donovan, D; Jorgesen, B; McGregor, C; Papadopoulos, A; Schulman, L; Shane, E; Silverberg, SJ; Staron, RB, 1996) |
| "Sodium fluoride has been used to treat established osteoporosis for nearly 30 years." | ( Coggon, D; Cooper, C; Hillier, S; Inskip, H, 1996) |
| "Unique features of treatment for osteoporosis in Japan include rare use of estrogen replacement therapy, common use of vitamin D derivatives (especially 1alpha(OH) vitamin D) without notable side effects, and use of calcitonin almost exclusively in a low-dose intermittent regimen (20 U/week)." | ( Fujita, T, 1996) |
| "We conclude that in the treatment of osteoporosis, NaF has a protective effect against vertebral and nonvertebral fractures, does not increase the risk of femoral fractures, but has a higher incidence of untoward symptomatology." | ( Armadans, L; Farrerons, J; Guañabens, N; López-Navidad, A; Renau, A; Rodríguez de la Serna, A; Vaqué, J; Yoldi, B, 1997) |
| "Agents for prevention or treatment of osteoporosis must now be tested in a large animal species that exhibits bone remodeling." | ( Jerome, CP; Lees, CJ; Turner, CH, 1997) |
| "There is no established treatment for osteoporosis in men, a common and disabling condition the incidence of which is increasing rapidly." | ( Anderson, FH; Francis, RM; Peaston, RT; Wastell, HJ, 1997) |
| "The paper concerns the nontraditional treatment of osteoporosis using endogenous substances regulating bone metabolism, and also new drugs." | ( Kanceva, RL; Zofková, I, 1997) |
| "Testosterone is an effective treatment for male osteoporosis associated with hypogonadism and is also promising in the treatment of osteoporosis in aged eugonadal males." | ( da Silva, JA; Porto, A, 1997) |
| "The number of agents for the treatment of osteoporosis has increased over the past few years allowing more and more differentiated therapy." | ( Koike, T; Orito, Y; Satoh, T; Yoshida, G, 1998) |
| "Alendronate is indicated for the treatment of osteoporosis in post-menopausal women." | ( Freemantle, SN; Mackay, FJ; Mann, RD; Pearce, GL; Wilton, LV, 1998) |
| "Fluorides salts are used in the treatment for osteoporosis for 30 years, since their anabolic action on trabecular bone is well documented, but safety and efficacy of this treatment is still debated." | ( Bohatyrewicz, A, 1998) |
| "Fluoride has been used in the treatment for osteoporosis for more than 30 years but its use is still controversial." | ( Lips, P, 1998) |
| "For the treatment of osteoporosis the best result could be obtained with a combined treatment with monofluorophosphate, stimulating osteoblasts and production of new bone, and a bisphosphonate, which simultaneously inhibits osteoclasts and bone resorption." | ( Duursma, SA; Raymakers, JA, 1998) |
| "Drugs for treating osteoporosis include hormone replacement therapy, alendronate, and nasal calcitonin." | ( O'Connell, MB, 1999) |
| "Cost/benefit analyses of alendronate treatment for osteoporosis should include costs of treating ARD." | ( Ettinger, B; Pressman, A; Schein, J, 1998) |
| "Evidence of the efficacy of treatment for osteoporosis is shown by a reduced probability of fracture." | ( Juby, A, 1999) |
| "Good evidence indicates that adequate treatment of osteoporosis can prevent fractures and thus reduce associated morbidity and mortality among vulnerable elderly people." | ( Juby, A, 1999) |
| "Exogenous estrogen can prevent and treat osteoporosis and is available in several delivery routes." | ( Meiner, SE, 1999) |
| "The longterm benefits of rhGH in the treatment of osteoporosis remain unclear." | ( Ansell, BM; Davies, UM; Preece, M; Reeve, J; Rooney, M; Woo, PM, 2000) |
| "One class of agents used to treat osteoporosis is the bisphosphonates, which inhibit bone resorption, cause an increase in bone mineral density and reduce the risk of future fractures caused by aging, estrogen deficiency and corticosteroid use." | ( Bone, H; Greenspan, SL; Harris, ST; Miller, PD; Orwoll, ES; Rosen, CJ; Watts, NB, 2000) |
| "Most CR investigated and treated osteoporosis themselves, 13% referred to other specialists for investigation, and 22% referred for treatment." | ( Adachi, JD; Bellamy, N; Campbell, J; Flynn, J; Pope, JE; Soucy, E; Sutton, E, 2000) |
| "Active vitamin D drugs are used for the treatment of osteoporosis in a number of countries, including Japan." | ( Ikeda, K; Ogata, E, 2000) |
| "The goal of drug treatment of osteoporosis is to prevent fractures." | ( Halbekath, J, 2000) |
| "The rate of diagnosis and treatment of osteoporosis in this patient group is unknown." | ( Bogoch, ER; Hajcsar, EE; Hawker, G, 2000) |
| "Possible treatment of osteoporosis in course of male hypogonadism is discussed." | ( Jóźków, P; Medraś, M, 2000) |
| "Studies of untreated and treated osteoporosis in postmenopausal women have also contributed to this knowledge and have provided unequivocal evidence for the potential of high-dose estrogen therapy to have anabolic skeletal effects." | ( Compston, JE, 2001) |
| "Drug treatments for osteoporosis are intended to inhibit bone resorption, reduce the rate of bone turnover, and increase bone mass." | ( Baran, D, 2001) |
| "In addition to treating osteoporosis, PTHs may be used to promote fracture healing, to restore bone loss in immobilized patients, or following excessive glucocorticoid or prolonged spaceflight, and to treat psoriasis." | ( Morley, P; Whitfield, JF; Willick, GE, 2001) |
| "We discuss this approach of treating osteoporosis with corticoids and immunosuppressors according to the present knowledge of bone biology." | ( Fassi, J; Plantalech, L, 2001) |
| "The diagnosis and treatment of osteoporosis is an important aspect of gynecologic training and practice." | ( Jennings, JC; Kauffman, RP; Overton, TH; Shiflett, M, 2001) |
| "Recent additions to the treatment of osteoporosis with potent bone active drugs produce an even greater need for calcium and total nutrition for restoration of lost bone." | ( Dowd, R, 2001) |
| "Specific treatment against osteoporosis was in most cases instituted secondary to osteoporotic complications." | ( Gudbjornsson, B; Gudjonsson, FV; Juliusson, UI, 2002) |
| "One of the major side-effects of this treatment is osteoporosis, which may result in the increased occurrence of fractures." | ( Boomsma, MM; Karsijns, M; Kramer, AB; Piers, DA; Stegeman, CA; Tervaert, JW, 2002) |
| "The majority of treatment for osteoporosis has focused on secondary and tertiary strategies that attempt to preserve acquired adult bone mass." | ( Durst, ES, 2000) |
| "Raloxifene a related SERM is used to treat and prevent osteoporosis with the potential beneficial side effect of preventing breast cancer." | ( Bentrem, DJ; Craig Jordan, V, 2002) |
| "Issues relating to the treatment of the osteoporosis as well as the lymphoma arise in patients that present in this way." | ( Atoyebi, W; Brown, M; Hatton, C; Littlewood, TJ; Wass, J, 2002) |
| "HRT is effective for treating osteoporosis, with improvement in bone density and reduction in vertebral fractures." | ( Ames, R; Clearwater, J; Evans, MC; Gamble, G; Reid, IR; Wu, F, 2002) |
| "For the drug treatment of osteoporosis in the first years after menopause, oestrogens, tibolone and raloxifene may be used." | ( Pols, HA; Wittenberg, J, 2002) |
| "Antiresorptive therapy are usual treatment of osteoporosis, but they prevent no more than 40 or 60% of osteoporotic fracture." | ( Chaouat, D, 2002) |
| "Alendronate has been approved for treatment of osteoporosis in men, and other treatments for men are under evaluation." | ( Deal, C; Srivastava, M, 2002) |
| "Up to 80-90% of patients with treatment-requiring osteoporosis are not receiving specific treatment." | ( Begerow, B; Hinz, C; Minne, HW; Pfeifer, M; Pollähne, W, 2002) |
| "Alendronate is an agent for the treatment of osteoporosis that has established safety with regards to bone quality since it neither inhibits bone calcification nor influences fracture healing in chronic administration." | ( Komatsu, S; Ohta, T; Tokutake, N, 2002) |
| "New drugs to treat osteoporosis, along with two new minimally invasive surgical procedures, are important options for preventing vertebral compression fractures and treating severe back pain and disability." | ( Mazanec, DJ; Mompoint, A; Podichetty, VK; Potnis, A, 2003) |
| "RSD is available for the treatment of osteoporosis." | ( Fukunaga, M, 2003) |
| "The aim of prevention and treatment of osteoporosis is to prevent the occurrence of future fractures." | ( Christodoulou, C; Cooper, C, 2003) |
| "Bisphosphonate drugs for treating osteoporosis are excreted by the kidney." | ( Cavanaugh, PF; Connelly, JE; Gordon, MJ; Klawansky, S; Komaroff, E; Mitchell, DY; Ross, SD, 2003) |
| "BSHXL could prevent and treat osteoporosis in male rats induced by DM." | ( Chen, K; Hou, L; Lu, D; Ma, X; Peng, K; Wang, T; Zhang, R; Zhu, X, 2003) |
| "In the treatment of osteoporosis, the tolerance of oral bisphosphonates is often low." | ( Burckhardt, P; Burnand, J; Fatio, S; Lamy, O; Pache, I; Sandini, L, 2003) |
| "The diagnosis and treatment of osteoporosis have changed dramatically in the last decade." | ( Black, DM; Greenspan, SL; Rosen, CJ, 2004) |
| "Diagnosis and treatment of osteoporosis are focused on demineralisation but bone mineral density is not directly correlated with bone strength." | ( Liverneaux, P, 2004) |
| "PE is effective in preventing and treating osteoporosis in ovariectomized rats." | ( Wang, YJ; Xu, JL; Zhang, J, 2004) |
| "For example, treatments for osteoporosis may have unanticipated effects on vascular calcification; the converse also applies." | ( Abedin, M; Demer, LL; Tintut, Y, 2004) |
| "This may lead to new strategies for the treatment of osteoporosis and the low turnover bone disease of some dialysis patients." | ( Bushinsky, D; Silver, J, 2004) |
| "The level of recognition and treatment of osteoporosis is not well characterized in primary care." | ( Clapham, S; Eisman, J; Kehoe, L, 2004) |
| "Subjects were patients that were treated for osteoporosis at Department for physical medicine and rehabilitation in Clinical hospital Dubrava." | ( Badovinac, O; Delija, A; Sakić, D; Sakić, VA, 2004) |
| "In recent years, treatments for osteoporosis have been developing rapidly, and many of these research results have been reported." | ( Nakamura, T, 2004) |
| "There is no well-established treatment for osteoporosis in male patients with leprosy, because no clinical trials have examined the efficacy of treatment on bone mineral density (BMD) or fracture incidence in patients with leprosy." | ( Ando, K; Higashi, M; Ichinose, H; Kanaji, A; Nakagawa, M; Namisato, M; Sakamaki, T; Yamada, H; Yato, Y, 2005) |
| "This may suggest new approaches to the treatment of male osteoporosis." | ( Alexandre, C, 2005) |
| "In this study of elderly men and women treated for osteoporosis (n=5,313), 60." | ( Dukas, L; Schacht, E; Stähelin, HB, 2005) |
| "We succeeded in treating osteoporosis in SAMP6 mice after the onset of this disease, using a newly developed method of bone marrow transplantation (BMT): Allogeneic bone marrow cells obtained from normal mouse strains were directly injected into the bone marrow cavity of irradiated SAMP6 mice (intra-bone marrow BMT [IBM-BMT])." | ( Baba, S; Hisha, H; Ichioka, N; Iida, H; Ikehara, S; Inaba, M; Mizokami, T; Taira, M; Takada, K; Ueda, Y; Wang, X, 2006) |
| "Pharmacological treatment of osteoporosis is based mainly on antiresorptive agents." | ( Alonso, G; Fernández-García, D; Muñoz-Torres, M, 2005) |
| "The bisphosphonates, widely used in the treatment of osteoporosis, act by inhibiting bone resorption." | ( Fleming, A; Goldsmith, P; Sato, M, 2005) |
| "Finally, 52% of patients had stopped treatment given for osteoporosis after a mean period of 1." | ( Bona, E; Carnevale, V; Minisola, S; Nieddu, L; Piemonte, S; Romagnoli, E; Scillitani, A, 2006) |
| "Drug treatment of osteoporosis is based on the knowledge of mechanisms of bone turnover and the manipulation of the cellular components of bone turnover in terms of recruitment, activation and apoptosis of the cells involved." | ( Geusens, P; Reid, D, 2005) |
| "However, the identification and treatment of osteoporosis in these high-risk patients are widely reported to be inadequate." | ( Beaton, DE; Bogoch, ER; Elliot-Gibson, V; Jamal, SA; Josse, RG; Murray, TM, 2006) |
| "Only one patient received advice or treatment regarding osteoporosis at the time of fracture." | ( Beringer, T; Finch, M; Keegan, D; Kelly, J; McKane, R; McNally, C; McQuilken, M; Taggart, H; Whithead, E; Wright, S, 2007) |
| "Vitamin K2 is widely used for the treatment of osteoporosis in Japan." | ( Iwamoto, J; Sato, Y; Takeda, T, 2006) |
| "Osteoporosis results in fractures and treatment of osteoporosis has been shown to reduce risk of fracture particularly in those who have had a history of fracture." | ( Jones, TJ; Petrella, RJ, 2006) |
| "The frequency of medication use for the treatment of osteoporosis including estrogen replacement therapy, bisphosponates, calcitonin, calcium and vitamin D therapy was determined on admission, at 6 weeks post discharge and one year following discharge." | ( Jones, TJ; Petrella, RJ, 2006) |
| "Icariin could effectively prevent and treat osteoporosis and promote the bone formation." | ( Chen, A; Guo, F; Xiao, Q, 2005) |
| "After 1 year of treatment, osteoporosis completely recovered in six patients (28." | ( Abaci, A; Bober, E; Büyükgebiz, A; Unal, E, 2006) |
| "In the medical treatment of osteoporosis and metabolic osteopathies bisphosphonates could be rightly denoted as groundbreaking." | ( Fassbender, WJ; Kurth, A; Stumpf, UC, 2006) |
| "Bisphosphonates form the mainstay of treatment in osteoporosis; however, current adherence with therapy is inadequate." | ( Burke, MS; Simonelli, C, 2006) |
| "There is no well-established treatment for osteoporosis in male patients with leprosy, because no clinical trials have examined the efficacy of treatment on bone mineral density (BMD) or fracture incidence in such patients." | ( Ando, K; Higashi, M; Kanaji, A; Namisato, M; Nishio, M; Yamada, H, 2006) |
| "Strontium ranelate is a new treatment for osteoporosis that results in large increases in BMD, much of which is an artefact caused by high bone strontium content." | ( Blake, GM; Fogelman, I, 2006) |
| "In 2002, Adequate Treatment of Osteoporosis (A-TOP) Research Group was organized to obtain the evidence for treatment of osteoporosis in Japan." | ( Kuroda, T; Miyakawa, N; Orimo, H, 2006) |
| "The most important goal in the treatment of osteoporosis is fracture prevention." | ( Inoue, D; Matsumoto, T, 2006) |
| "Prompt diagnosis and treatment of osteoporosis reduce refracture rates." | ( Cho, T; Freedman, BA; Kuklo, TR; Nesti, LJ; Potter, BK, 2007) |
| "Patients undergoing treatment for osteoporosis have reported hardening of their fingernails." | ( Chowdhury, S; German, MJ; Lawson, NS; Lyons, D; Moran, P; Pillay, I; Pollock, HM; Saunders, J; Towler, MR, 2007) |
| "Fifty-four patients were treated for osteoporosis-related fractures and 5 had malignant disease." | ( Kobayashi, N; Matsusako, M; Numaguchi, Y; Rahman, M; Saida, Y; Uemura, A, 2007) |
| "But many physicians concerning treatment of osteoporosis had been interested in increase of bone mineral density, decrease of fracture rate and improvement of bone quality, instead of relief of the pain." | ( Hayashi, Y, 2007) |
| "They are indicated for the treatment of osteoporosis." | ( Beirne, JC; Khosa, AD; Nayyar, MS, 2007) |
| "Bisphosphonates have been used to treat osteoporosis for more than ten years." | ( Choo, KS; Kim, JS; Ryu, JH; Won, JH; Yang, KH; Yoon, HK, 2007) |
| "Long-term treatment of osteoporosis is required for optimal efficacy, but adherence to therapy is suboptimal with daily and weekly oral bisphosphonates." | ( Babic-Naglic, D; Curkovic, B; Grazio, S; Kehler, T, 2008) |
| "To investigate alendronate for treating osteoporosis in men." | ( Davison, KS; Olszynski, WP, 2008) |
| "Most drugs for treating osteoporosis seem safe for patients with mildly decreased renal function (glomerular filtration rate [GFR] 60-90 ml/min)." | ( Eiken, PA; Vestergaard, P, 2008) |
| "To effectively treat osteoporosis and other bone-loss disorders, small compounds that potently induce bone formation are needed." | ( Chung, UI; Hojo, H; Igawa, K; Ikeda, T; Komiyama, Y; Lichtler, AC; Nakajima, K; Ohba, S; Takato, T; Woo, JT; Yano, F; Yonezawa, T, 2008) |
| "Vitamin K2 has been approved for the treatment of osteoporosis in Japan since 1995." | ( Ishida, Y, 2008) |
| "Current approved medical treatments for osteoporosis reduce fracture risk to a greater degree than predicted from change in BMD in women with postmenopausal osteoporosis." | ( Busse, C; Cheng, Z; Lane, NE; Ritchie, RO; Yao, W; Zimmermann, EA, 2009) |
| "To describe new agents for the treatment of osteoporosis, discuss a conceptual framework of agents that are antiresorptive or anabolic, and review pathways that affect bone turnover and steps in those pathways that are targets for new therapeutic agents." | ( Deal, C, 2009) |
| "Trends in the use of different treatments for osteoporosis among the civilian, ambulatory U." | ( Blalock, SJ; Farley, JF, 2009) |
| "Pharmacomedical treatments for osteoporosis were applied." | ( Gulan, G; Novak, S; Sestan, B; Tudor, A; Vrbanić, TS, 2008) |
| "Diagnosis and treatment of osteoporosis are evolving from BMD (bone mineral density) dependent manner to bone quality conscious manner." | ( Azuma, K, 2009) |
| "Individual patients who are treated for osteoporosis in clinical practice commonly differ from subjects enrolled in these clinical trials according to confounding factors that include age, sex, comorbidities, compliance, and persistence." | ( Lewiecki, EM, 2010) |
| "For the treatment of osteoporosis, anti-resorptive agents including bisphosphonates and raloxifene are widely used." | ( Endo, I; Matsumoto, T, 2010) |
| "Diagnosis and treatment of osteoporosis are often delayed especially in men, because the concept of male osteoporosis has not been fully penetrated." | ( Kawate, H; Takayanagi, R, 2010) |
| "The efficacy of treatments for osteoporosis can be evaluated using these techniques." | ( Ferrari, S, 2010) |
| "Women undergoing treatment for osteoporosis require long-term dosing therapeutic regimens, that offer no symptomatic relief, and may cause side effects." | ( Altavilla, D; Bitto, A; D'Anna, R; Granese, R; Irrera, N; Marini, H; Minutoli, L; Polito, F; Squadrito, F, 2010) |
| "The indication for BP was prevention or treatment of osteoporosis in 11 cases and breast with bone metastases in one case." | ( Barrier, A; Descroix, V; Goudot, P; Lescaille, G; Rigolet, A; Ruhin, B, 2010) |
| "Therapies to treat osteoporosis remain underutilized and minimally evaluated in frail elderly patients." | ( Abellan Van Kan, G; Boonen, S; Gillette-Guyonnet, S; Rolland, Y; Roux, C; Vellas, B, 2011) |
| "The imperative to treat osteoporosis appears to be greatest in frail patients since similar relative risk reductions would avert more fractures in frail than in non-frail elderly patients." | ( Abellan Van Kan, G; Boonen, S; Gillette-Guyonnet, S; Rolland, Y; Roux, C; Vellas, B, 2011) |
| "Poor persistence to treatment of osteoporosis should consequently be acknowledged as an important and costly health problem, and be taken into account when evaluating osteoporosis interventions." | ( Landfeldt, E; Lundkvist, J; Ström, O, 2011) |
| "Undertreatment of osteoporosis is common, even for high-risk patients." | ( Arora, T; Becker, DJ; Colon-Emeric, C; Curtis, JR; Delzell, E; Kilgore, ML; Matthews, RS; Morrisey, MA; Saag, KG; Safford, MM; Taylor, A; Warriner, A, 2010) |
| "Prevention and treatment of osteoporosis in COPD should therefore be based on population specific risk assessments which combine measures of bone mineral density and clinical factors." | ( Decramer, M; Janssens, W; Lehouck, A; Troosters, T; van Remoortel, H, 2010) |
| "In order to improve the treatment of osteoporosis, identification of anabolic and orally available agents with minimal side effects is highly desirable." | ( Chen, D; Huang, J; Shi, Q; Tang, DZ; Wang, YJ; Yang, F; Yang, Z, 2011) |
| "Primary exposure was medical treatment for osteoporosis, and the outcome was all-cause mortality." | ( Juntunen, M; Lüthje, P; Nurmi-Lüthje, I; Sund, R, 2011) |
| "Early prevention and treatment of osteoporosis in COPD is, therefore, important and should be based on integrated risk assessment tools such as FRAX, which take bone mineral density, history of fragility fractures, and population-specific clinical factors into account." | ( Boonen, S; Decramer, M; Janssens, W; Lehouck, A, 2011) |
| "The most common treatment of osteoporosis is N-containing bisphosphonates, a class of non-hydrolyzable pyrophosphate analogs." | ( Leong, WF; Li, B; Ling Chau, JF; Wang, X, 2011) |
| "The more recent guidelines for treating osteoporosis now include men, but the recommendations for screening and treatment are not necessarily gender specific." | ( Das, S; Gates, BJ, 2011) |
| "Intense treatment for osteoporosis is warranted in diabetics who have other established fracture risks such as those with prevalent fractures or postmenopausal state." | ( Okazaki, R, 2011) |
| "In order to effectively treat osteoporosis and other bone-loss disorders, small compounds that could induce bone formation are needed." | ( Du, J; Jiang, YP; Peng, C; Qin, LP; Rahman, K; Ran, X; Wei, YJ; Zhang, H, 2011) |
| "Due to the recent advances in the treatment of osteoporosis, clinicians can utilize many kinds of drugs to prevent fractures." | ( Shiraki, M, 2011) |
| "The mainstay of the treatment of osteoporosis is the bisphosphonate group that includes effective anti-resorptive compounds mitigating bone loss and fragility." | ( Lakatos, P, 2011) |
| "Current treatments for osteoporosis are associated with various side effects and do not prevent the age-related decrease in osteoblast number." | ( Chang, K; Cheong, M; Deng, W; Hsiao, W; Lam, G; Lee, C; Liu, H; Tsai, C; Wang, M; Wu, C, 2011) |
| "In addition to systemic treatment, osteoporosis may be treated topically by incorporating calcium and phosphate into the bone." | ( Boda, K; Gomez, I; Pap, L; Szabó, A; Szekanecz, Z, 2012) |
| "Prevention and treatment for osteoporosis in the transplant recipient are also discussed." | ( Borba, VZ; Custódio, MR; Kulak, CA; Kulak, J, 2012) |
| "Drugs used for the prevention and the treatment of osteoporosis exert various favourable and unfavourable extra-skeletal effects whose importance is increasingly recognized notably for treatment selection." | ( Bergmann, P; Body, JJ; Boonen, S; Devogelaer, JP; Gielen, E; Goemaere, S; Kaufman, JM; Reginster, JY; Rozenberg, S, 2012) |
| "Bisphosphonates are used widely to treat osteoporosis in adults and are used increasingly for primary and secondary osteoporosis in children." | ( Briody, J; McQuade, M; Munns, CF; Ooi, HL, 2012) |
| "Current methods of bone defect treatment for osteoporosis are not always satisfactory." | ( Cao, L; Dai, K; Fan, Q; Gan, Y; Liu, G; Tang, T; Yang, F; Zhang, X, 2012) |
| "Persistence and compliance during the treatment of osteoporosis were found to be insufficient." | ( Boeckhoff, J; Hadji, P; Kostev, K; Kyvernitakis, I; Ziller, V, 2012) |
| "The methods used in treatment of osteoporosis induced by glucocorticosteroids are not effective enough." | ( Kaczmarczyk-Sedlak, I; Rotko, K; Sedlak, L; Zych, M, 2012) |
| "Most medication used for the treatment of osteoporosis is antiresorptive; however, strontium ranelate (Sr) therapy in postmenopausal women has shown a double effect on resorption and bone formation." | ( Berköz, M; Comelekoglu, U; Eroglu, P; Sagír, O; Yalin, S, 2012) |
| "Undertreatment of osteoporosis was common in rural patients." | ( Ang, WM; Lai, MM; Larke, AB; McGuiness, M, 2012) |
| "Both RAL and RIS could treat osteoporosis in ORX rats; they reduced bone turnover markers and maintained BMD." | ( El-Abd, EE; El-Ashmawy, NE; El-Bahrawy, HA; Haggag, AA; Khedr, NF, 2013) |
| "Most drugs for treating osteoporosis seem safe in terms of affecting renal function for patients with mildly to moderate decreased renal function." | ( Eiken, PA; Vestergaard, P, 2012) |
| "The use of bisphosphonates for the treatment of osteoporosis is increasing." | ( De Smet, L; Degreef, I; Didden, K; Sciot, R; Vandenberghe, L, 2012) |
| "Clinically, Sr was applied for treatment of osteoporosis, composite biomaterials in tissue engineering, and treatment of bone tumors and bone metastases." | ( Lei, Y; Li, L; Meng, Z, 2012) |
| "Prevention or treatment of osteoporosis should be considered in all patients who received a daily dose of at least 7." | ( Briot, K; Roux, C, 2013) |
| "Specific agents used for treatment of osteoporosis include bisphosphonates, calcitonin, hormonal therapy, and raloxifene." | ( Carey, EJ; Yadav, A, 2013) |
| "Alendronate is commonly used in the treatment of osteoporosis and other bone diseases." | ( Bee, J; Hanna, J; Sataloff, RT, 2012) |
| "Current treatments for osteoporosis are limited by lack of effect on cortical bone, side effects, and, in some cases, cost." | ( Hamilton, CJ; Jamal, SA; Reid, LS, 2013) |
| "Older hypogonadal males should be treated in cases of osteoporosis, reduced muscle strength and increased risk of falling." | ( Mosekilde, L; Rejnmark, L; Vestergaard, P, 2013) |
| "The guidance given in treating osteoporosis can potentially enhance adherence." | ( Chen, SH; Cheng, TT; Hsu, CY; Su, BY; Yang, TS; Yu, SF, 2013) |
| "Raloxifene is a drug for the treatment of osteoporosis and for the prevention of estrogen receptor-positive breast cancer because it guarantees a safety profile on the endometrium." | ( Ancona, E; Berretta, R; Bertocco, A; Capobianco, G; D'Antona, D; Di Gangi, S; Gizzo, S; Nardelli, GB; Noventa, M; Patrelli, TS; Saccardi, C; Vacilotto, A, 2013) |
| "Compliance of oral alendronate to treat osteoporosis in elderly male patients is poor." | ( Fang, FS; Hou, HR; Jiang, Y; Li, CL; Liu, MY; Pei, Y; Pi, HY; Yan, YF, 2013) |
| "Pharmaceutical countermeasures to treat disuse osteoporosis are rarely studied." | ( Fung, KP; Hung, LK; Ko, CH; Lau, CB; Lau, CP; Leung, PC; Siu, WS, 2013) |
| "The first use of zoledronic acid in the treatment of osteoporosis appears high incidence of APR." | ( Chen, DC; Chen, Y; Guo, YH; Liu, T; Lu, CY; Wang, Q, 2013) |
| "Multiple therapies are approved for the treatment of osteoporosis (OP), but many patients with osteoporosis may not initiate treatment upon osteoporosis diagnosis." | ( Gandhi, S; Modi, A; Sen, S; Siris, ES; Tang, J, 2014) |
| "Bisphosphonates are first-line treatment for osteoporosis." | ( Cadarette, SM; Juurlink, DN; Krahn, MD; Lévesque, LE; Mamdani, MM; Tadrous, M; Wong, L, 2014) |
| "In order to effectively treat osteoporosis, there has been an extended research on the biological activities of traditional medicines since synthetic medicines possess several side effects that reduce their efficacy." | ( Mohamed, N; Rufus, P; Shuid, AN, 2013) |
| "Despite substantial improvements in the treatment of osteoporosis over the last few decades, osteoporotic fractures are still a major clinical challenge in the elderly population due to impaired healing." | ( Guelcher, SA; Sterling, JA, 2014) |
| "Zoledronic acid is used in the treatment of osteoporosis." | ( Arkfeld, DG; Ibrahim, M; Metyas, S; Solyman, J; Yeter, KC, 2014) |
| "Antiresorptive agents, used in the treatment of osteoporosis, inhibit either osteoclast formation or function." | ( Ng, KW; Sims, NA, 2014) |
| "In order to improve the treatment of osteoporosis, available agents with roles of regulating the balance is highly desirable." | ( Hao, YQ; Lu, ZM; Yang, F; Yuan, PW, 2014) |
| "Two new approaches for the treatment of osteoporosis are summarized, each having arisen out of important new discoveries in bone biology." | ( Martin, TJ; Ng, KW, 2014) |
| "Individual agents used to treat human osteoporosis reduce fracture risk by ∼ 50-60%." | ( Amugongo, SK; Dai, W; Dave, NK; Jia, J; Jiang, L; Lane, NE; Lay, YA; Li, CS; Olivera, D; Panganiban, B; Ritchie, RO; Walsh, D; Yao, W, 2014) |
| "And it can have synergy effects on the treatment of osteoporosis if it is used combining with estrogen." | ( Bai, G; Di, J; Jiang, L; Lin, Z; Sun, Z, 2014) |
| "Different treatments for osteoporosis are available." | ( Gambacciani, M; Levancini, M, 2014) |
| "Bisphosphonates have been used to treat secondary osteoporosis in children, but limited experience and potential long-term toxicity warrant caution in routine use." | ( Cimaz, R; Corbin, KJ; Stagi, S; Stefano, S; von Scheven, E, 2014) |
| "The present treatments for osteoporosis relies on systemic medications intended to increase the bone mineral density (BMD)." | ( Gong, K; Liu, D; Pan, XM; Quan, Y; Wang, CR; Wu, ZX; Xie, QY; Zhang, B; Zhang, Y, 2016) |
| "Real-world persistence to treatment of osteoporosis is well-understood, but little is known of the posttreatment residual effect on fractures." | ( Garellick, G; Landfeldt, E; Ström, O, 2015) |
| "Despite the lack of consensus on the treatment of osteoporosis in NF1, risedronate may hold a promise as a potential therapy for osteoporosis complicating NF1." | ( Benlidayi, IC; Kozanoglu, E; Ortac, EA, 2015) |
| "We term this strategy as the "local treatment of osteoporosis"." | ( Li, G; Tang, H; Wang, J; Zhao, J, 2014) |
| "Drugs now approved for treatment of osteoporosis in men include the anti-resorptive bisphosphonates alendronate, residronate and zoledronic acid, the anti-resorptive drug denosumab, the bone-forming agent teriparatide, and (not in the US) strontium ranelate with mild opposite effects on resorption and formation." | ( Goemaere, S; Kaufman, JM; Lapauw, B, 2014) |
| "Recently, simvastatin has been used to treat osteoporosis more frequently; however, its clinical effect and treatment mechanism are still unknown." | ( Dai, L; Hu, M; Shen, Z; Wang, Y; Wu, H; Xu, M; Xue, L; Yuan, D; Zhao, H, 2016) |
| "The target to treat osteoporosis is prevention for future fractures." | ( Gorai, I, 2015) |
| "Bisphosphonates are widely used for the treatment of osteoporosis and other bone-degrading disorders; however, bisphosphonate therapy is an important risk factor for osteonecrosis of the jaws." | ( Kaneko, K; Takahashi, H, 2014) |
| "Eldecalcitol can be used for the treatment of osteoporosis without Ca supplementation to reduce the incidence of hypercalcemia and hypercalciuria, and enough hydration is recommended in order to avoid hypercalcemia, urolithiasis and deterioration of renal function." | ( Kondo, S; Matsumoto, T; Ono, Y; Saito, H; Takano, T, 2015) |
| "Denosumab is a biologic agent used to treat osteoporosis." | ( Chen, L; Curtis, JR; Delzell, E; Saag, KG; Xie, F; Yun, H, 2015) |
| "Many drugs for the treatment of osteoporosis have also been associated with increased risks of serious adverse events." | ( Aspenberg, P; Järvinen, TL; Michaëlsson, K; Sievänen, H, 2015) |
| "Bisphosphonates (BP) are used in the treatment of severe osteoporosis and metastasis of malignant diseases." | ( Koy, J; Koy, S; Lauer, G; Ney, M; Sabatowski, R; Schubert, M, 2015) |
| "Given the need for easily managed treatment of osteoporosis in HIV-infected patients, we evaluated the efficacy and tolerability of two doses of zoledronate, by comparing three groups of patients: those with annual administration, those with biennial administration (one dose in 2 years) and a control group with no administration of zoledronate." | ( Bonjoch, A; Clotet, B; del Río, L; di Gregorio, S; Echeverría, P; Estany, C; Herrero, C; Negredo, E; Ornelas, A; Pérez-Álvarez, N; Puig, J, 2015) |
| "Currently, there are several treatments for osteoporosis however; they all display some sort of limitation and/or side effects making the need for new treatments imperative." | ( Ghayor, C; Gjoksi, B; Ruangsawasdi, N; Siegenthaler, B; Weber, FE; Zenobi-Wong, M, 2015) |
| "The preferred treatment for osteoporosis in men is debated, and pairwise meta-analysis cannot obtain hierarchies of these treatments." | ( Chen, LX; Feng, SQ; Li, YL; Ning, GZ; Zhang, D; Zhang, TS; Zhou, ZR, 2015) |
| "Bisphosphonates are effective for the treatment of osteoporosis despite recent reports of safety concerns such as atypical femur fracture." | ( Bhattacharyya, T; Jha, S; Laucis, N; Wang, Z, 2015) |
| "Current treatments for osteoporosis involve the administration of high doses of bisphosphonates (BPs) over a number of years." | ( Hilborn, J; Kootala, S; Leeuwenburgh, S; Ossipov, D; van den Beucken, JJ, 2015) |
| "Bisphosphonates are widely used to treat osteoporosis, but have been associated with atypical femoral fractures (AFFs) in the long term, which raises a critical health problem for the aging population." | ( Acevedo, C; Allen, MR; Bale, H; Burr, DB; Busse, B; Gludovatz, B; Ritchie, RO; Schaible, E; Tang, SY; Wang, M; Wat, A; Zimmermann, EA, 2015) |
| "The use of SIM-loaded TC-PLGA NPs in treating osteoporosis was tested through animal pharmacodynamics analyses performed in ovariectomized rats, and the results suggested that the SIM-loaded TC-PLGA NPs can improve the curative effects of SIM on the recovery of bone mineral density compared to either SIM-loaded PLGA NPs or SIM alone." | ( Chai, G; Hu, FQ; Liu, J; Tao, S; Wang, H; Wang, J; Yuan, H, 2015) |
| "Active vitamin D3 is used for the treatment for osteoporosis in Japan." | ( Marumo, K; Saito, M, 2015) |
| "The prevention and treatment of osteoporosis is an increasingly important topic in the solid organ transplant (SOT) population." | ( Early, C; Stuckey, L; Tischer, S, 2016) |
| "This drug is used for treating osteoporosis, a major bone disease affecting hundreds of millions of people worldwide, especially postmenopausal women." | ( Farina, M; Querido, W; Rossi, AL, 2016) |
| "Bisphosphonates have been used to treat osteoporosis and have shown great success in conserving bone mass and reducing fracture incidence." | ( Curtin, CM; Duffy, GP; Lee, TC; McCoy, RJ; Mulcahy, LE; O'Brien, FJ; Taylor, D, 2015) |
| "However, the effects of treatment for osteoporosis on body composition are not well known." | ( Inoue, S; Kuroda, T; Shiraki, M; Tanaka, S; Uenishi, K; Urano, T, 2017) |
| "Although the patients with treated osteoporosis also showed lower BMD values, these were not statistically significant compared to group 3." | ( Čellár, R; Lacko, M; Schreierová, D; Vaško, G, 2015) |
| "Denosumab is currently used to treat osteoporosis and in prevention of skeletal related events in patients suffering from bone metastases due to solid tumors." | ( Kiesel, L; Kohl, A, 2016) |
| "Diagnosis and treatment of osteoporosis are extremely important." | ( O'Connor, KM, 2016) |
| "With life standard improved, the treatment of osteoporosis attracted more attention." | ( Bi, Y; Li, Y; Pu, W; Yan, Z; Yuan, X; Zhou, K, 2016) |
| "Current treatments of osteoporosis encompass changing lifestyles, taking orthopedic drugs, and invasive surgeries." | ( Jung, J; Stout, DA; Wei, D; Yang, H; Yang, L, 2016) |
| "In order to establish standards for the treatment of osteoporosis in AN, studies on pharmacological treatment are conducted." | ( Bartoszewicz, Z; Jagielska, GW; Przedlacki, J; Racicka, E, 2016) |
| "New drugs that appear promising in the treatment of osteoporosis include the cathepsin K inhibitor, monoclonal antibodies against sclerostin and parathyroid hormone-related protein analog." | ( Chan, CK; Cooper, C; Dennison, E; Mason, A, 2016) |
| "Denosumab is a relatively safe treatment of osteoporosis." | ( Chen, J; Smerdely, P, 2017) |
| "In most patients, treatment of osteoporosis is a long-term challenge." | ( Abrahamsen, B; Eiken, PA, 2017) |
| "Many of the therapeutic agents used to treat osteoporosis are known to be affected by the renal function." | ( Nitta, K; Tsuchiya, K; Yajima, A, 2017) |
| "Although the pharmacological treatment of osteoporosis has been extensively developed, alternative treatments are still needed." | ( Chen, S; Fan, S; Jie, Z; Qin, A; Sun, X; Tang, P; Wang, J; Xie, Z; Yu, H, 2018) |
| "To study the adequacy of evaluation and treatment of osteoporosis after fragility fractures of the hip." | ( Al Habsi, KSK; Al Harthy, HHS; Al Ruzaiqi, HAH; Venugopal Menon, K, 2018) |
| "Teriparatide, a hallmark treatment for osteoporosis, has been shown to increase BMD and bone turnover." | ( Beckett, T; Burkard, D; Kourtjian, E; Messingschlager, C; Padley, M; Sipahi, R; Stubbart, J, 2018) |
| "We reviewed the files of 53 patients treated for severe osteoporosis with teriparatide for 6 to 24 months between May 2008 and January 2016." | ( Bégin, MJ; Coupal, L; Ethier, J; Räkel, A; Ste-Marie, LG, 2018) |
| "Bisphosphonates are the primary treatment for osteoporosis." | ( Das, N; Gupta, T; Imran, S, 2019) |
| "Intravenous alendronate is an effective treatment for osteoporosis in SMID patients." | ( Aihara, M; Ishii, S; Kaga, Y; Kamiya, Y; Kanemura, H; Kuroda, I; Nakamura, K; Sugita, K, 2017) |
| "Interestingly, other treatments for osteoporosis have been developed, such as antibodies against the osteocyte-secreted protein, sclerostin." | ( Aghaloo, TL; Bezouglaia, O; Boyce, RW; Dry, SM; Dwyer, D; Gkouveris, I; Hadaya, D; Pirih, FQ; Soundia, A; Stolina, M; Tetradis, S, 2019) |
| "Commonly used drugs for the treatment of osteoporosis have severe side effects." | ( Han, W; Jia, Y; Jiang, J; Lu, X; Qian, Y; Yang, W; Zhang, T; Zhao, K, 2019) |
| "Current treatments for osteoporosis have many limitations, including the non-obvious therapeutic effect and long-term safety issues." | ( Bian, T; Huang, J; Li, C; Liu, Z; Lyu, J; Pi, F; Sun, X; Wei, J; Zhong, Z, 2019) |
| "Pharmacologic prevention and treatment for osteoporosis are recommended for all patients receiving glucocorticoids." | ( Adachi, JD; Hu, K, 2019) |
| "This behavior recommends that treatment of osteoporosis via calcitonin does not provide the required upshots." | ( Asif, A; Javed, S; Nutini, A; Sohail, A, 2020) |
| "Strategies for the treatment of osteoporosis involve inhibition of bone resorption by osteoclasts and an increase of bone formation by osteoblasts." | ( Choi, Y; Kim, JK; Kim, P; Kim, WJ; Lee, G; Lee, JS; Nam, YJ; Seo, JH; Song, MJ; Yang, J; Yi, SS, 2019) |
| "Men with self-rated poor health, those treated for osteoporosis; anxiety, depression or high blood cholesterol, and those who lived in major cities or were aged 55–74 years had greater odds of TRT initiation." | ( Bateson, D; Cheng, Y; Concepcion, K; Estoesta, J; Lowy, M; McGeechan, K; Stewart, M; Sweeney, S, 2018) |
| "The basic treatment for osteoporosis remained unchanged in both groups(600 mg of calcium carbonate D3 and 0." | ( Huang, K; Wan, JM; Zhang, JF; Zhang, PL; Zhu, SY, 2019) |
| "Combination and sequential treatments using osteoporosis medications with different mechanisms of action have also been tested with promising results." | ( Cheng, C; Shoback, DM; Wentworth, K, 2020) |
| "Individuals being treated for osteoporosis should be reevaluated for fracture risk routinely, including via patient education about osteoporosis and fractures and monitoring for adverse treatment effects." | ( Adib, G; Adler, RA; Åkesson, KE; Alexander, IM; Amenta, KC; Blank, RD; Brox, WT; Carmody, EE; Chapman-Novakofski, K; Clarke, BL; Cody, KM; Conley, RB; Cooper, C; Crandall, CJ; Dirschl, DR; Eagen, TJ; Elderkin, AL; Fujita, M; Greenspan, SL; Halbout, P; Hochberg, MC; Javaid, M; Jeray, KJ; Kearns, AE; Khosla, S; Kiel, DP; King, T; Koinis, TF; Koontz, JS; Kužma, M; Lindsey, C; Lorentzon, M; Lyritis, GP; Michaud, LB; Miciano, A; Morin, SN; Mujahid, N; Napoli, N; Olenginski, TP; Puzas, JE; Rizou, S; Rosen, CJ; Saag, K; Thompson, E; Tosi, LL; Tracer, H, 2020) |
| "Excessive treatment of osteoporosis weakens immunity and self-repair." | ( Jing, W; Liu, Z; Wu, J; Xiong, Z, 2020) |
| "In this review the problem of how to treat osteoporosis in patient with diabetes is also discussed." | ( Jackuliak, P; Kužma, M; Payer, J, 2019) |
| "Several pharmacological treatment of osteoporosis has been developed; however, new treatments are still necessary." | ( Cheng, HM; Li, HJ; Li, P; Thu, PM; Xu, X; Zheng, ZG; Zhou, YP; Zhu, ST, 2020) |
| "Bisphosphonates are widely used in the treatment of osteoporosis in postmenopausal women and older men." | ( Compston, J, 2020) |
| "There is no gold standard of treatment for osteoporosis." | ( Chen, K; He, W; Li, B; Li, Z; Wu, Q; Xia, J; Xu, S; Yang, Y; You, X; Yu, T; Zhao, Y; Zhou, H; Zhu, H, 2020) |
| "Steps to prevent or treat osteoporosis should be considered in all patients who take the equivalent of prednisone at a dose of 2." | ( Hayat, S; Magrey, MN, 2020) |
| "For this, apart from the treatment of osteoporosis, effective prevention of both the development of the disease and related fractures is extremely important." | ( Brzezińska, O; Makowska, J; Walczak, K; Łukasik, Z, 2020) |
| "Alendronate was later reintroduced as treatment for osteoporosis and the patient once again presented with severe hypophosphataemia in subsequent routine blood tests." | ( Bagger, LW; Hansen, PKD; Nielsen, BR; Schwarz, P, 2020) |
| "Gumi Bao decoction is effective for the treatment of osteoporosis, but the theoretical and scientific basis is unknown." | ( Cheng, J; Feng, H; Gong, Z; Liang, G; Liu, H; Shen, X; Su, F; Yang, L, 2020) |
| "Many drugs have been utilized to treat osteoporosis but the most effective one is the bisphosphonates (BPs) family." | ( Oryan, A; Sahvieh, S, 2021) |
| "Since currently available treatments for osteoporosis, such as administration of female hormones or hormone receptor modulators, show serious side effects, SPC has potential as a new agent for osteoporosis treatment." | ( Bae, YS; Cho, KM; Choi, CY; Kim, H; Kim, HH; Kim, KK; Kim, MK; Lee, HY; Lee, M; Park, JS, 2021) |
| "Current methods to treat osteoporosis include medical and surgical options such as bone implants." | ( Chiu, YC; Huang, TH; Kao, CT; Lee, AK; Lin, YH; Liu, YC; Shie, MY, 2021) |
| "Drugs for treating osteoporosis generally inhibit osteoclast (OC) activity, but are rarely aimed at encouraging new bone growth and often cause severe systemic side effects." | ( Hachim, D; Jones, JR; Li, S; McFarlane, T; Naruphontjirakul, P; Pinna, A; Porter, AE; Stevens, MM; Torki Baghbaderani, M; Vigil Hernández, V, 2021) |
| "deserticola for the treatment of osteoporosis and the potential mechanisms." | ( Jiang, Y; Tu, P; Wang, F; Zeng, K, 2021) |
| "Berberine has been reported to treat osteoporosis due to its beneficial actions on bone formation." | ( Bi, J; Chen, QC; Pu, YL; Zhang, Y, 2021) |
| "Group 1 included 83 patients treated for osteoporosis alone, and group 2 included 76 patients treated for both osteoporosis and symptomatic LSS." | ( Baek, IH; Ha, JY; Kim, KW; Lee, JS; Park, HY; Park, SB, 2021) |
| "Although the pharmacological treatment of osteoporosis has been extensively developed, a safer and more effective treatment is still needed." | ( An, Q; Fan, S; Jiang, C; Jie, Z; Ma, Q; Shen, Y; Wang, S; Xie, Z; Yuan, P; Zheng, B, 2021) |
| "Pharmaceutical treatment for osteoporosis involves bisphosphonates, calcium and vitamin D3, denosumab, teriparatide, raloxifene, and strontium ranelate." | ( Kosiorowska, J; Szymańska-Chabowska, A; Tański, W, 2021) |
| "Current treatments for osteoporosis are very frequently inadequate." | ( Berry, TM; Moustafa, AA, 2021) |
| "Bisphosphonate is used widely in the treatment of adult osteoporosis." | ( Hurley, T; McDonald, D; McDonnell, C; Molloy, E; Stewart, P; Zareen, Z, 2021) |
| "To conclude, Epimedin B is effective in treating osteoporosis in mice via regulating PI3K-Akt, MAPK and PPAR signalling pathway." | ( Bi, Y; Diao, X; Song, L; Wang, L; Zhou, K; Zhou, Y, 2021) |
| "Most agents for treating osteoporosis focus primarily on anti-resorption by inhibiting osteoclast activity." | ( Dai, M; Lai, Q; Li, X; Liu, X; Liu, Y; Mo, F; Xu, H; Xu, Q; Zhan, P; Zhang, B, 2021) |
| "Zoledronate is widely used for the treatment of osteoporosis." | ( Eastell, R; Khwaja, A; Peel, N; Salam, S; Schini, M; Thomas, E; Toronjo-Urquiza, L; Walsh, JS, 2022) |
| "Bisphosphonates are first-line treatment of osteoporosis, and we aimed to investigate whether the risk of developing type 2 diabetes was associated with prior use of alendronate." | ( Al-Mashhadi, Z; Starup-Linde, J; Vestergaard, P; Viggers, R, 2021) |
| "However, the treatment of osteoporosis is challenging." | ( Gan, L; Li, A; Li, L; Zhu, L; Zuo, L, 2022) |
| "Denosumab is a newly approved treatment for osteoporosis in China." | ( Fan, T; Li, W; Ning, Z; Wang, J; Wang, M; Wen, A; Yang, Z; Yao, M; Zhang, W, 2022) |
| "Considering the massive treatment gap for osteoporosis, and the related fracture risk, clinicians should continue treatment, even during a pandemic." | ( Behanova, M; Haschka, J; Kocijan, R; Reichardt, B; Resch, H; Stockinger, T; Zwerina, J, 2022) |
| "The drugs most commonly used in the treatment of osteoporosis are bisphosphonates." | ( Jakubowski, M; Ratajczak, M; Sandomierski, M; Voelkel, A, 2022) |
| "Zoledronic acid (ZA) is used for the treatment of osteoporosis (OP)." | ( Fixen, CW; Fixen, DR, 2022) |
| "Met may also treat diabetic osteoporosis through Wnt/β-catenin activation." | ( Huang, X; Li, S; Lu, W; Xiong, L, 2022) |
| "Osthole is an effective treatment for osteoporosis." | ( Lu, JH; Wang, WY; Wu, B; Yang, XQ; Zhu, XF, 2022) |
| "Continued treatment with osteoporosis medications was associated with reductions of fracture rates in a real-world setting." | ( Bartsch, R; Borchert, J; Hadji, P; Kossack, N; O'Kelly, J; Pignot, M, 2022) |
| "Continued treatment with osteoporosis medications was associated with reductions of fracture rates in a real-world setting." | ( Bartsch, R; Borchert, J; Hadji, P; Kossack, N; O'Kelly, J; Pignot, M, 2022) |
| "During 12 months of abaloparatide treatment, men with osteoporosis exhibited rapid and significant improvements in BMD with a safety profile consistent with previous studies." | ( Adachi, J; Binkley, N; Cardona, J; Chen, Y; Czerwinski, E; Kendler, D; Knychas, D; Lewiecki, EM; Li, YH; Mitlak, B; Orwoll, E; Pearman, L; Plebanski, R; Recknor, C; Saag, KG; Vokes, T, 2022) |
| "Antiresorptive therapy, first-line treatment for osteoporosis, is relatively contraindicated in HPP." | ( Ashkar, C; Ebeling, PR; Ng, E; Nguyen, H; Schneider, HG; Seeman, E; Sztal-Mazer, S, 2023) |
| "Antiresorptive therapy, first-line treatment for osteoporosis, is relatively contraindicated in HPP." | ( Ashkar, C; Ebeling, PR; Ng, E; Nguyen, H; Schneider, HG; Seeman, E; Sztal-Mazer, S, 2023) |
| "Antiresorptive therapy, first-line treatment for osteoporosis, is relatively contraindicated in HPP." | ( Ashkar, C; Ebeling, PR; Ng, E; Nguyen, H; Schneider, HG; Seeman, E; Sztal-Mazer, S, 2023) |
| "It is widely employed in the treatment of osteoporosis." | ( Ding, YF; Li, F; Liu, W; Liu, YY; Sui, HJ; Zhang, ZQ, 2023) |
| "It is widely employed in the treatment of osteoporosis." | ( Ding, YF; Li, F; Liu, W; Liu, YY; Sui, HJ; Zhang, ZQ, 2023) |
| "However, treatment of osteoporosis is far from satisfactory due to poor adherence to existing medications and adverse reactions, there is an urgent to develop novel therapies for osteoporosis." | ( Guo, J; Guo, Z; He, J; Ren, R; Shao, J; Sun, K; Wang, X, 2023) |
| "The number and proportion of patients treated with any osteoporosis medication were evaluated." | ( Diffenderfer, BW; Pearman, L; Pyrih, N; Wang, Y; Williams, SA, 2023) |
| "Bisphosphonates are prescribed to treat secondary osteoporosis in patients with rheumatoid arthritis (RA)." | ( Amano, K; Iida, S; Kogo, M; Sugauchi, A; Yamada, C, 2023) |
| "While overall diagnosis and treatment for osteoporosis have improved, osteoporosis in men remains underdiagnosed and undertreated." | ( Cheong, YR; Chuah, SL; Jobli, AT; Lee, KH; Lee, WWH; Samsudin, A; Singh, BSM; Teh, CL; Tiong, IK; Tiong, JK; Wan, SA, 2023) |
| "These medications are effective in treating osteoporosis but have side effects." | ( Gao, Z; Li, D; Li, Q; Liu, H; Liu, X, 2023) |
| "Zoledronic acid is used to treat osteoporosis, hypercalcemia, Paget's disease, and solid malignancies, including multiple myeloma, breast cancer, and prostate cancer." | ( Karpuz, S, 2023) |
| "Zoledronate (ZOL) is widely used to treat osteoporosis clinically." | ( Bi, W; Dong, W; Jia, S; Liang, Y; Qi, M; Song, Z; Wen, G; Xie, S; Zhang, Y, 2023) |
| "Developing novel drugs for treating osteoporosis is a popular research direction." | ( Gu, R; Li, W; Liu, H; Shao, Y; Xie, Z; Zeng, L; Zhou, Y; Zhu, Y, 2023) |
| "Drugs are normally prescribed to treat osteoporosis, especially after surgical treatment of osteoporotic fractures." | ( Bai, J; Chu, PK; Gao, A; Ge, G; Geng, D; Liu, X; Wang, G; Wang, H; Wang, Q; Wang, W; Wu, Z; Yu, L, 2023) |
| "BSHX treatment in osteoporosis model rats promoted tightening of the morphological structure of the trabecular bone and increased the bone mineral density (BMD)." | ( Chen, Y; Shi, H; Wang, Y; Wei, R; Wei, Z; Wen, X, 2023) |